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The global burden of infectious disease has declined in recent decades. Yet, patients who are 
immunocompromised and individuals in resource-limited settings remain at high risk of infection. In this 
dissertation, I will present several next generation sequencing assays that we have created that enable new 
ways to monitor and study infectious diseases. I will present two classes of technologies that target two 
different analytes: (1) cell-free DNA (cfDNA) in biological fluids and (2) viral transcripts within single 
cells. We have developed a library preparation assay that is sensitive to ultrashort cfDNA, which captures 
information about the pathogen and host. We applied this cfDNA sequencing assay to a large number of 
urine samples collected from patients with viral and bacterial urinary tract infections. Our findings indicate 
cfDNA sequencing can accurately detect a broad range of uropathogens and describe functional information 
about the infectious agent and host. We have also developed a complementary analytical pipeline to reduce 
false-positive identifications and background contamination. We have recently applied this pipeline in the 
monitoring of infectious diseases that are endemic in low-income countries. Using DNA sequencing, we 
proved that genome replication dynamics can be observed during MTB infections and that an abundance 
of enteric bacteria is present in the plasma of children suffering environmental enteropathy. In the second 
part of the dissertation, I will introduce a new high-throughput single-cell RNA sequencing tool that 
combines enrichment measurements of targeted RNA sequences with unbiased profiling of the 
polyadenylated transcriptome across thousands of single cells in the same biological sample. We applied 
this technique to simultaneously characterize the non-A-tailed transcripts of a segmented dsRNA viruses 
 
 
and the transcriptome of the infected cells. In addition, we applied the technology to simultaneously 
determine the natively paired, variable region heavy and light chain amplicons and the transcriptome of B 
lymphocytes. In summary, we have created new tools to capture and sequence nucleic acids in biological 
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A5 pentanucleotide sequence part of segment M3 is shown (arrow). Dotted lines, DART-seq target 
positions. d, Per-base coverage upstream (5′ end) of ten custom primers of DART-seq design-1 (light 
red; average shown in dark red), and mean coverage achieved with Drop-seq (yellow). e, Per-base 
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coverage of S2 gene segment achieved with DART-seq design-2 (bottom; dashed lines indicate custom 
primer positions) and Drop-seq (top). f, Frequency and pattern of base mutations (top); histogram of 
nucleotide ratios for positions with reference nucleotide G detected in single cells (bottom). g, 
Clustering analysis for variable gene expression of reovirus-infected L cells (DART-seq design-1; 
yellow/purple indicates higher/lower expression). Similar clustering was observed in all three 
experiments with infected cells. h, Relative abundance of viral transcripts in L cell clusters (P values 
determined by two-tailed Wilcox rank-sum test). Lower and upper hinges correspond to 25th and 75th 
percentiles, respectively. Lower/upper whisker corresponds to smallest/largest value within 150% of 
the interquartile range from the nearest hinge (cluster 1, n = 411; cluster 2, n = 397; cluster 3, n = 50; 
cluster 4, n = 69). i, Fraction of cells in metaclusters for four experiments depicted in panel a with 
assay type and infection status (+ or −) indicated. {36} ........................................................................... 105 
Figure 2.2.3.1 DART-seq measures paired heavy and light chain B cell transcripts at single-cell 
resolution. (a) DART-seq custom primer design targeting the constant region of human heavy and light 
isotypes. (b) cDNA copies of immunoglobulin (Ig) transcripts relative to GAPDH as a function of the 
number of custom primers included in the ligation reaction (left panel, LC-λ + V primers; right panel, 
IgG + V primers; 62,500 cells, 12,000 beads, bulk assay). Points are mean of two replicate 
measurements; bars indicate minimum and maximum. (c) Percentage of B cells for which heavy and/or 
light chain transcripts were detected as a function of the UMI count per cell. Cells were binned by the 
number of UMI detected (bin width 200 UMI, 0–2,400 UMI per cell, bins with fewer than 20 cells 
omitted, 26–2,396 cells per bin). Distributions were fit with a sigmoid curve (Methods). (d) Drop-seq 
and DART-seq assays of human PBMCs. Experiments were performed on two distinct PBMC samples 
(n = 2). Representative t-SNE for one DART-seq assay shown here (4,997 single cells). Cells are 
colored on the basis of heavy and/or light chain transcript detection. € Bar graph of isotype distribution 
for CD27+ B cells and B cells for which CD27 was not detected. (f) CDR3L and CDR3H length 
distribution. n = 818 B cells. (g) Paired heavy (IGHV) and light (IGKV and IGLV) variable chain 
usage in B cells; n = 164 single cells. {37} ............................................................................................... 108 
Figure 2.3.1.1 Targeted sequencing is not necessary for all viral transcripts. (a) The number of A(5) 
repeats per kilonucleotide (knt) is shown for three dsRNA, segmented viruses. (b) Mean normalized 
sequencing coverage across eleven rotavirus segments was calculated based on experimental results. 
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Figure 2.3.1.2 Rotavirus infected fibroblast quality analysis in single cells sequencing. (a-d) For 
Mock, Low MOI (MOI 0.1), and High MOI (MOI 5.0) single-cell sequencing analysis revealed the 
number of (a) UMI per cell, (b) genes per cell, (c) percentage of transcripts from the mitochondria, 
and (d) the percentage of transcripts from rotavirus. (e) Sequencing coverage across the rotavirus 
genome segments (ordered largest to smallest) 25 cells with the highest percentage of viral reads. 
Traces of each cell are in grey and mean of the traces is shown in black. Scale is square-root 
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Figure 2.3.1.3 Viral gene transcription is altered through infection progression. Viral mRNAs are 
averaged in groups of thirty cells after ordering by the percent of transcripts of viral origin in each cell. 
The fractional abundance of each transcript in the cell bin (30 cells) is shown as a stacked barplot. Line 
indicates the fraction of reads originating from the virus in each cell bin. Dotted line represents the 
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Figure 2.3.2.1 Dissociation of organoids leaves cellular aggregates but represents all cell types. (a) 
10x phase contrast image of dissociated enteroid on Fuchs-Rosenthal hemocytometer. (b-c) The 
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Figure 2.3.2.2 Differential gene expression and clustering analysis of low quality cells from 
enteroids. (a) The percentage of transcripts originating from the mitochondria is compared to the total 
number of genes expressed. Dotted lines represent cutoffs for filtering. Density plot overlaid on cells 
(colored by experiment). (b,c) t-SNE dimensional reduction of cell-cycle regressed gene expression. 
(b) Colors indicate Mock and Infected datasets. (c) Colors indicate increased expression of Sis, Lyz1, 
Chga, and Tff3. Intensity of color corresponds to intensity of gene expression. (1) Enterocyte cluster. 
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In October 2014, I attended an evening lecture given by Alfonso Torres, a former Associate Dean 
at Cornell University College for Veterinary Medicine, where he described West African Ebolavirus 
outbreak. Alfonso’s presentation expressed deep concern about the epidemic, but also described the heroism 
of veterinary and medical assistants who were performing science in the field. Underlying his talk was the 
success analysis using molecular epidemiology – the use of molecular detection to infer the spatiotemporal 
dynamics of epidemics. I was absorbed by analysis of the viral genetics over time and geographical space, 
and became interested in using genome sequencing to surveil pathogens. Around the same time, I was 
fortunate to discover a lab where I could combine my joy in performing benchtop research and my interest 
in applied mathematics with Iwijn De Vlaminck. My work in the De Vlaminck lab has focused on two 
separate aspects of genomics as applied to understanding infectious disease. These areas of study will make 
up the major two parts of this dissertation.  
In Part I, I aim to describe the field of cell-free diagnostics as it was when I started my research in 
2015. Prior to that time, few studies have analyzed the presence of non-host cell-free DNA (cfDNA) in 
bodily fluids. Work by De Vlaminck et al. determined the presence of an abundant virome observable in 
the plasma cell-free DNA of lung and heart transplant recipients [1–3]. The sequencing data from this work 
was brought into the newly-formed De Vlaminck lab and led to an investigation on using donor and 
recipient identified cell-free DNA molecules to predict cases of rejection from mitochondrial cfDNA [4]. 
As we discovered through means detailed in this dissertation, these molecules are much smaller than cfDNA 
fragments derived from chromosomes, owing mostly to the lack of protection from histone octamers and 
large, persistent transcription factors. 
We designed a method with the ability to capture and sequence short fragments of mitochondrial 
cell-free DNA. The technique also captured cell-free DNA fragments from other non-nucleosome bound 
sources (Part I, Chapter 2). We realized the potential of this new assay to identify viral and bacterial 
pathogens alongside host cell-free DNA, and expanded earlier studies of plasma cell-free DNA in lung 
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transplant recipients [4] to include cell-free DNA extracted from urine and peritoneal dialysis effluent in 
kidney transplant recipients [5] (Part I, Chapter 3). Furthermore, these studies have enabled us to develop 
analytic tools to overcome shortcomings inherent to cfDNA sequencing, such as background contamination 
and cell-free DNA originating from microbial sources with annotated reference genomes (Part I, Chapter 
4).  We also show that exploratory datasets derived from plasma cell-free DNA from individuals in 
developing nations has yielded insights into cell-free DNA diagnostics as a tool for molecular epidemiology 
genomes (Part I, Chapter 5). Recently published work from Karius, Inc. have shown the potential in using 
microbial cell-free DNA sequencing as a rapid diagnostic tool, able to return reports of identified pathogens 
in 24-36 hours back to the consumer [6]. I believe our advances, coupled with the progress made in the 
private sector, will lead to microbial cell-free DNA sequencing as a clinically useful diagnostic in the 
coming years. 
Part II of this thesis focuses on the insights gained by analyzing transcriptomes of single cells 
infected with viruses. Single-cell transcriptomics and genomics is a nascent field, with the first sequencing 
experiments performed and published in 2009. Since then the ability to simultaneously and affordably (< 
$0.10 per cell) prepare sequencing libraries for tens of thousands of cells has been achieved [7]. These 
methods, however, are often unable to capture non-polyadenylated or non-5’-end capped transcripts, the 
signatures of eukaryotic messenger RNAs. We identified the need to enrich for transcripts that current gold-
standard technologies fail to capture, while still using the framework that these technologies have advanced. 
To meet our goal, we created a cheap and multiplexable technology to capture dozens of targeted amplicons 
alongside polyadenylated messenger RNAs, allowing, in principle, the sequencing of any RNA species, 
regardless of origin or property [8] (Part II, Chapter 2). 
I will describe the validation of this new technique, as we applied it to infections with mammalian 
orthoreovirus in cell culture and provide evidence of its use in other areas analysis of host-pathogen 
interaction (such as immunology). We have recently expanded this work to include other viral systems, in 
particular, orthoreovirus in complex intestinal organoids and rotavirus in cell culture (Part II, Chapter 3). 
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Through analysis at the single-cell level, interesting phenomena can be observed during the infection cycle 
that otherwise would not be observed in bulk RNA studies. In summary, the proof of our new method and 
follow-up studies provide a new tool to understand innate and adaptive immunity during infection. 
While these two areas of study, single-cell ‘omics and cell-free nucleic acid diagnostics, are 
somewhat disparate, they overlap in both molecular biology techniques used to generate libraries for 
sequencing and the bioinformatics principles used to organize and analyze the sequencing data. Moreover, 
they reflect a similarity in my own curiosity and motivations when we are pursuing novel genomics 
technologies, namely, answering the following questions: “what information are we missing?” and “what 
elegant methods are available to capture it?”. Recent works from some labs around the world are utilizing 
single-cell ‘omics technologies to determine novel biomarkers of disease, accessible in the form of nucleic 
acids circulating through the body. The last portion of the dissertation will summarize my work and describe 
new technologies to diagnose infections using single-cell and single-molecule sequencing technologies. 
 
Published works referred to in this dissertation: 
Burnham P, Kim MS, Agbor-Enoh S, Luikart H, Valantine HA, Khush KK, De Vlaminck I. Single-stranded 
DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. Scientific 
Reports. 2016. (Part I, Chapter 2). 
Burnham P, Dadhania D, Heyang M, Chen F, Westblade L, Suthanthiran M, Lee JR, De Vlaminck I. 
Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. Nature Comm. 
2018. (Part I, Chapter 3). 
Saikia M*, Burnham P*, Keshavjee SH, Wang MFZ, Heyang M, Moral-Lopez P, Hinchman MM, 
Danko CG, Parker JSL, De Vlaminck I. Simultaneous multiplexed amplicon sequencing and 
transcriptome profiling in single cells. Nature Methods. 2019. (Part II, Chapter 2). 
* indicates equal contribution.  
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PART I: Cell-free DNA sequencing to monitor infection 
 
“Once the cells in a biological machine stop working, it can never be started again. It goes into a cascade 
of decay, falling toward disorder and randomness...”  




Chapter 1: Physiological and historical origins of cell-free DNA 
 
Insights into the origin of cell-free DNA (cfDNA) and its association with disease began before 
there was true knowledge of the medium itself. The observation of cell-free DNA predated the publications 
of the double helix structure of DNA by Watson, Crick, and Franklin in 1952-1953. Mandel and Metais 
first published their discovery in 1948, recognizing the presence of nucleic acids in plasma extracted from 
the blood of individuals with various medical conditions [9]. Earlier work had described the presence of 
nucleic acids in blood, and researchers had optimized the techniques used to extract DNA from biological 
fluid [10]. However, Mandel and Metais recognized that these works likely misrepresented discoveries of 
cfDNA and instead captured whole genomic DNA from white blood cells (WBCs). By extracting plasma, 
and thus depleting the biological fluid of blood cells, they showed the presence of significant amounts of 
nucleic acids in the plasma – roughly 4.7 ng per mL of plasma – across ten healthy patients. 
Mandel and Metais also extracted cell-free nucleic acids for fifteen patients with known pathologies 
or conditions (including pregnancy, autoimmune disorders, and tuberculosis). While the sample size for 
each of these conditions was small (n of 1 or 2), their importance and foresight cannot be overstated. In the 
case of a 23-year-old, seven-month pregnant female, the detected amount of nucleic acid in plasma was six 
standard deviations above the mean of non-pregnant patients.  
Half a century later, Lo et al. followed up on Mandel and Metais’ observation of elevated cell-free 
DNA in pregnancy, seeking to determine the origin of the cfDNA molecules in plasma [11]. The researchers 
isolated cfDNA from serum, plasma, and whole blood from women who were at least twelve weeks 
pregnant. A polymerase chain reaction (PCR) assay was designed to amplify a fragment of DNA from the 
Y chromosome [11]. It follows that such an amplicon should only be observed in women pregnant with 
male fetuses, and would be indicative of cfDNA originating from the fetus. For 24 of 30 samples with male 
fetuses, Y chromosome cfDNA was detected in plasma (in 21 of the 30 samples for serum). Importantly, 
the signal was not observed in the plasma of women pregnant with female fetuses.  
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These observations of fetal cfDNA in maternal plasma preempted the understanding that 
vascularized tissues within the body can release cfDNA into surrounding blood vessels. Furthermore, the 
work by Lo et al. effectively moved cfDNA research from a simple observation into a biomarker by which 
we can to monitor disease. Diagnostic tests have been created to detect trisomy 21 and other genetic 
abnormalities early on in pregnancy [12]. These tests are now frequently used in clinics to determine fetal 
abnormalities. Later work has shown that cfDNA could be used to inform oncogenesis and as a predictive 
biomarker of transplant rejection [2, 3, 13, 14]. Both of these diseases often require tissue biopsy for 
diagnostic confirmation – procedures that are expensive, invasive, and often lack the ability to reflect tissue 
heterogeneity. The sequencing of cell-free DNA to determine such maladies permits a fast and noninvasive 
test that avoids some of the technical challenges of standard biopsies. For example, cfDNA from 
cerebrospinal fluid has indicated the polygenetic composition of a glioma [15]. This identification using 
standard methods would have otherwise required open brain surgery to remove, dissociate, and sequence 
the whole tumor.  
Since 1947, our understanding of the properties of cfDNA has increased along with our 
appreciation of its utility. It is now understood that cfDNA enters the circulatory system through a variety 
of mechanisms including apoptosis, necrosis, pyroptosis, and, in some cases, active release [16]. In blood 
circulation, as was first speculated, dying neutrophils and leukocytes release the majority of cell-free DNA 
in the blood of healthy individuals. However, other basic studies in the field have found that certain diseases 
lead to higher amounts of cell-free DNA into the bloodstream from inflammation or injury. For example, 
individuals suffering traumatic injury and systemic inflammation have shown high amounts of cell-free 
DNA in the days following disease onset [17, 18]. Once in the circulation, cfDNA is degraded via 
circulation exonucleases and or immune cells. Naked DNA (i.e. that lacking bound proteins) is degraded at 
a much faster rate than fragments occupied by proteins [19]. 
The captured fragments of cell-free DNA statistically represent those with longer lifetimes in the 
biological fluid in which they are released. Since naked cell-free DNA is degraded by environmental 
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nucleases, those fragments bound to proteins are often protected from degradation. This stabilization leads 
to, on average, a higher abundance of protein-bound cfDNA in datasets. Evidence of this protection is 
immediately observable when plotting a histogram of the fragmented lengths of sequenced cfDNA. If only 
naked DNA were released into the environment and nonspecifically degraded, one would expect an 
exponentially decaying distribution of fragment lengths. Instead, we observe a strong peak at ~167 bp for 
cfDNA fragment lengths originating in blood plasma (Fig. 1.1.0.1a). The presence of this peak is explained 
by the presence of nucleosomes bound to nuclear eukaryotic DNA. Nucleosomes consist of an octamer of 
four histone proteins to which 145 bp of DNA are wrapped, and an H1 linker histone is then added between 
nucleosomes [12]. Moreover, the distribution of cfDNA fragment lengths below 167 bp show periodic local 
maxima roughly every 10 bp (Fig. 1.1.0.1b, Fast Fourier Transform of distribution from Fig. 1.1.0.1a 
between 60 and 170 bp after background removal). This pattern suggests that the local enrichment is based 
Figure 1.1.0.1 cfDNA properties strongly indicate nucleosomal origin. (a) Histogram of fragment 
length distribution for a plasma cfDNA sample prepared using standard, commercial library preparation. 
(b) Fourier transform was performed on distribution in (a) between 60 and 170 bp, peak indicates most 
prominent periodicity. (c) A dinucleotide heatmap is shown for cfDNA fragments of varying length, 
relative to central position. (A/T) dinucleotide combinations are scored with a value of 1, other 
combinations are scored with value 0, heatmap reflects mean score. Cross-section of heatmap shown 
above for 167 bp. In (a) and (c) dashed line corresponds to most abundant fragment length, 167 bp. {1} 
 
Figure 1.1.0.1 cfDNA properties strongly indicate nucleosomal origin. (a) Histogram of fragment length 
distribution for a plasma cfDNA sample prepared using standard, commercial library preparation. (b) 
Fourier transform was performed on distribution in (a) between 60 and 170 bp, peak indicates ost 
prominent periodicity. (c) A dinucleotide heatmap (colored by mean A/T frequency) is shown for cfDNA 
fragments of varying length, relative to central position. (A/T) dinucleotide combinations are scored with 
a value of 1, other combinations are scored with value 0, heatmap reflects mean score. Top: Cross-section 
of heatmap shown above for 167 bp. In (a) and (c) dashed line corresponds to most abundant fragment 
length, 167 bp. {1} 
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on protection from the interaction between DNA and the nucleosome core particle with partial degradation 
at the edges of the molecules [20].  
Proteins bound to DNA often do so in a specific manner, determined by the physical properties of 
nucleotides that act as a signal [21]. This results in the observation of sequence motifs [22]. If one selects 
human aligned sequences from plasma cfDNA at a particular fragment length, a bias to A/T becomes 
apparent at positions 0 ± 10n from the center of the molecule, where n is an integer value (Fig. 1.1.0.1c, 
top). We can visualize this bias by plotting the dinucleotide frequency across all molecules of various 
lengths (Fig. 1.1.0.1c, bottom). Histones have a strong affinity to the minor groove of particular DNA 
motifs, particularly AAA/TTT and AAT/TTA [20, 22]. Again, this observation supports the reflection of 
intrinsic helicity of nucleosome-bound DNA (10.4 bp to complete an internal rotation of the DNA double 
helix). The observations of partial protection and corresponding AT-rich sequences at ~10.4 bp intervals 
for molecules below 167 bp suggest that many sequences are derived from nucleosomes. 
cfDNA fragments can also be directly mapped to the human genome to observe the nucleosomal 
origin of cell-free DNA. This observation requires a high depth of sequencing (i.e. many reads covering a 
random genomic position, on average), but is striking. Figure 1.0.1.2 shows the coverage for 140-180 bp, 
blood plasma cell-free DNA). By observing a genomic region which is known to have strong nucleosome 
Figure 1.1.0.2 Patterns of cfDNA fragmentation observed by sequencing depth along reference genome. 
Sequencing coverage of human aligned cfDNA originating from plasma across a small section of the 
genome for 140-180 bp fragments. Plasma cfDNA prepared for sequencing using standard, commercial 
library preparation. Positions illustrated are from human chromosome 12. {2} 
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signals (Fig. 1.1.1.2, Chr12: 104,291,750-104,293,250), we can observe the presence of peaks separated by 
210 bp, corresponding well to the expected distance between nucleosomes [23]. Conversely, in regions of 
the genome that are expected to be less compacted for enzymatic accessibility (e.g. a transcription start site 
of a housekeeping gene), one can see a gap in the nucleosomal occupancy, and a high ordering of 
nucleosomes surrounding the transcription start site [24]. 
Because of the strong nucleosomal signals present in cfDNA sequencing data, it could be assumed 
that other non-nucleosomal sources are of limited scope from their low signal. In fact, cell-free DNA has 
been observed from non-nucleosomal sources, including from the host and microbial organisms living 
within the host [1, 23, 25]. In Part I of this dissertation, I will describe the development of a novel library 
preparation protocol that has allowed researchers to capture and analyze non-nucleosomal cfDNA, which 
tends to be very short (< 100 bp), and is not captured by traditional commercial methods. Utilizing a ssDNA 
library preparation of cfDNA has allowed us to expand cfDNA sequencing into underrepresented biological 
fluids in cfDNA studies, including urine, peritoneal dialysis effluent, and amniotic fluid. Most importantly, 
we have used this novel library preparation to evaluate cfDNA sequencing as an analytical pipeline to 
determine viral and bacterial infections. I will show the efficacy of cfDNA as a comprehensive analyte to 





Chapter 2: Single-stranded DNA library preparation uncovers the origin and diversity of ultrashort cell-
free DNA in plasma 
 
“Circulating cell-free DNA (cfDNA) is emerging as a powerful monitoring tool in cancer, pregnancy and 
organ transplantation. Nucleosomal DNA, the predominant form of plasma cfDNA, can be adapted for 
sequencing via ligation of double-stranded DNA (dsDNA) adapters. dsDNA library preparations, however, 
are insensitive to ultrashort, degraded cfDNA. Drawing inspiration from advances in paleogenomics, we 
have applied a single-stranded DNA (ssDNA) library preparation method to sequencing of cfDNA in the 
plasma of lung transplant recipients (40 samples, six patients). We found that ssDNA library preparation 
yields a greater portion of sub-100 bp nuclear genomic cfDNA, and an increased relative abundance of 
mitochondrial and microbial cfDNA. The higher yield of microbial sequences from this method increases 
the sensitivity of cfDNA-based monitoring for infections following transplantation. We detail the 
fragmentation pattern of mitochondrial, nuclear genomic and microbial cfDNA over a broad fragment 
length range. We report the observation of donor-specific mitochondrial cfDNA in the circulation of lung 
transplant recipients. A ssDNA library preparation method provides a more informative window into 
understudied forms of cfDNA, including mitochondrial and microbial cfDNA and short nuclear genomic 
cfDNA, while retaining information provided by standard dsDNA library preparation methods.” 
 
Chapter adapted from [4]: 
Burnham P, Kim MS, Agbor-Enoh S, Luikart H, Valantine HA, Khush KK, De Vlaminck I. Single-stranded 
DNA library preparation uncovers the origin and diversity of ultrashort cell-free DNA in plasma. Scientific 




1.2.0 A single-stranded ligation strategy to enrich ultrashort cfDNA 
Cell-free DNA exists in circulation in many shapes and forms, including as fragments of the nuclear 
genome, the mitochondrial genome and microbial genomes [25]. The predominant type of cfDNA is 
derived from the nuclear genome and has a fragment size centered around 167 bp, approximately the length 
of a segment of DNA wound around a histone octamer [26, 27]. These nucleosomal fragments of cfDNA 
are readily accessible for sequencing using standard library preparation methods that are based on ligation 
of dsDNA sequencing adapters. The most commonly used implementations of this method rely on multiple 
bead-based size-selective steps that eliminate unwanted adapter-dimer products.  
If the host-aligned (i.e. human-aligned) cell-free DNA is separated by chromosome, cell-free DNA 
originating from the mitochondria may be observed. The evolution of eukaryotic cells and the eventual 
production of multicellular life rested on integration of a bacterium inside of another cell [28]. Due to the 
bacterial origin of the mitochondrial organelle, these genomes lack nucleosomal packaging and are more 
rapidly degraded when removed from the cell [29]. We hypothesized that current library preparation 
techniques removed many cfDNA molecules that were non-nucleosomal in origin, including mitochondrial 
cfDNA, in an effort to eliminate adapter-dimer products from sequencing libraries. Adapter-dimer products 
are often the same size or larger than degraded cfDNA, making it difficult to separate the two using size 
selection. These methods, although relevant to a wide range of applications, are not sensitive to the full 
diversity of circulating cfDNA [30]; in particular shorter fragments, highly degraded fragments, nicked 
dsDNA and single-stranded fragments of DNA in circulation remain undetected.  
We confirmed an abundance of short mitochondrial cell-free DNA molecules via digital PCR 
(dPCR) assays and subsequently sought to establish a library preparation protocol sensitive to short cfDNA. 
A parallel exists with genomic analyses of ancient DNA samples, where the target DNA is often in low 
abundance and less than 50 bp in length. To address size and abundance issues, researchers introduced a 
sequencing library preparation technique based on the binding of single-stranded DNA molecules to 
magnetic beads for enzymatic extension and cleanup [31]. The technique was demonstrated to produce high 
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quality, low contamination sequencing reads across a Denisovan individual from antiquity [32]. This single-
stranded ligation is, in principle, sensitive to the full diversity of cfDNA in the circulation, including 
ultrashort (< 100 bp) dsDNA, ssDNA and dsDNA with nicks in both strands.  
We adapted this protocol and applied it to plasma cfDNA originating from patients receiving 
bilateral lung transplants. To evaluate the performance of the ssDNA library preparation method, we 
directly compared data of fragment types, lengths and abundance to results from conventional library 
preparations performed on the same plasma DNA extracts [1, 3]. Transplant recipients are subject to 
immunosuppressive therapies that reduce the risk of rejection, but increase their susceptibility to 
opportunistic infections. Analyses of microbial cfDNA in plasma are therefore particularly relevant in the 
context of transplantation. Here, we examined the yield of microbial cfDNA that results from the ssDNA 
and conventional library preparations. Donor-specific nuclear genomic cfDNA is present in the circulation 
of solid-organ transplant patients and is a marker of transplant rejection [2, 33]. In this study, we used a 
single-stranded library preparation to study the properties of donor and recipient specific cfDNA across a 
wide length range. To test whether donor-specific mitochondrial cfDNA can be found in the circulation of 
transplant recipients, we directly compared data of cfDNA to reference sequences of amplified 
mitochondrial genomes obtained from pre-transplant samples. 
 
1.2.1 Mitochondrial cfDNA in plasma measured by digital PCR  
This study was prompted by a retrospective analysis of sequencing data of cfDNA in plasma of 
transplant recipients available from a previous study [3], which revealed a fractional abundance of 
mitochondrial cfDNA of 2 x 10-3 %, which is in line with a recent observation [25], but is low considering 
that there are 50-4,000 mitochondrial genomes per cell [34]. We used digital PCR (dPCR) assays with 
varying amplicon length (49-304 bp) to assess the abundance of mitochondrial cfDNA prior to library 
preparation and compared this to the abundance of nuclear genomic cfDNA (Fig. 1.2.1.1). Whereas qPCR 
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requires a dilution series of a template oligo for each primer set in order to determine the concentration of 
a template, digital PCR provides a reference-free technique in which tens of thousands of PCR assays are 
carried out simultaneously within femtoliter-sized droplets [35]. It is expected that each droplet will contain 
zero, one, or countably few template molecules. The template in each droplet can then be amplified and a 
fluorescent dye (such as SYBR green) is bound to DNA to discern template-positive and negative droplets. 
The Poisson model is applied to determine the initial concentration of the template based on the fractional 
amount of template positive droplets [35]. 
The experimental design with variable amplicon lengths provided information about the underlying 
fragment length distribution [26]. The genomic abundance of cfDNA, as measured by PCR, is expected to 
decrease monotonically with amplicon length, with a gradient that is a function of the underlying fragment 
length distribution. It can then be calculated that the relative fraction of target molecules of length x, 
detected in a PCR assay with amplicon of length L: 
𝑓(𝑥, 𝐿) =
𝑥 − 𝐿 + 1
𝑥
∶ 𝐿 ≤ 𝑥 . 
Figure 1.2.1.1 Digital PCR measurements reveal an abundance of ultrashort cfDNA originating from the 
mitochondria. Number of genomic copies (per milliliter of plasma) is shown as a function of amplicon 




And the abundance of a template measured via the digital PCR assay then corresponds to: 




where G(k) is the underlying fragment length distribution (expressed as a density). When fitting the 
observed dPCR abundance with the model it is apparent the nuclear cell-free DNA fragments can be 
modeled as a Gaussian (mean = 165 bp, s.d. = 20 bp) and the mitochondrial fragments modeled as an 
exponential decay.  
These experiments revealed that mitochondrial cfDNA is more fragmented than nuclear genomic 
cfDNA, but present in much greater abundance in plasma (56-fold greater representation, genome 
equivalents). The exponential shape of the curve indicates that further enrichment could be achieved below 
the minimum amplicon length used in this study. However, the ability to amplify, sequence, and map 
molecules shorter than 40 bp is technically challenging. The consequence of the short fragment size of 
mtDNA is that conventional dsDNA library preparation protocols, which require multiple bead-based size-
selective steps to eliminate unwanted adapter-dimer products, are relatively insensitive to mitochondrial 
sequences. We generalized this finding to hypothesize that all cfDNA of non-nucleosomal origin is likely 
undersampled by gold-standard preparation and sequencing approaches. 
 
1.2.2 ssDNA library preparation and fragmentation profiles 
We implemented a ssDNA library preparation protocol first described by Meyer et al. that does not 
require size-selective steps that eliminate shorter fragments [36] (Fig. 1.2.2.1 and described in Section 
1.2.5). We used paired-end sequencing to determine the fragment lengths of nuclear, mitochondrial, and 
microbial cfDNA (see Section 1.2.5). We found that cfDNA shorter than 100 bp becomes more accessible 
for sequencing following ssDNA library preparation. The lower limit of efficient capture, as shown by the 
local maxima of the short fragment cfDNA, for the ssDNA library preparation, was 40-60 bp (for all 
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subclasses), pointing to a limit set by the DNA isolation method. Ancient DNA molecules 30 bp in length 
were sequenced using a similar preparation, so it is possible to obtain shorted fragments depending on 
isolation method [32]. 
The peak in the length profile at 160-167 bp for cfDNA fragments assigned to the nuclear genome 
(Fig. 1.2.2.2) is a consequence of the protection of these molecules from degradation by nucleases in the 
blood through tight association with histones. This property has been reported in previous studies and is 
observed for both the ssDNA and dsDNA library preparation protocols [37]. A second peak at shorter 
lengths (< 100 bp) is unique to the libraries prepared by single-stranded ligation [2]. The relative proportion 
of nuclear genomic DNA shorter than 100 bp made up a substantial proportion of nuclear cfDNA (20.54% 
± 11.51%). We partitioned cfDNA prepared via ssDNA ligation into two groups, those with length under 
and over 100 bp, to examine distinguishing features. The GC content between the groups differed 
significantly (Fig. 1.2.2.2, inset; p << 10-5, Mann-Whitney U Test); the GC content of the super-100 bp 
group was 40.9%, while that of the sub-100 bp group was 43.5%. These observations confirm previous 
observations of high AT density for nucleosome associated cfDNA molecules. Furthermore, the data 
indicates that a considerable amount of cfDNA originating from the nucleus is not nucleosome protected 
and, thus, subject to degradation by nucleases in the blood. Previous reports suggest that fetal- and tumor-
derived cfDNA are shorter than cfDNA derived from maternal [38] and normal [25] tissue, respectively. 
Figure 1.2.2.1 Schematic overview of single-stranded library preparation for cfDNA. (i) cfDNA from 
biofluid is extracted and is highly heterogeneous with respect to degradation patterns. (ii) cfDNA is 
denatured at 95 °C. (iii) single-stranded cfDNA is ligated to biotinylated adapters and bound to streptavidin-
coated magnetic beads. (iv) Bound ssDNA is end-repaired, extended, and adapted with double-stranded 
sequencing primers. (v) Sequencing libraries are PCR amplified and indexed. Final libraries represent 
degradation diversity present in original set. {4} 
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The sensitivity of the ssDNA library preparation protocol to molecules over a wider length range is therefore 
a feature that will be useful for applications in prenatal testing and tumor monitoring.  
 
1.2.3 Improved recovery of mitochondrial and microbial cfDNA 
We next examined the coverage of mitochondrial and microbial genomes relative to the nuclear 
genome for the dsDNA and ssDNA library preparations. While conventional library preparation resulted in 
detection of only a few molecules of mitochondrial and microbial cfDNA with length shorter than 100bp, 
the use of a ssDNA library preparation revealed an abundance of such molecules with lengths between 40 
and 100 bp. We found that the ssDNA library preparation gives rise to an increase in the relative number 
of mitochondrial sequences in the datasets (10.7 fold mean increase, p << 10-5, Mann-Whitney U test) and 
an increase in the relative coverage of the mitochondrial genome (7.22 fold mean increase, p << 10-5, Mann-
Whitney U test; Figure 1.2.3.2). This observation is consistent with the greater sensitivity of the ssDNA 
library preparation to short fragment DNA described above.  
Figure 1.2.2.2 Single-stranded library preparation reveals an abundance of ultrashort cfDNA molecules. 
Density plot of the fragment sizes of nuclear genomic cfDNA measured after ssDNA (blue) and dsDNA 
(red) library preparation. The inset shows the sample-to-sample variability (n = 40), as well as the 
difference in GC content for short (< 100 bp) and long (> 100 bp) fragments. Significance of p << 10-5, 
Mann-Whitney U Test. Boxplot description given in section 1.3.9. {5} 
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A direct comparison of the fraction of sequencing sets made of microbial reads also showed much 
higher abundance in the instances of using ssDNA library preparation, compared to standard techniques 
(Fig. 1.2.3.2b). To study the efficiency of recovery of microbial cfDNA, we estimated the genome coverage 
of each microbe detected across all samples relative to the coverage of the human genome (see Section 
1.2.5). We compared the relative genomic coverage of strains or subspecies detected by both methods in 
matched samples (n = 36). We examined over 1,100 direct comparisons and found a significant correlation 
(corr. = 0.6373, Spearman, p << 10-5) in the relative genomic abundance as measured following ssDNA 
and dsDNA library preparation (Fig. 1.2.3.3b); the range in the ratio was 0.277x – 3950x, indicative that 
for most species the ssDNA method led to more efficient detection (p << 10-5; Mann-Whitney U Test). 
Importantly, library preparation by ssDNA ligation gave rise to a mean 71-fold increase in the relative 
genomic coverage of microbial species (74-fold for bacteria, which made up 89% of the sampled species 
comparisons; Fig. 1.2.3.3a-b). Consistent with the greater recovery efficiency of the ssDNA protocol, we 
find that most of the species detected in the dsDNA library preparation assays were also detected following 
ssDNA library preparation (95% species recovery, 934/984). 55% of all species detected were uniquely 
observed in the ssDNA library preparation assays.  
Figure 1.2.3.1 ssDNA ligation based library preparation reveals enrichment for microbial and 
mitochondrial cell-free DNA. Fragment length distribution for matched samples using ssDNA ligation and 
traditional library preparation techniques is compared, as normalized to nuclear cfDNA molecules, for (a) 
mitochondrial-aligned and (b) microbial-aligned fragments. {6} 
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The greater efficiency in recovery of microbial cfDNA is in line with the greater sensitivity of the 
ssDNA library preparation protocol to ultrashort cfDNA. This feature offers the potential to profile the 
bacterial and viral components of the microbiome in plasma both more broadly, in terms of the number of 
microbes accessible for testing, as well as more deeply. Such an increase in microbial sequencing depth 
permits infectious disease diagnostics based on sequencing of cfDNA with increased precision and at lower 
cost. The ssDNA library preparation detected viral fragments with clinical relevance in transplantation, 
including polyomaviruses (BK polyomavirus, one sample, and Merkel cell polyomavirus, two samples) and 
single-stranded DNA, transfusion-associated viruses (torque teno virus, 18 samples; SEN virus, 19 
samples); the impact of these viruses on the outcome of solid organ transplant patients has been investigated 
previously [1]. Current methods to detect infections are predominantly limited to testing one pathogen at a 
time. Metagenomics approaches have the potential to broadly screen for all known pathogens (with a DNA 
genome) in a single test [1, 39, 40]. Blood can be collected non-invasively and the majority of tissues in the 
body are connected to the blood circulation, making cfDNA an attractive sample type for such approach. A 
number of caveats remain; for example, it may be difficult to inform about an infection by organisms that 
Figure 1.2.3.2 ssDNA library preparation captures more bacterial cfDNA with higher diversity than 
standard methods. (a) Single-stranded ligation method has significantly more microbial cell-free DNA than 
the traditional method (double-stranded ligation). (b) The abundance of microbial genomes is compared by 
ligation method, for matched species within matched samples. Species are colored by superkingdom (Non-
fungi eukaryotes are grey in color). {7} 
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are part of the normal flora in certain body sites, but are pathogenic in others. cfDNA may be of limited use 
in such cases as it lacks body-site specificity. 
 
1.2.4 Donor-specific cfDNA from the mitochondria and autosomes 
Donor-specific cfDNA is present in the circulation of organ transplant recipients [33] and recent 
studies have shown that the proportion of donor-specific cfDNA is predictive of acute rejection in heart and 
lung transplantation [2, 3]. We compared the fractional abundance of donor-specific cfDNA in the lung 
transplant samples measured following dsDNA and ssDNA library preparation (36 matched samples, six 
patients, Fig. 1.2.4.1). We found an excellent agreement between matched measurements (corr. = 0.980, 
Pearson, p << 10-5). Here, sequences were assigned to the donor and recipient based on genotypic 
information (single-nucleotide polymorphisms, SNPs) obtained from pre-transplantation whole blood 
samples [3]. Importantly, we discovered that the number of donor-aligned sequences in patients does not 
differ significantly, regardless of the increase in microbial reads. The ability to capture high numbers of 
reads allowed for the maintenance of high precision measurements of the donor fraction (as determined by 
Figure 1.2.4.1 Single-stranded library preparation captures donor fraction information from autosomal 
cfDNA in matched samples. The donor fraction from autosomes was calculated and compared for both 
library preparation methods. Error bars represent standard error in measurement in error calculated from 
sampling error. Red line indicates exact correspondence. {8} 
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sampling error). In one sample, we observed preparation via ssDNA ligation increased precision by an order 
of magnitude (Fig. 1.2.4.1). One patient suffered from a severe rejection event at month 12 post-transplant. 
The fraction of donor-specific cfDNA measured for this patient using both library preparation methods was 
elevated, coinciding with the biopsy-proven rejection event.  
Because of the high copy number of mtDNA in cells and the relatively high genetic diversity 
between two unrelated individuals [41, 42], mtDNA is often used in forensic analyses [43] and in studies 
of population genetics [44]. The same attributes make mitochondrial cfDNA a promising candidate marker 
of post-transplant graft injury. We asked whether donor-specific mitochondrial cfDNA can be detected in 
the plasma of transplant recipients. We built mitochondrial reference sequences to assign mitochondrial 
cfDNA to the transplant donor or recipient. To this end, DNA was extracted from whole blood samples 
collected from the donor and the recipient prior to the transplant procedure. Mitochondrial DNA was 
selectively amplified and sequenced. One million sequences led to a per-base coverage greater than 100-
fold (genome size 16.5 kb), sufficient to determine subject-specific mitochondrial variants. Based on the 
Figure 1.2.4.2 Donor-specific cfDNA originating from the mitochondria reveals graft damage. (a) 
Schematic representation of analysis workflow used to discriminate donor and recipient specific mt-cfDNA. 
Examples of an ambiguous assignment and a fragment assigned to the donor are shown. (b) Fraction of 
donor-specific mt-cfDNA as function of time post-transplant for five double lung transplant patients (25 
samples, samples with fewer than 20 informative fragments excluded); Inset: The fraction of donor-specific 




reference sequences, we compiled lists of SNPs that are unique to either the donor or recipient (Fig. 1.2.4.2a, 
see Methods). On average, 152 informative SNPs were found per donor-recipient pair, leading to a SNP 
every 114 bp. For samples prepared via ssDNA ligation, 8.7% ± 3.4% of the mitochondrial sequences were 
informative, and 9.5% of the informative SNPs were assigned to the donor. Donor- and recipient-specific 
sequences spanned the entire mitochondrial genome. 
To the best of our knowledge, this is the first direct observation of graft-derived mitochondrial 
DNA in the circulation of transplant recipients. We computed the fractional abundance of donor-specific 
mt-cfDNA as the number of donor-specific mt-cfDNA molecules divided by the total number of 
informative mt-cfDNA molecules. We studied the variability and time dependence of the levels of donor-
specific mt-cfDNA. We observed a higher-than-average fraction of donor-derived mt-cfDNA in the month 
following transplantation (Fig. 1.4.2.2b). Such an observation echoes elevated levels of donor-derived 
cfDNA in heart and lung transplant recipients during the first few weeks post-transplant, in the absence of 
acute rejection [2, 3]. The fraction of donor-specific mt-cfDNA was only modestly correlated (corr. = 0.480, 
Pearson, p = 0.0152) with the fraction of nuclear genomic DNA. Samples for which there were less than 20 
informative mitochondrial fragments were removed (11 of 36 samples). Deeper sequencing and an analysis 
of a greater set of samples will be needed to investigate the relationship between acute rejection and the 
release of mitochondrial DNA from the graft. It is also likely that the mitochondrial donor fraction does not 
correspond exactly with the nuclear donor fraction. Cell-free DNA is the collection of all tissues 
contributing to the nucleic acid abundance in a biological fluid, and each cell contributes a similar (if not 
exact) amount of nuclear genomic DNA upon death. However, distinct cell types hold various amounts of 
mitochondria (50-40,000) each with five to ten genome copies, depending on conditions and replication 
potential [45]. As a result, without knowledge of mitochondrial abundance per cell-type, donor fractions 
may be confounded due to the underlying physiology. 
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Previous studies have found differences in fragment lengths for fetal and maternal cfDNA [38], 
tumor and somatic cfDNA [30] and hematopoietic and non-hematopoietic cfDNA [25]. Here, we compared 
the length of mitochondrial fragments derived from the graft (n = 265) to those specific to the recipient (n 
= 1855, 40 samples). We generated 10,000 random subsamples of the total collection of recipient-specific 
fragments (subsampled to the total number of donor fragments detected, n = 265). We next computed the 
median lengths for the random subsamples and compared to the median length of donor fragments (inset 
Fig. 1.2.4.3). We found that donor sequences were slightly shorter (-9 ± 3 bp) than recipient-specific 
mitochondrial sequences. This shortening in fragment length may be indicative of differences in the 
mechanisms of release, or differences in processes of degradation, of donor and recipient mt-cfDNA.  
 
1.2.5 Methods and sampling cohort description 
ssDNA sequencing libraries were prepared from cfDNA purified from plasma using a spin column 
approach (Qiagen QiaAMP nucleic acid extraction kit, 1 mL plasma). We followed a paleogenomics-based 
protocol with the following exceptions: (1) uracil excision steps using endonuclease VIII were not 
performed, (2) the amount of CircLigase II enzyme in the protocol was reduced from 4 μL to 0.8 μL and 
Figure 1.2.4.3 Smoothed (distribution five nearest-neighbor running mean) of donor mt-cfDNA (red) is 
compared to that of recipient mt-cfDNA (blue). Inset: median fragment size for the donor mt-cfDNA (red 
line) compared to the fragment size of 10,000 subsets sampled from the recipient mt-cfDNA length set 
(median depicted by black line). {10} 
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amounts of MnCl2 and CircLigase II buffer were halved, (3) editing of oligos including extension primer 
CL9, had an addition N*N*N*N overhang on the 5′ end (described by Karlsson et al. [46]) to prevent 
formation of adapter-dimers. Briefly, cfDNA libraries were denatured at 95 °C for one minute. ssDNA 
libraries were dephosphorylated and biotinylated adapters were ligated via single-stranded DNA ligation 
(Circligase II enzyme). Primer extension was performed on streptavidin functionalized magnetic beads (T4 
DNA polymerase) and a second set of adapters was ligated by double-stranded DNA ligation (T4 DNA 
ligase).  
Molecules complementary to the original cfDNA molecules were denatured from the beads at 95 
°C and isolated in 25 μL of elution buffer. 1 μL of eluted library was aliquoted and qPCR was performed 
to determine the optimum number of indexing PCR cycles. Finally, the full library was PCR amplified. A 
positive control (1 μL of 500 μM, synthetic ssDNA) and a negative control were included with each batch 
of samples. The efficiency of ligation of cfDNA fragments to biotinylated probes and ligation of double 
stranded adapters to primer-extended products was estimated using quantitative PCR [36]. On average 
0.8 × 109 unique ssDNA molecules (0.02–8.2 × 109) were ligated and PCR amplified (8 to 15 cycles). 
Adjusting the extension sequence primer with a 4-N overhang on the 5′ end (as in Karlsson et al. [46]), 
limited the occurrence of adapter dimers to, on average, one in 1,700 sequences. Libraries were sequenced 
on the Illumina MiSeq or HiSeq platform (2 × 75 bp). These settings resulted in an average of 5.7 ± 1.4 
million paired-end reads per sample, leading to an average human genome coverage of 0.23x ± 0.06x. 
Forty samples of cfDNA extracted from plasma of six double-lung transplant recipients were 
analyzed in this study. Results from ssDNA library preparation were compared against sequence data 
obtained for the same samples following conventional dsDNA library preparation where available (36 
matched samples, 18.8 ± 9.1 million paired-end reads per sample). The analysis of matched samples enabled 
us to assess the effect of different library preparations on measurements of cfDNA.  
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Mitochondrial consensus sequences were established for every transplant donor and recipient. 
DNA was extracted from whole blood samples (Qiagen DNeasy Blood & Tissue kit) collected pre-
transplant. Mitochondrial DNA was selectively amplified (Qiagen REPLI-g Mitochondrial DNA Kit), and 
sheared to 300 bp (Covaris). Libraries were prepared for sequencing using the NEBNext Ultra library 
preparation, characterized (Advanced Analytical Fragment Analyzer and dPCR) and sequenced 
(2 × 250 bp, Illumina MiSeq). One million sequences led to a per-base coverage greater than 100-fold 
(genome size 16.5 kb), sufficient to determine subject-specific mitochondrial variants. Fastq files were 
trimmed (Trimmomatic [47], LEADING:25 TRAILING:25 SLIDINGWINDOW:4:30 MINLEN:15) and 
aligned against the human reference genome [GenBank:GCA_000001305.2] using BWA-mem [48]. 
Sequences that mapped to the mitochondrial reference sequence (edited from GenBank:NC_012920) were 
extracted. A BCF file of SNPs was created and a FASTA consensus sequence was determined. A list of 
informative SNPs was created. 
Nuclear genomic sequences were assigned to the donor or recipient using methods previously 
described [2, 14]. Briefly, sequences were assigned to the donor or recipient based on SNP genotyping 
information (IlluminaHumanOmni2.5–8 or HumanOmni1 whole genome arrays) obtained from pre-
transplant whole blood samples. Mitochondrial sequences were assigned to the donor and recipient as 
follows: Raw sequencing datasets were trimmed (Trimmomatic [47], LEADING:20 TRAILING:20 
SLIDINGWINDOW:4:20 MINLEN:25), and low quality reads were filtered (FASTX toolkit  [49], -q 21 
-p 50) and aligned (BWA-mem [48]) to the human reference genome [GenBank:GCA_000001305.2], 
with changes made to the mitochondrial genome to account for the circular structure. Sequences that 
mapped to the mitochondrial reference [GenBank:NC_012920] were collected and SNPs were listed 
using SAMtools [50]. Sequences were assigned to the donor or recipient through comparison to the list 
of informative SNPs compiled for the donor-recipient pair. 
The analysis workflow used to quantify non-human cfDNA sequences is described in detail [2, 
3, 14]. Briefly, Low-quality bases and Illumina specific sequences were trimmed (Trimmomatic 0.32 
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[47]), and read pairs were merged using FLASH 1.2.7 [51]. Reads were aligned (Bowtie 2.1.0 [52]; very 
sensitive mode) against the human reference (UCSC hg19; https://genome.ucsc.edu/). Unaligned reads 
were extracted and BLASTed (2.2.28+) against a NCBI database [53]. Alignments were required to 
have an identity of at least 90% across 90% of the bases of the query. A relative genomic abundance of 
species was determined using GRAMMy [54]. Supplementary material pertinent to this data can be found 
at https://www.nature.com/articles/srep27859#supplementary-information. 
1.2.6 Ultrashort cell-free DNA provides a new perspective of origin and pathology 
  In this work, we have demonstrated that a ssDNA library preparation is sensitive to cfDNA of a 
broad range of types and lengths. Few studies have focused on ultra-short cfDNA (with lengths shorter than 
100 bp) or cfDNA that is not derived from the nuclear genome, including mitochondrial and microbial 
derived cfDNA. Our present work indicates that these relatively overlooked forms of cfDNA provide a 
unique window into physiology. 
We applied a ssDNA library preparation to the analysis of cfDNA in the plasma of lung transplant 
recipients. We report the first observation of graft-derived mitochondrial DNA in the plasma of these organ 
transplant recipients. Donor-derived mitochondrial cfDNA has not been investigated as a marker of acute 
rejection in solid-organ transplantation, but offers several advantages: (1) the mitochondrial genome is 
small and relatively straightforward to deeply characterize via sequencing, (2) the mitochondrial genome 
contains a great number of variants that enables differentiation of donor and recipient sequences, and (3) 
with thousands of copies of mitochondrial DNA present in every cell, mitochondrial cfDNA is abundant in 
plasma. Mitochondrial DNA has conserved similarities to bacterial DNA and contains inflammatogenic 
unmethylated CpG motifs [55]. It is therefore not surprising that mitochondrial DNA was identified as a 
powerful damage associated molecular pattern – an endogenous molecule that can activate innate immunity 
when released during cellular injury [56]. It is conceivable that the release of mitochondrial DNA that 
accompanies graft injury promotes many of the harmful immunologic responses observed in solid-organ 
transplantation. The results presented here provide the first window into this relationship. 
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Microbial cfDNA is present in the circulation and is the product of microbial degradation across 
the body or originates from microorganisms that infect the blood or translocate to the blood [57]. We found 
that the ssDNA library preparation is more effective at recovering bacterial and viral cfDNA, as compared 
to a dsDNA library preparation method. We furthermore found that the fragmentation profiles of microbial 
and mitochondrial DNA in plasma are highly similar, suggesting that they are exposed to similar 
degradation processes. These observations enable measurement of the bacterial and viral microbiome in 
plasma with greater sensitivity and at a reduced cost.  
Previous studies of the molecular size of nuclear genomic cfDNA have provided insight into the 
origin and nature of these molecules [58]. Many studies have noted that the predominant fragment size of 
cfDNA is consistent with the size of DNA wrapped around a single histone octamer [57]. Distinct length 
profiles are observed for cfDNA depending on their cellular origin with hematopoietically-derived DNA 
being longer than that of nonhematopoietically-derived [38]. Here, we found that the sequencing library 
preparation method can have a significant effect on length profile measurements. We report the 
fragmentation profile of nuclear genomic cfDNA in plasma over a broad range of lengths, and we conclude, 
in agreement with a recent report [23], that a considerable fraction of nuclear genomic cfDNA is non-
nucleosomal and subject to degradation by nucleases, in much the same way that we described for 
mitochondrial cfDNA. 
Figure 1.2.6.1 Fragment length distributions indicate the heterogeneity of degradation in various 
biological fluids. Fragment length distributions are shown for cfDNA originating from plasma (n = 40), 
urine (n = 40), and peritoneal dialysis effluent (n = 40). Samples were prepared using ssDNA library 
preparation. Figure assembled by Fanny Chen. {11} 
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In its current implementation, the ssDNA library preparation requires more hands-on time 
compared to standard protocol (~13 hours versus ~6 hours, for 12 samples) at a similar cost per sample 
($35-$40). This work focused on the cfDNA in plasma, but the methods described herein will further be 
relevant for genomic measurements of cfDNA in urine. We performed follow-up studies in a number of 
biological fluids relevant to clinical studies, including urine, amniotic fluid, and peritoneal dialysis effluent. 
The median fragment length of cfDNA originating in these fluids can vary considerably (Fig. 1.2.6.1). 
While plasma seems to have the largest fragments, on average, urinary cfDNA is highly fragmented, with 
relatively few fragments indicating the full nucleosome wrapping length of 167 bp (Fig. 1.2.6.1). It is, thus, 
necessary for library preparation assays to enrich ultrashort molecules for future discovery of noninvasive 
biomarkers. The widespread interest in circulating cfDNA as a marker of disease, warrants further 
investigation into the properties, types and origins of cfDNA and motivates further advances in genomic 
measurement techniques.  
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Chapter 3: Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract 
 
“Urinary tract infections are one of the most common infections in humans. Here we tested the utility of 
urinary cell-free DNA (cfDNA) to comprehensively monitor host and pathogen dynamics in bacterial and 
viral urinary tract infections. We isolated cfDNA from 141 urine samples from a cohort of 82 kidney 
transplant recipients and performed next-generation sequencing. We found that urinary cfDNA is highly 
informative about bacterial and viral composition of the microbiome, antimicrobial susceptibility, bacterial 
growth dynamics, kidney allograft injury, and host response to infection. These different layers of 
information are accessible from a single assay and individually agree with corresponding clinical tests based 
on quantitative PCR, conventional bacterial culture, and urinalysis. In addition, cfDNA reveals the frequent 
occurrence of pathologies that remain undiagnosed with conventional diagnostic protocols. Our work 
identifies urinary cfDNA as a highly versatile analyte to monitor infections of the urinary tract.” 
 
Chapter adapted from [5]: 
Burnham P, Dadhania D, Heyang M, Chen F, Westblade L, Suthanthiran M, Lee JR, De Vlaminck I. 





1.3.0 cfDNA sequencing to inform infections of the urinary tract 
Urinary tract infection (UTI) is one of the most common medical problems in the general 
population [59]. Among kidney transplant recipients, UTIs occur at an alarmingly high rate [60]. Bacterial 
UTI affects approximately 20% of kidney transplant recipients in the first year after transplantation [61] 
and at least 50% in the first three years after transplantation [62]. In addition, complications due to viral 
infection often occur. Up to 8% of kidney transplant recipients suffer nephropathy from BK polyomavirus 
(BKV) infection in the first three years after transplantation [63, 64]. Other viruses that commonly cause 
complications in kidney transplantation include adenovirus, JC polyomavirus, cytomegalovirus (CMV), 
and parvovirus [65]. The current gold standard for diagnosis of bacterial UTI is in vitro urine culture [66]. 
Although improved culture methods are being investigated [67, 68], bacterial culture protocols 
implemented in clinical practice remain limited to the detection of relatively few cultivable organisms [67]. 
Furthermore, urinalysis is often required in conjunction with culture to make treatment decisions [66]. A 
large number of ultrashort cfDNA fragments are present in plasma and urine [11, 27, 38, 69]. These 
molecules are the debris of the genomes of dead cells and offer opportunities for precision diagnostics based 
on ‘omics principles, with applications in pregnancy, cancer and solid-organ transplantation [2, 11–13].  
Here, we investigate the utility of urinary cfDNA to comprehensively monitor host and pathogen 
interactions that arise in the setting of viral and bacterial infections of the urinary tract. Using shotgun DNA 
sequencing, we assay cfDNA isolated from 141 urine samples collected from a cohort of 82 kidney 
transplant recipients, including recipients diagnosed with bacterial UTI and BKV nephropathy (BKVN). 
We recently developed a single-stranded DNA (ssDNA) library preparation, optimized for the analysis of 
short, highly fragmented DNA [4, 32, 36], and were able to sequence cfDNA isolated from relatively small 
volumes of urine supernatant (1 mL or less) with this method. We find that urinary cfDNA sequencing 
agrees in the vast majority of cases with conventional diagnostic testing, while also uncovering frequent 
occurrence of bacteria and viruses that remain undetected in conventional diagnostic protocols. We further 
investigated cfDNA-based analytic methods that go beyond microbial identification and provide a deeper 
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understanding of the infectious process. We show that rate of bacterial population growth can be estimated 
from an analysis of the bacterial genome structure and that this measurement can inform diagnosis of UTI. 
We further mined cfDNA for antimicrobial resistance (AR) genes and show that AR gene profiling can be 
used to evaluate AR. We observe that the relative proportion of kidney donor-specific cfDNA correlates 
with graft tissue injury in the setting of viral infection, and host immune cell activation in the setting of 
bacterial infection. As a follow-up study, we chose a subset of cfDNA patient samples from the cohort, 
treated them with sodium bisulfite, performed ssDNA library preparation [4], and used analysis of 
differentially methylated regions (DMRs) from methylated cytosines. These measurements indicate the 
tissue-of-origin of the cfDNA ensemble, which we used to show high abundance of kidney-derived and 
leukocyte-derived cfDNA in cases of BKVN and UTI, respectively. Collectively, our study supports the 
use of shotgun DNA sequencing of urinary cfDNA as a comprehensive tool for monitoring patient health 
and studying host-pathogen interactions. 
 
1.3.1 Biophysical properties of urinary cfDNA 
Urinary cfDNA is composed of human chromosomal, mitochondrial, and microbial cfDNA 
released from host cells and microbes in the urinary tract, and of plasma-derived cfDNA that passes from 
blood into urine [70]. Urine can be collected non-invasively in large volumes, and therefore represents an 
attractive target for diagnostic assays. Compared to plasma cfDNA, relatively few studies have examined 
the properties and diagnostic potential of urinary cfDNA. The urinary environment degrades nucleic acids 
more rapidly than plasma resulting in fewer DNA fragments that are also shorter [71]. Consequently, 
sequence analyses of urinary cfDNA have to date required relatively large (> 10 mL) volumes of urine [38, 
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72]. Here, we applied a ssDNA library preparation technique that employs ssDNA adapters and bead 
ligation to create diverse sequencing libraries that capture short, highly degraded cfDNA [4, 36] (Fig. 
1.2.2.1). We find that single-stranded library preparation enables sequence analyses of urinary cfDNA from 
just one milliliter of urine supernatant. We tested 141 urine samples collected from 82 kidney transplant 
recipients, including subjects diagnosed with bacterial UTI and BKVN (overview of post-transplant dates 
and categories depicted in Fig. 1.3.1.1a). We obtained 43.5 ± 17.3 million paired-end reads per sample, 
yielding a per-base human genome coverage of 0.49x ± 0.24x. Many fragments derived from microbiota; 
for example, for subjects diagnosed with bacterial UTI, bacterial cfDNA accounted for up to 34.7% of the 
raw sequencing reads and in cases of BKVN, BKV cfDNA accounted for up to 10.3% of raw sequencing 
reads. To account for technical variability and sources of environmental contamination during extraction 
and library preparation, a known-template control sample was included in every sample batch and 
sequenced (see Section 1.3.9). 
We analyzed the fragment length profiles of urinary cfDNA at single nucleotide resolution using 
paired-end read mapping [48]. This analysis confirmed previous observations of the highly fragmented 
nature of urinary cfDNA compared to plasma cfDNA [72] (Fig. 1.3.1.1b). We observed a 10.4 bp 
periodicity in the fragment length profile of chromosomal cfDNA (Fourier analysis, Fig. 1.3.1.1b, inset), 
Figure 1.3.1.1 Shotgun sequencing assay and biophysical properties of urinary cfDNA. (a) Study design 
included patient samples, in health and infection, from one day to six years after transplant. Fragment length 
distributions and Fast Fourier Transform (FFT, 60 – 140 bp, inset) for cfDNA from organisms with 
nucleosomal packaging (b) and without such packaging (c). {12} 
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consistent with the periodicity of DNA-histone contacts in nucleosomes [73]. BKV is known to hijack 
histones of infected host cells, and to form mini-chromosomes after infection [74]. The periodicity in the 
fragment length profiles of BKV cfDNA in urine reflect this biology (Fig. 1.3.1.1b). We did not observe a 
similar nucleosomal footprint for bacterial and mitochondrial cfDNA, or cfDNA arising from parvovirus 
B19, which is expected given the non-nucleosomal compaction of the genomes that contribute these cfDNA 
types (Fig. 1.3.1.1c).  
 
1.3.2 Screening the infectome for multiple pathogenic agents 
We assessed the presence of cfDNA from bacterial and viral pathogens reported by conventional 
diagnostic assays. We used bioinformatics approaches to estimate the relative genomic representation of 
different species (see Section 1.3.9) [1, 54]. To directly compare the microbial abundance across samples, 
we computed the representation of microbial genome copies relative to human genomes copies, and 
expressed this quantity in relative genome equivalents (RGE).  
Figure 1.3.2.1 Diagnostic comparison of microbial cfDNA sequencing in UTI to gold standard 
technologies. (a) The relative genomic abundance is shown for BK polyomavirus for patients who tested 
positive or negative for polyomavirus nephropathy via renal biopsy, and for those untested. (b) Bacterial 
species were ranked according to relative genomic abundance within each sample for patients with culture-
diagnosed UTI. The ranked position of the species was compared to that identified by standard urine culture. 
(c) Receiver-operator characteristics for samples originating from samples with Enterococcus, E. coli, and 
P. aeruginosa UTI. {13} 
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We detected a very high load of BKV cfDNA in all 25 samples collected from 23 subjects 
diagnosed with BKVN by needle biopsy (mean 1.49 ± 1.08 x 105 RGE, Fig. 1.3.2.1a), but not in 10 samples 
from 10 subjects that were BKVN negative per biopsy (all below detection limit). In these 35 biopsy-
associated samples, the BKV cfDNA abundance correlated with a matched urine cell pellet BKV VP1 
mRNA copy measurement that we previously validated as a noninvasive marker for BKVN (corr. = 0.74, 
Spearman, p = 3.48 x 10-7) [75, 76].  
We quantified bacterial urinary cfDNA in 43 urine samples from 31 subjects who had a 
corresponding positive culture from urine obtained on the same day. For 41 of the 43 positive urine 
specimens, a bacterial organism was reported to the species level by conventional culture. In 40 of these 41 
samples, sequencing of urinary cfDNA detected the clinically reported organisms to the species level (Fig. 
1.3.2.1b). For a single sample, urinary cfDNA did not match with the bacterial culture: Raoultella 
ornithinolytica was isolated in culture, but not detected by cfDNA sequencing (see Methods for a detailed 
discussion of this discordant readout). For two of the 43 clinically positive samples, the suspected etiologic 
agent was identified to the genus level (Staphylococcus, reported as coagulase-negative Staphylococcus 
species [CoNS], and Streptococcus, reported as viridans group streptococci) by culture. In both these cases 
the reported organism was detected as the most prevalent within the sample. From the 43 cultures, we 
examined six with polymicrobial bacterial infection (defined as two individual bacterial taxon detected at 
the genus or species level). For five out of six of these cases, we observed both species among the 10 most 
abundant species by cfDNA sequencing. In one sample, the secondary bacterial agent, CoNS (< 10,000 
colony forming units [cfu]/mL), was not detected. 
To further assess the performance of urinary cfDNA for microbial identification, we compared the 
relative genomic abundance (in RGE) of bacterial cfDNA for subjects diagnosed with bacterial infection 
(49 bacterial isolates identified from 43 clean-catch midstream cultures), to the relative genomic abundance 
(in RGE) measured for 43 negative clean-catch midstream urine cultures, (Fig. 1.3.2.1c). We found 
agreement between urinary cfDNA and culture based isolation of Enterococcus faecalis (number of 
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matched positive cultures, n = 11, Area Under the Curve [AUC] = 0.97, 95% Confidence Interval [CI] = 
0.935-1), Enterococcus faecium (n = 2, AUC = 0.98, CI = 0.976-1), Escherichia coli (n = 21, AUC = 0.97, 
CI = 0.93-1), Klebsiella pneumoniae (n = 3, AUC = 1.00, CI = 1), Pseudomonas aeruginosa (n = 3, AUC 
= 1.00, CI = 1), CoNS (n = 4, AUC = 0.78, CI = 0.46 - 1). Here, receiver operating characteristic (ROC) 
analysis was performed for bacterial species where there was at least one positive culture of the same 
organism available (n > 1).  
In only 60% of examined samples (26/43 UTI cases) was the organism identified in culture the 
most prevalent organism in the sample as measured by cfDNA (Fig. 1.3.2.1b). Whereas bacterial culture is 
skewed towards species that are readily isolated on routine bacteriological media employed for urine 
culture, cfDNA sequence analyses permit the identification of a broader spectrum of bacterial species. To 
evaluate this concept further, we assayed two samples collected from one of the subjects included in the 
analysis above diagnosed with Haemophilus influenzae bacteriuria. H. influenzae is an uncommon 
uropathogen that does not routinely grown on media employed for conventional urine culture (tryptic soy 
agar with sheep blood and MacConkey agar) [77]. Repeated urine cultures for this patient were negative, 
but given a urinalysis suggestive of a UTI and given that the patient developed H. influenzae bacteremia, 
the original urine specimen collected at presentation was re-plated onto chocolate agar, upon which H. 
influenzae was isolated. We observed H. influenzae cfDNA in the sample taken at the time of presentation 
and a sample taken four days after presentation (0.037 RGE and 0.41 RGE, respectively). This case supports 
the utility of urinary cfDNA to identify infections where conventional culture fails. 
  
1.3.3 Profiling the urinary microbiome 
The urinary tract was regarded as sterile but recent studies have revealed that it may harbor 
microbiota [68, 78, 79]. We examined the composition of the urinary microbiome by urinary cfDNA 
profiling (absence of UTI, n = 43), or collected within the first three days post-transplant (n = 12). We find 
35 
 
that the species-level abundance and the species-level diversity of the bacteriome are a function of the 
transplant recipient gender but not the donor gender (Fig. 1.3.3.1). On average, we observed two to three 
orders of magnitude more cfDNA from Gardnerella (6125x), Ureaplasma (1686x), and Lactobacillus 
(321x) across female transplant recipients who did not have a UTI at time of sampling compared to male 
recipients who did not have UTI; these bacterial genera have been characterized as microbial components 
of the vaginal microbiome [80]. We examined the relationship between urine collection methods and the 
abundance and diversity of the bacteriome and find a notably reduced bacterial load for samples collected 
by indwelling catheter (samples collected within four days after transplant) versus clean catch urine 
samples. cfDNA may be an ideal tool to study the urinary microbiome, but such future studies need to 
account for effects of gender and sample collection approaches.  
 
1.3.4 Broad screening for viruses via cfDNA 
We next screened for the occurrence of cfDNA derived from viruses. Nearly half of the samples 
(66/141) had detectable levels of cfDNA derived from eukaryotic viruses that are potentially clinically 
relevant. Figure 1.3.4.1 highlights the frequent occurrence of JC polyomavirus, parvovirus B19, Merkel 
cell polyomavirus, CMV, human herpesvirus 6A, human herpesvirus 6B, and various known oncoviruses 
Figure 1.3.3.1 Bacterial diversity and abundance measurements in urinary cfDNA for patient samples 




across different patient groups. In several samples, we detected cfDNA from multiple polyomavirus species 
concurrently (JC polyomavirus or BKV). To shed light on the potential clinical utility of broad screening 
for viruses via cfDNA, we assayed serial urine from three subjects diagnosed with viral infections that are 
relatively uncommon in kidney transplant recipients and consequently not routinely screened for in our 
patient cohorts. In samples from two subjects with clinically diagnosed parvovirus B19 infection, we 
detected urinary cfDNA from parvovirus B19 eight days prior to the clinical diagnosis in one subject and 
urinary parvovirus B19 cfDNA 80 days before diagnosis and 25 days after diagnosis in another subject. In 
the former subject, we observed a high abundance of both BKV (3.54 x 104 RGE) and parvovirus B19 (2.48 
x 104 RGE), which correlated with positive results of individual viral-specific PCR tests for BKV and 
parvovirus B19. For a third patient, we observed a high abundance of human adenovirus B DNA, in samples 
obtained 15 days before (2.52 x 103 RGE) and nine days after (5.08 x 102 RGE) adenovirus infection 
diagnosis by clinical urine DNA PCR. These data support the utility of urinary cfDNA sequencing for the 
detection of both common and uncommon viral agents. 
Figure 1.3.4.1 Urinary cfDNA profiles the human virome. Viral cfDNA was detected in 66 samples of 
the 141 samples. cfDNA reveals frequent occurrence of viruses that are potentially clinically relevant 
(left panel); red crosses identify samples belonging to subjects who developed an infection of the 
corresponding viral agent. Right-most panel shows boxplots of the viral cfDNA abundance across all 
samples. Color of points and boxplots by viral family. {15} 
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The high prevalence of cfDNA attributed to viral genomes allows additional, more detailed genetic 
analysis. Multiple BK polyomavirus genomic subtypes exist in the global population with various antigenic 
properties [81]. Recently, Morel at al. have demonstrated a method to rapidly subtype BK polyomavirus 
through algorithmic query of SNPs [82]. To our knowledge, it is unknown if certain BK polyomavirus 
subtypes are more likely to result in more acute cases of BKVN or higher viral abundance during 
reactivation. However, it is accepted that the pathogenic BK polyomavirus is derived from the donor, and 
HLA mismatches result in faster and more severe cases of BK reactivation in renal transplant recipients 
[83].  
Figure 1.3.4.2 Phylogenetic reconstruction of BK polyomavirus VP1 consensus sequences assembled 
from urinary cfDNA. BEAST software was used to find the most likely tree given a constant population 
over time. Nodes represent points of genetic separation. Leaves are annotated with sample identifier and 
positioned at time of sampling. Colors correspond to BK polyomavirus spread assessed in renal biopsy 
samples (blue = low, magenta = moderate, orange = diffuse). {16} 
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The ability to construct viral genomes at single nucleotide resolution allowed us to subtype BK 
polyomavirus using a SNP-based decision tree [82]. Of the twenty-two patients in this study with BKVN, 
we identified most had BK polyomavirus subtype I (seven patients with subtype Ia, three patients with 
subtype Ib-1, eight patients with subtype Ib-2), while few had BK polyomavirus subtypes II (n = 2) and III 
(n = 2). We did not observe an association between BK subtype and clinical measurements of pathogenicity, 
though studies have indicated subtype distribution differs by geographic location [84]. For two patients 
with follow up time points, we compared VP1 sequences to identify any selective evolution on shorter time 
scales (~50 days) within a singular patient. In both cases we observed identical VP1 consensus regions.  
Our patient sampling method did not allow for us to observe BK subtype changes in kidney 
recipients over time. However, we were able to reconstruct a phylogenetic tree for the twenty-two patients 
with clinically diagnosed BKVN. We aligned non-human reads directly to the BK polyomavirus reference 
genome [48] (NCBI accession NC_001538) and removed duplicate regions (Samtools removedup) [50]. 
We then constructed a consensus sequence by calling the most abundant nucleotide at each positive across 
the genome (Samtools mpileup and vcftools). We restricted the consensus sequence to the VP1 gene 
segment (positions 1564 to 2652 bp) on the forward strand. BK polyomavirus VP1 protein is the outer 
capsid protein and is most often used for subtyping. We used sampling dates recorded by clinicians and the 
988 bp VP1 consensus regions for all twenty-two samples into BEAST [85], a tool to construct phylogenetic 
trees using Bayesian evolutionary analysis. We ran 250 million samplings in the Monte Carlo simulator 
assuming constant population size and heterogeneous rates of evolution among the three positions in each 
codon. The program produced a highest maximum likelihood tree (Fig. 1.3.4.2) that identified two distinct 
lineages beginning in 2008 (21 of 22 samples were sequenced after this point). We analyzed the tree with 
respect to dispersion of polyomavirus particles as seen in needle biopsies. We observed a higher likelihood 
of diffuse infection for patients with BK polyomavirus in the upper branch of the phylogenetic tree 
(Fig.1.3.4.2). The probability of six of the seven diffuse cases in the upper branch is low, P = 0.118, but not 
significant. By comparing the date of biopsy with the phylogenetic information, we could determine the 
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average rate of mutation of polyomavirus among those infected in the cohort as 7.6 x 10-6 substitutions per 
site per year on the VP1 exon. This is similar to previous reports for BK polyomavirus isolated from 
transplant recipients [86]. Our analysis indicates the addition of more samples and samples taken 
longitudinally from the same patients will identify the inter- and intrahost evolutionary patterns. 
 
1.3.5 Quantifying bacterial growth rates 
Conventional metagenomic sequencing can provide a snapshot of the microbiome, yet does not 
inform about microbial life cycles or growth dynamics. In a recent study, Korem and colleagues reported 
that the pattern of metagenomic sequencing read coverage across a microbial genome can be used to 
quantify microbial genome replication rates for microbes in complex communities [87]. We tested whether 
this concept can be used to estimate bacterial population growth from measurements of cfDNA. Figure 
Figure 1.3.5.1 Estimating bacterial population growth rates from urinary cfDNA. (a) Normalized bacterial 
genome coverage for four representative bacterial species. The coverage was binned in 1 kbp tiles and 
normalized. Each panel represents a single sample, with the exception of C. acnes (*) for which the 
coverage was aggregated across 99 samples (solid line is a LOESS filter smoothing curve, span = 0.70). 
The non-uniform genome coverage for E. coli and K. pneumoniae, with an overrepresentation of sequences 
at the origin of replication, is a result of bi-directional replication from a single origin of replication. The 
initial and final 5% of the genome is removed for display. (b) Box plots of growth rates for species in 14 
genera grouped by patient groups (at least 2500 alignments, 41 samples, see Methods for definition of 
pre/post-UTI). Each point indicates a bacterial species in a sample. Triangles indicate culture-confirmed 
bacteria by genus. Boxplot features are described in Section 1.3.9. {17} 
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1.3.5.1a shows the urinary cfDNA sequence coverage for four bacterial species, E. coli, K. pneumoniae, 
Gardnerella vaginalis and Cutibacterium acnes. For two subjects diagnosed with E. coli and K. pneumoniae 
UTI (Fig. 1.3.5.1a), the E. coli and K. pneumoniae genome coverage was non-uniform, with an 
overrepresentation of sequences at the origin of replication and an underrepresentation of sequences at the 
replication terminus. The shape of the E. coli and K. pneumoniae genome coverage is a result of bi-
directional replication from a single origin of replication. The skew in genome coverage reflects the 
bacterial population growth rate, where a stronger skew signals faster population growth [88]. The genome 
coverage of a common inhabitant and sometimes uropathogenic bacterial species, G. vaginalis, exhibited 
non-uniform genome coverage (Fig. 1.3.5.1a), similar to the E. coli and K. pneumoniae cases above but 
less pronounced. C. acnes has been recognized as a common skin commensal and contaminant in the setting 
of molecular assays [89]. The genome coverage for C. acnes, was highly uniform, indicative of slow or no 
growth (aggregate across 99 samples, which had C. acnes cfDNA detected, Fig. 1.3.5.1a).  
We asked whether this measure of bacterial growth can be used to inform bacterial UTI diagnosis. 
We calculated an index of replication based on the shape of the sequencing coverage using methods 
described previously [88]. We used BLAST to identify abundant bacterial strains and then re-aligned all 
sequences with BWA [48] to a curated list of bacterial species. Samples for which the genome coverage 
was too sparse were excluded from this analysis (see Section 1.3.9). Figure 1.3.5.1b compares the index of 
replication for bacteria detected by cfDNA in samples from subjects diagnosed with UTI, to the index of 
replication for bacteria detected by cfDNA in samples from subjects with negative cultures and in samples 
collected from subjects prior to UTI development (Pre-UTI Group) or after UTI development (Post-UTI 
Group). Species categorized in the UTI group had markedly greater growth rates, than those in the no UTI 




1.3.6 Antimicrobial resistome profiling 
For 42 of 43 samples collected from subjects with clinically confirmed UTIs, we determined the 
relative abundance of genes conferring resistance to several classes of antimicrobials (a single sample, for 
which no AR gene fragments were observed, was excluded from this analysis). We used blastp to align 
non-human sequences against known AR genes and mutations [90]. AR gene sequences were aggregated 
and called against the non-redundant Comprehensive Antibiotic Resistance Database that indicates the drug 
resistance conferred by the given gene [90]. 
We compared the results of phenotypic antimicrobial susceptibility testing (see Section 1.3.9) to 
the resistance profiles determined by cfDNA sequencing. For most samples, there was a high diversity in 
alignments with highly abundant resistance classes including resistance to macrolides, aminoglycosides, 
and beta-lactams (Fig. 1.3.6.1). We studied vancomycin-resistant Enterococcus (VRE) infections, which 
Figure 1.3.6.1 cfDNA-based antimicrobial resistome profiling reveals vancomycin resistant 
enterococcus. For 42 samples from subjects with clinically confirmed UTI, AR gene profiling reveals the 
presence of genes conferring resistance to various antimicrobial classes. These data are organized in three 
sample groups: samples from subjects with vancomycin-resistant Enterococcus (Resistant), samples from 
subjects with vancomycin-susceptible Enterococcus (Susceptible), and samples from subjects for which 
vancomycin resistance testing was not performed. Blue highlight indicates the AR class in which 
vancomycin resides. Black squares indicate at least one alignment. More than one alignment is indicated 
by red shading. {18} 
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often lead to complications after transplantation [65], in depth. Resistance to vancomycin was clinically 
assessed via measurement of the minimum inhibitory concentration value using broth microdilution on the 
MicroScan WalkAway platform according to the manufacturer’s instructions. We detected fragments of 
genes conferring resistance to the glycopeptide antibiotic class, of which vancomycin is a member, for all 
VRE positive samples (n = 4). Moreover, for samples with Enterococcus that tested as vancomycin 
susceptible (n = 7), we did not detect fragments of glycopeptide class resistance genes (Fig. 1.3.6.1). These 
data indicate potential to predict antimicrobial susceptibility from measurements of urinary cfDNA.  
 
1.3.7 Measuring the host response to infection 
We next examined the host response to viral and bacterial infections. Recent work has identified 
transplant donor-specific cfDNA in plasma as a marker of graft injury in heart, lung, liver and kidney 
transplantation [2, 3, 33, 91]. Here, we quantified donor-specific cfDNA in urine for sex-mismatched donor 
recipient pairs (i.e., male donor, female recipient; female donor, male recipient) by counting cfDNA 
molecules aligning to the human Y chromosome (Fig. 1.3.7.1a). We observed elevated levels of donor 
cfDNA in the urine of subjects diagnosed with BKVN (mean proportion of donor DNA 65.1%, n = 12) 
compared to the urine of subjects who had normal biopsies (no BKVN, mean 51.4%, n = 4) and samples 
from subjects who did not develop a clinical UTI in the first three months of transplantation (mean 25.5%, 
n = 11, samples collected within five days after transplant excluded). The release of donor DNA reflects 
severe cellular and tissue injury in the graft, a hallmark of BKVN. In contrast to subjects with BKVN, 
subjects diagnosed with bacterial UTI had lower proportions of donor DNA as compared to individuals 
without bacterial UTI. This is likely explained by an elevated number of recipient immune cells in the 
urinary tract following immune activation. Indeed, comparison to clinical urinalysis indicates that the donor 
fraction decreases with increasing white blood cell (WBC) count per high power field (HPF) 400x 
microscope magnification (inset Fig. 1.3.7.1a; corr. = -0.57, Spearman, p = 1.3 x 10-4). Furthermore, clinical 
cases of pyuria, defined as greater than ten WBC per HPF [92], had a lower donor fraction than those 
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without (two-tailed Wilcox test, p = 8.0 x 10-4). In addition, we found that the level of donor cfDNA in the 
first few days after transplant was elevated, consistent with early graft injury. We tracked the relative and 
absolute abundance of donor-specific urinary cfDNA in the first few days after transplantation for a small 
Figure 1.3.7.1 The host response to infection can be quantified using urinary cfDNA. (a) Proportion of 
donor-specific cfDNA in urine of subjects that are BKVN positive per kidney allograft biopsy (BKVN) in 
urine collected in the first 5 days after transplant surgery (Early), urine collected from subjects that are 
bacterial UTI negative per culture in the first month following transplantation (No UTI), samples collected 
before or after bacterial UTI (Pre-/Post-UTI), and samples collected at the time of bacterial UTI diagnosis 
(UTI). The single outliers in Pre-/Post-UTI and UTI groups correspond to the same patient, who suffered 
an acute rejection episode in the months prior. Low donor fractions in the Pre-/Post-UTI and UTI groups 
are likely due to increased immune cell, i.e., WBC, presence in the urinary tract; subjects with higher WBC 
counts have lower donor fractions (inset, red color indicates pyuria). (b) Absolute abundance of donor 
cfDNA in the urine of subjects not diagnosed with infection in the first month post-transplant (red line is 
a LOESS filter smoothing curve, span = 1). Dotted lines connect samples from the same patient. (c) 
Genome coverage at the transcription start site, binned by the gene expression level across all samples in 
the study. TSS = transcription start site. FPKM = fragments per kilobase of transcript per million mapped 
reads, an RNA-seq measure of gene expression. {19} 
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subset of subjects (n = 5). The initial elevated level of donor cfDNA quickly decayed to a lower baseline 
level (Fig. 1.3.7.1b), in line with previous observations in heart and lung transplantation [2, 3]. 
Two studies recently demonstrated that the structure of chromatin in gene promoters is conserved 
within circulating cfDNA in plasma [23, 24]. Ulz et al. employed whole-genome sequencing of plasma 
DNA to show that nucleosomal occupancy at transcription start sites results in different read depth coverage 
patterns for expressed and silent genes [24]. Here, we found that footprints of nucleosomes in gene 
promoters and transcriptional regulatory elements are conserved within urinary cfDNA (Fig. 1.3.7.1c, 
aggregation and normalization across all samples), and that the extent of nucleosomal protection is 
proportional to gene expression. Measurements of nucleosomal depletion can serve as a proxy for increased 
gene expression and may be used to investigate host-pathogen interactions in more detail. 
Mitochondrial cfDNA (mt-cfDNA) in the urine was recently identified as a possible biomarker for 
hypertensive kidney damage [93]. Furthermore, recent data indicate a role for extracellular mitochondrial 
DNA as a powerful damage-associated molecular pattern (DAMP) [55]. Elevated levels of mtDNA in 
plasma have been reported in trauma, sepsis and cancer, and recent studies have identified mtDNA released 
into the circulation by necrotic cells [94]. For a small subset of subjects diagnosed with BKVN (eight 
samples from seven subjects), we quantified donor- and recipient-specific mt-cfDNA in urine, using an 
approach we have previously described in Section 1.2 [4]. We found that the graft is the predominant source 
of mitochondrial urinary cfDNA in seven of the eight samples (two-tailed Student’s t-test, p < 10-6; see 
Section 1.3.9). Molecular techniques to track DAMPs in urine released in the setting of kidney graft injury 





1.3.8 Identification of the tissue-of-origin of urinary cfDNA 
Metagenomic cfDNA sequencing is only able to determine donor from recipient molecules by 
analysis of SNPs [2, 3, 95] or sex chromosomes, as shown in Section 1.3.7. It follows that tissue- and cell-
level origin of molecules is difficult to determine due to the lack of SNP markers. We have previously 
mentioned techniques using cfDNA sequencing coverage to infer tissue-of-origin of the collection of 
cfDNA molecules [23, 24], though these techniques require sequencing at high depth. However, epigenetic 
marks are unique to DNA originating from particular organs, tissues, and cell lines within an individual 
organism [96]. One such signature present with tissue-level uniqueness is the presence of cytosine 
methylation in eukaryotic DNA [97]. 5-methylcytosine is a transcriptional regulator and is most often 
associated with the suppression of transcription for particular genes [97]. These marks persist on cfDNA 
molecules, but are not observed using standard sequencing methods. However, when sodium bisulfite is 
applied to the single-stranded DNA, unmethylated cytosines are deaminated into uracils, and methylated 
cytosines are unaffected [98]. When standard library preparation is carried out on these molecules, the 
resulting sequencing libraries carry a thymine in the place of unmethylated cytosines and retain their 
identity as a cytosine if a methyl group was present originally [98]. By comparing the treated sample to 
reference genomes, it is possible to determine the location of methylated CpGs at single base resolution 
[99]. 
 Recent studies have applied the bisulfite treatment (BT) protocol to plasma and urine cfDNA [100, 
101]. However, the bisulfite conversion process requires that DNA molecules are single-stranded, thus 
reducing the efficiency of library preparation using standard methods [102]. We applied our single-stranded 
library preparation approach to a subset of samples from the kidney transplant cohort (n = 51), to test the 
efficiency of the library preparation process from cfDNA acquired from a milliliter of urine or less. 
Conversion efficiencies for this process exceeded 90% in samples (as measured at CH dinucleotides), and 
we were able to sequencing hundreds of millions of molecules per sample, with low duplication rates.  
46 
 
 A full description of techniques used in BT cfDNA sequencing analysis are outside of the scope of 
this work. Briefly, a collection of differentially methylated regions (DMRs) from a series of reference 
databases from whole-genome BT sequencing is filtered to reveal regions of the genome uniquely 
describing the methylation state of tissues within the reference [96, 99]. The methylation percentage is then 
calculated across the genome of the cfDNA sample and quadratic programming is used to delineate the 
contribution of reference tissues to the samples [103]. We applied the sex-mismatched donor fraction 
measurements described above to the BT cfDNA samples and compared that to the fraction of molecules 
determined to originate from the kidney (Fig. 1.3.8.1a). The measurements were highly correlated with one 
another (corr. = 0.879, Spearman, p < 10-10, n = 44), and agreed with donor fraction determined in matched 
samples in our previous work. Using linear regression (with y-intercept fixed at 0) we found the tissue 
Figure 1.3.8.1 Bisulfite-treated cfDNA sequencing indicates tissue of origin of cfDNA ensemble. (a) 
Measured donor fraction is compared to the kidney fraction for bisulfite-treated urinary cfDNA samples. 
Solid line indicates exact match. (b) The mean tissue proportion for each pathological group in the study 
is shown. (c) Tissue fraction is multiplied by total cfDNA extracted in urine to determine amount of 
cfDNA originating from organ. We compare Kidney (left) and White Blood Cell (WBC, right) cfDNA 
levels (ng / mL urine) across four pathological groups. {20} 
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fraction was 84.7% of the measured donor fraction, on average. In two samples we identified a high donor 
fraction but a low kidney fraction. This patient received a bone marrow transplant from the kidney donor, 
making it impractical to determine the donor fraction, while the kidney fraction could still be obtained. 
 Importantly, when breaking the samples down into patient groups, an average profile of all the 
tissues contributing to the cfDNA in the urinary tract can be observed (Fig. 1.3.8.1b). For instance, in 
samples with corresponding BK polyomavirus infections (with and without nephropathy), we observed an 
enriched fraction in cfDNA originating from the kidney compared to other tissue types (~50% from kidney). 
In samples with clinically-confirmed UTIs, we determined an enrichment in neutrophils and other WBC 
groups compared to healthy controls, confirming the insights we made in the previous study (Fig. 1.3.8.1b).  
 To further stratify the patient groups, we multiplied the tissue fractions by the concentration of 
cfDNA in urine, measured after cfDNA extraction. This measurement revealed the total amount of cfDNA 
originating from each tissue present in the urine. We observed significant enrichment (p < 0.01, two-tailed 
Wilcox rank sum test) in the amount of kidney-derived cfDNA between patients with BK polyomavirus 
nephropathy compared to patients with BK polyomavirus reactivations without nephropathy (BKV+/N-) 
(Fig. 1.3.8.1c). Similarly, cfDNA originating from leukocytes was enriched in patients with BKVN and 
BKV+/N-, compared to patients with normal biopsies. These measurements allow for the stratification of 
samples by pathology with high resolution. We also determined that the use of bisulfite treatment does not 
alter measurements of the relative abundance of microbial pathogens. Our results indicate that BT cfDNA 
sequencing may be used to more deeply describe the origin of cfDNA as well as distinguish cases of 
infection from infectious disease.  
 
1.3.9 Detailed methods and sample selection 
Study cohort and sample collection. One hundred and forty one urine samples were collected from kidney 
transplant recipients who received care at New York Presbyterian Hospital–Weill Cornell Medical Center. 
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We assayed urine samples from a total of 82 subjects. We assayed urine samples from a total of 82 subjects. 
The study was approved by the Weill Cornell Medicine Institutional Review Board (protocols 9402002786, 
1207012730, 0710009490). All patients provided written informed consent. Bacterial group: We included 
99 urine samples from 34 subjects who developed bacterial UTI diagnosed within the first 12 months of 
transplantation and 14 subjects who never developed UTI within the first 3 months of transplantation. For 
the 34 subjects who developed UTIs, we assayed 43 urine samples corresponding to same day positive 
urine cultures (UTI group); we assayed 15 urine samples from 15 subjects, collected at least 2–16 days 
(median 7 days) prior to development of the positive urine cultures (Pre-UTI group), and we assayed 12 
urine samples from 9 subjects, collected at least 3–26 days (median 9 days) after development of the positive 
urine cultures (Post-UTI group) (7 of the 9 subjects were treated with antibiotics). We assayed a total of 29 
samples collected within 3 months after transplantation from 14 subjects who never developed UTI in the 
first 3 months of transplantation. Viral group: The study further included 25 samples from 23 subjects who 
had a corresponding positive diagnosis of BKVN by needle biopsy of the kidney allograft (BKVN-positive 
group, 1 sample was also associated with a positive bacterial urine culture) and 10 samples from 10 subjects 
who had a normal protocol biopsy and were negative for BKV (BKVN-negative group). Finally, the study 
analyzed seven samples from three subjects who developed clinically diagnosed rare viral infections, 
including parvovirus or adenovirus.  
Conventional bacterial culture, bacterial identification. Ninety of the 141 samples in the study had a 
corresponding same day urine culture. Each of these clean-catch midstream culture urine samples was 
inoculated onto tryptic soy agar with sheep blood (Becton, Dickinson and Company [BD], Franklin Lakes, 
NJ) and MacConkey agar (BD) using a 1-μL inoculation loop and incubated in ambient air at 35 °C. Four 
urine samples were reported as mixed bacterial flora and were excluded because of lack of further 
identification and 86 samples were defined as either negative urine culture (n = 43) or positive urine culture 
(n = 43) for the cfDNA/bacterial correlation analyses and ROC analyses. A positive urine culture was 
defined as a culture growing an organism identified to at least the genus level (almost all bacterial isolates 
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were recovered at a colony count ≥10,000 cfu/mL, while three isolates were recovered at a colony count < 
10,000 cfu/mL). A urine culture was defined as negative when either no organism was isolated in culture 
(35 cultures, < 1000 cfu/mL) or the organism was unidentified to either the genus or species level (i.e., 
unidentified) and the colony count was < 10,000 cfu/mL (8 cultures). Bacterial isolates were identified 
using either abbreviated identification algorithms [104] or MicroScan (Beckman Coulter, Inc., West 
Sacramento, CA) identification panels: Neg ID Type 2 panel for Gram-negative bacteria and Pos Combo 
33 panel for Gram-positive bacteria, in conjunction with the WalkAway plus system (Beckman Coulter, 
Inc.). In two cases, the organism isolated in culture was identified using the MALDI Biotyper CA System 
(Bruker Daltonics, Inc., Billerica, MA). Testing on the WalkAway plus and MALDI Biotyper CA systems 
was performed per the manufacturer’s instructions.  
Antimicrobial susceptibility testing. Antimicrobial susceptibility testing was performed using broth 
microdilution or disk diffusion. Broth microdilution testing was accomplished using MicroScan 
antimicrobial susceptibility testing panels on the WalkAway plus system according to the manufacturer’s 
instructions. Gram-negative organisms were tested using the Neg MIC 42 panel or the Pos Combo 33 panel 
for Gram-positive organisms. In a single instance, an E. faecalis isolate was assayed with the Pos MIC 34 
panel. An isolate of H. influenzae was tested using the disk diffusion method as recommended by the 
Clinical and Laboratory Standards Institute (CLSI) M02-A12 [105]. All antimicrobial susceptibility data 
were interpreted according to the CLSI M100 document. The M100 version used for interpretation varied 
depending on the year the isolate was recovered in culture: M100-S25 (2015) [106], M100-S26 (2016) 
[107], and M100-S27 (2017) [104]. 
Conventional viral identification. Quantitative adenovirus and parvovirus B19 PCR was performed on urine 
samples in an outside reference laboratory (Viracor Eurofins, Lee’s Summit, MO). 
Analysis of discordance against bacterial culture. In a single sample, urinary cfDNA did not identify the 
organism reported by conventional culture: R. ornithinolytica. The patient had developed an E. coli UTI on 
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postoperative day 6 and was treated initially with aztreonam but switched to cephalexin for a 14-day course. 
The subject subsequently developed a UTI that conventional bacterial culture revealed to be R. 
ornithinolytica on postoperative day 25. cfDNA analysis on urine samples collected on postoperative days 
6 and 25 revealed a high abundance of E. coli cfDNA and no evidence of R. ornithinolytica cfDNA. Given 
the discordant results, it is unclear if the second culture growing R. ornithinolytica is a recurrence as 
suggested by the cfDNA analysis or is an infection with a different organism as suggested by the urine 
culture data. 
Urine collection and supernatant isolation. Most urine samples were collected via the conventional clean-
catch midstream culture method (n = 130). Samples obtained prior to post-transplant day 4 were collected 
via indwelling catheter (n = 11). Approximately 50 mL of urine was centrifuged at 3000 × g on the same 
day for 30 min and the supernatant was stored at −80 °C in 1 or 4 mL aliquots (except for a single H. 
influenzae UTI sample which was centrifuged for cfDNA analysis 5 days after collection). cfDNA was 
extracted from 1 mL (131 samples) or 4 mL (10 samples) of urine according to the manufacturer’s 
instructions (Qiagen Circulating Nucleic Acid Kit, Qiagen, Valencia, CA). 
Negative control. To control for environmental and sample-to-sample contamination, a known-template 
control sample (IDT-DNA synthetic oligo mix, lengths 25, 40, 55, 70 bp; 0.20 µM eluted in TE buffer) was 
included with every sample batch and sequenced to a fraction of the depth of the cfDNA extracts (~5 million 
fragments). The number of bacterial and viral reads detected in the controls was quantified for each genus 
and normalized to the total reads across the controls. This fractional representation was used to filter out 
genera detected at low level in the clinical samples: any genus for which the fractional representation in the 
clinical sample was within five standard deviations from the mean measured in the controls was removed. 
Possible sources of contamination in these experiments include: environmental contamination during 
sample collection in the clinic, nucleic acid contamination in reagents used for DNA isolation and library 
preparation, and sample-to-sample contamination due to Illumina index switching [108]. 
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Library preparation and next-generation sequencing. Sequencing libraries were prepared using a single-
stranded library preparation optimized for the analysis of ultrashort fragment DNA, described in Section 
1.2. Libraries were characterized using the AATI fragment analyzer. Samples were pooled and sequenced 
on the Illumina NextSeq platform (paired-end, 2 × 75 bp). Approximately 45 million paired-end reads were 
generated per sample. 
Determining the composition of the urinary microbiome. Low-quality bases and Illumina-specific 
sequences were trimmed (Trimmomatic-0.32 [47]). Reads from short fragments were merged and a 
consensus sequence of the overlapping bases were determined using FLASH-1.2.7. Reads were aligned 
(Bowtie2, very sensitive mode [52]) against the human reference (UCSC hg19). Unaligned reads were 
extracted, and the non-redundant human genome coverage was calculated (Samtools 0.1.19 rmdup [50]). 
To derive the urinary microbiome, reads were BLASTed (NCBI BLAST 2.2.28+) to a curated list of 
bacterial and viral reference genomes [109]. The relative abundance of different species in a sample was 
estimated based on the BLAST reports using GRAMMy, a software that implements a maximum likelihood 
algorithm and takes into account the ambiguity of read mapping [1, 3, 54]. The relative abundance of higher 
level taxa was determined based on the relative abundance at the strain or species level. For positive 
identification of viruses, we required at least 10 BLAST hits. In addition, due to the high load and genetic 
similarity of BK and JC polyomaviruses, we implemented a conservative filter for incompleteness and 
heterogeneity of genome coverage (Gini index < 0.8 with at least 75% of the genome covered) for these 
two species only.  
ROC analysis. ROC analyses were performed using the function “roc” in the R package pROC. For each 
species, we compared the relative genomic abundance of species (in RGE) in urine samples matched to a 
positive culture to the relative genomic abundance of the same species in culture-negative samples. 
Bacterial growth dynamics. Bacterial genome replication rates were determined using the approach 
described by Brown et al. [88]. Briefly, all bacterial strains within a sample were sorted and the GC-skew 
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was used to identify the origin and terminus of replication (minimum and maximum GC-skew, 
respectively). Bacterial genomes were binned in 1 kbp tiles. The coverage was smoothed based on a running 
mean of 100 nearest neighboring tiles. The coverage in each tile was quantified and tiles were sorted by 
coverage. Linear regression was performed between the origin and terminus of replication after further 
removing the 5% least and most covered bins. The product of the slope of the regression line and the genome 
length was defined as the growth rate, a metric applied in previous analyses. We applied the analysis to all 
bacterial strains with genome lengths > 0.5 Mbp, R2 linear regression correlation, as previously described, 
> 0.90, and Gini coefficient < 0.2, for which at least 2500 BLAST hits were detected in the sample. 
Nucleosome footprints in gene bodies. Paired-end reads were aligned using BWA-mem [48]. The sequence 
read coverage in 2-kbp windows around the transcription start sites of all genes was determined using the 
SAMtools depth function [24]. A list of transcription start sites organized by transcriptional activity was 
obtained from Ulz et al. [24]. The depth of coverage was summed across genes with similar transcriptional 
activity. 
Proportion of donor-specific cfDNA in urine. The fraction of donor-specific cfDNA in urine and plasma 
samples was estimated for sex-mismatched, donor–recipient pairs. The donor fraction was determined 
as: {2𝑌/𝐴 , 1 − (2𝑌/𝐴)}, depending if the recipient is female or male, respectively. Y and A represent the 
sequencing coverage of the mappability-adjusted Y chromosome and autosomes, respectively. Sequence 
mappability was determined using HMMcopy [110]. 
Mitochondrial donor fraction. The proportion of donor-specific mt-cfDNA was quantified using methods 
previously described in Section 1.2 [4]. Briefly, mtDNA was extracted from pre-transplantation whole 
blood samples, amplified, underwent library preparation, and was sequenced. Processing was separate for 
donor and recipient samples. Raw sequencing data was trimmed and aligned to the human genome, and 
mitochondrial sequences were selected. We estimated the presence of each nucleotide at each position using 
bam-readcount (https://github.com/genome/bam-readcount), and a mitochondrial consensus sequence was 
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determined for the donor and recipient. The consensus sequences were compared and single-nucleotide 
polymorphisms (SNPs) discriminating the two individuals were identified. Downstream cfDNA sequence 
data aligning to the mitochondrial were compared to the bases with SNPs that discriminate the donor and 
recipient. For each SNP position across the mitochondrial genome, we determined the donor fraction by 
dividing the donor SNP count by the total number of donor and recipient counts at the SNP. We discarded 
a donor fraction estimation at a point if the depth of sequencing was < 50x. We determined the mean of the 
estimated donor fraction at all SNPs to quantify the mitochondrial donor fraction. One sample was removed 
owing to low depth of sequencing across all SNPs. 
Antimicrobial resistance profiling. Paired-end nonhuman sequencing reads were merged (FLASH-1.2.7). 
Subsequently, reads were aligned to a database of protein sequences, in fasta format, of known AR genes 
(CARD 1.1.5, 2158 genes) using blastx [111] (e-value 10−7, culling limit 8 blastx hits). We implemented a 
filter post-alignment that eliminated reads with < 90% similarity between the query and reference. Hits with 
the highest identity and overlap length were selected for each read. CARD data includes an ontology for 
the AR class to which each gene confers resistance, if known [90]. We matched ontology-derived 
antimicrobial classes to the gene alignment from blastx, giving a measure of each antimicrobial class for 
each gene hit. If a gene conferred resistance to multiple antimicrobial classes, each class was attributed a 
hit. The hits were aggregated to provide an antimicrobial susceptibility profile of the sample. 
Bisulfite treatment. 5 µL to 20 µL of cfDNA in elution buffer was isolated . We applied a sodium bisulfite 
treatment protocol to the eluate (Zymo EZ DNA Methylation Kit, Irvine CA). After treatment, samples 
were eluted in 30 uL of buffer. We applied ssDNA library preparation to 15 µL in the manner described 
above and sequenced to a depth of roughly 2x across the human genome (Illumina NextSeq 2x75 bp). 
BT cfDNA sequencing pipeline. BT cfDNA sequencing libraries were aligned to the human reference 
genome (hg19) using bwa-meth [112]. Tissue-of-origin measurements were calculated by quadratic 
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programming (using limSolve package in R) where the reference was based on DMRs of a tissue panel. 
DMRs were found using metilene [99]. 
Statistical analysis. All statistical analyses were performed using R version 3.3.2. Unless otherwise noted, 
groups were compared using the nonparametric Mann–Whitney U test. Fourier analyses were performed 
using the spec.pgram function, part of the standard stats package, in R. 
Boxplots. Boxes in the boxplots indicate the 25th and 75th percentiles, the band in the box indicates the 
median, lower whiskers extend from the hinge to the smallest value at most 1.5× IQR of the hinge, and 
higher whiskers extend from the hinge to the highest value at most 1.5× IQR of the hinge. 
Data availability. The sequencing data that support the findings of this study are made available in the 
database of Genotypes and Phenotypes (dbGaP), accession number phs001564.v1.p1. 





1.3.10 Urinary cfDNA accurately predicts infections and host cell damage 
We have presented a strategy to identify and assess infections of the urinary tract based on profiling 
of urinary cfDNA and ‘omics analysis principles. We show that different layers of clinical information are 
accessible from a single assay that are either inaccessible using current diagnostic protocols, or require 
parallel implementation of a multitude of different tests. In nearly all samples with clinically reported viral 
or bacterial infection of the urinary tract, cfDNA sequencing identified the suspected causative agent of 
infection. In addition, cfDNA sequencing revealed the frequent occurrence of cfDNA from bacteria that 
remain undetected in current clinical practice. In many samples, including those from subjects regarded as 
clinically stable, we detected cfDNA from viruses that may be clinically relevant but not routinely assayed 
in the screening protocol at our institution. The assay we present has the potential to become a valuable tool 
to monitor bacteriuria and viruria in kidney transplant cohorts, and to ascertain their potential impact on 
allograft health.  
Beyond measurement of the abundance of different components of the microbiome, urinary cfDNA 
provides a wealth of information about bacterial phenotypes. We show, for the first time, that analyses of 
the structure of microbial genomes from cfDNA sequencing allows for the estimation of bacterial 
population growth rates, thereby providing information about dynamics from a single snapshot. We 
compared the bacterial growth rates in samples with clinically-diagnosed UTI to those without diagnosed 
UTI and we observed higher growth rates for clinically-reported bacteria in subjects diagnosed with UTI. 
We further show that metagenomic analysis of urinary cfDNA can be used to infer antimicrobial 
susceptibility. We mined cfDNA sequencing data for AR genes, and found a good agreement between the 
presence of AR genes and in vitro phenotypic antimicrobial susceptibility testing results. cfDNA resistome 
profiling may have added potential over conventional AR testing methods as these methods typically use 
one or a few cultured colonies. cfDNA profiling can potentially capture AR gene fragments from the entire 
bacterial population which may be particularly important since cfDNA profiling revealed frequent putative 
co-infections within the UTI group.  
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Several new methodologies have been introduced in recent years to characterize the urinary 
microbiome and to diagnose UTI, including 16S ribosomal RNA sequencing [79, 113, 114] and expanded 
culture techniques [67, 115]. These approaches have challenged the clinical dogma that urine from healthy 
individuals is sterile [68], and have revealed potential deficiencies in the culture protocols that are used in 
clinical practice today [67]. The cfDNA shotgun sequencing assay described here provides a versatile 
alternative that will be particularly useful for monitoring kidney transplant recipients, given the potential to 
enable viral and bacterial pathogen detection, AR profiling, and graft injury assessment from a single assay. 
More than 15,000 patients receive lifesaving kidney transplants in the United States each year 
[116]. Viral and bacterial infections of the urinary tract occur frequently in this patient group and often lead 
to serious complications, including graft loss and death. In the general population, UTI is one of the most 
frequent medical problems that patients present with [59]. Shotgun DNA sequencing of urinary cfDNA 
offers a comprehensive window into infections of the urinary tract and could be a valuable diagnostic tool 
to monitor and diagnose bacterial and viral infections in kidney transplantation as well as in the general 
population. The assay we have presented is compatible with a short assay turnaround time (one to two 
days), and will benefit from continued technical advances in DNA sequencing that will reduce cost and 
increase throughput in years to come.  
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Chapter 4: Pathogen screening and microbiome profiling from low-biomass isolates of cell-free DNA 
 
“Cell-free DNA (cfDNA) in biological fluids provides a rich window into human health. A small fraction 
of cfDNA is derived from the genomes of bacteria, viruses and fungi, creating opportunities for pathogen 
screening and microbiome profiling from blood via ‘omics approaches. However, the total mass of 
microbial-derived cfDNA in blood is low, making such metagenomic analyses prone to environmental 
contamination. We present a scheme to identify and remove contaminating microbial DNA, as well as 
falsely-assigned taxa, thereby greatly improving the resolution of metagenomic assays of cfDNA. The 
scheme takes advantage of the coefficient of variation in genomic coverage, anti-correlation between the 
proportion of environmental DNA and the total biomass of the sample, and the natural and large variation 
in biomass across samples assayed in a single batch. We analyzed profiles of microbial cfDNA in the urine 
of kidney transplant patients. We compare results against clinical gold standards and demonstrate that 
background subtraction leads to dramatic reductions in false positive rates while minimally affecting the 
true positive rates. Following parameter optimization, we applied the background correction algorithm to 
deduce the microbiome in a novel cohort of forty-four samples derived from pregnant women, with and 
without chorioamnionitis. Our results support the identification of a subgroup of patients with culture-
negative chorioamnionitis. We make a bioinformatics toolkit that implements the approach available as an 
open access R library.” 
 
Chapter is being prepared for submission as a journal article.  
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1.4.0 Factors contributing to false-positive microbial identification 
The use of metagenomic sequencing to uncover the microbial composition of environments has 
become an invaluable tool to medical microbiologists and ecologists in recent years. Researchers have 
revealed cause, response, and association relating the microbiome, the collection of microbial organisms, 
to several diseases and disorders [117, 118]. Other work has determined the persistence of these 
microbiomes over time and when introduced to extrinsic factors, including the use of pharmacological 
agents [119]. However, only recently has contamination been thoroughly addressed in these samples [120]. 
In order to produce sequencing data representative of the community, samples must be collected and stored 
and their DNA needs to be extracted, prepared, and sequenced. The ubiquitous nature of bacteria and other 
microorganisms can introduce external agents to the samples at any of these steps. This may lead to the 
false-positive identification in communities.  
Microbial contamination could be introduced at one of several steps in the process of extracting 
biological fluids to eventually producing sequencing libraries. For example, microbes existing on the skin 
from the patient could be coincidentally extracted into a vial at the collection point. We have observed the 
abundance of gut-associated bacteria more strongly in urine samples received from women, compared to 
similar samples taken from men or blood samples acquired from either individual - likely from the transfer 
of bacteria from the rectum to the genitourinary tract [121]. Bacteria, or fragmented bacterial fragments, 
could also be present in contaminated tubes at collection or introduced accidentally by medical or laboratory 
staff after collection.  
Processing steps may also introduce microbial contaminants into samples. The production process 
of some enzymes and kits necessitates the use of microbial components (e.g. replication enzymes). A recent 
study highlights the perils of associating newly observed microbes with diseased patients [122, 123]. In this 
work, a nonhuman parvovirus was identified at low abundance in many patient samples, leading the authors 
to suggest the discovery of a virus in the human population [123]. However, a careful investigation of the 
materials in the extraction process determined that the viral genetic sequences were introduced into their 
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samples via silica columns [122]. These columns capture DNA extracted from cells and fluid, and they are 
sourced from ocean diatoms, which are the natural host of these parvoviruses [124]. 
It is difficult to determine the exact point in sample processing pipelines wherein environmental 
contamination occurs. For example, in the library preparation of cfDNA sequencing libraries there are 
dozens of steps to go from cfDNA suspended in biological fluid to a representative library prepared for 
next generation sequencing. These steps involve the introduction of reagents, containment vessels, pipette 
tips, etc…, all of which may introduce contaminating microbial genome fragments into samples. In addition 
to contamination, algorithms used to assign sequences to microbial taxa, via alignment or k-mer matching, 
may incorrectly assign identity due to genetic similarity. Furthermore, the nature of horizontal gene transfer 
among various species of bacteria can make it difficult to determine which organism is present. Finally, 
recent evidence has indicated the phenomenon of “barcode hopping” on next generation sequencing 
platforms [108]. In such cases, samples multiplexed and sequenced on the same flow cell may be incorrectly 
assigned to the respective samples. These modes of digital cross-contamination have not been thoroughly 
addressed. 
While many of these phenomena have been identified and addressed separately, few approaches 
have integrated corrective measures for all contamination and false assignment issues, particularly in cases 
of low microbiome biomass metagenomic sequencing. In this section, we comprise a series of filtering steps 
taken to address background contamination and taxonomic assignment failures in cell-free DNA 
sequencing data sets. Cell-free DNA from humans has been shown to be a valuable biomarker for disease 
in pregnancy and following organ transplantation [2, 3, 12]. We have recently shown that bacterial and viral 
cell-free DNA may be obtained from the urine to diagnose urinary tract infections [5], and recent work has 
shown the diversity of viral cell-free DNA detectable in blood plasma [1]. Non-host cell-free DNA can 
often make up over 99% of identifiable sequencing reads, even in the case of infections in 
immunocompromised patients. Thus, microbial cell-free DNA represents a case of low-biomass 
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metagenomics, in which positive biomarkers of infection may be overwhelmed with the presence of the 
host and contaminating sequences. 
Here we present our approach to identification and removal of contaminants and improperly 
assigned microbes in metagenomic cell-free DNA sequencing datasets, termed low-biomass background 
correction (LBBC). Our pipeline utilizes extraction and library preparation information, cfDNA biomass 
input, and microbial sequencing coverage statistics to filter false-positive identifications. We implemented 
a scoring system to optimize filtering parameters and applied the filtering scheme to a subset of samples 
from a previously published dataset for kidney transplant recipients with and without urinary tract infection.  
As a follow-up study, we then applied the filtering scheme to a novel cfDNA dataset collected via 
amniocentesis from a cohort of pregnant women with and without chorioamnionitis. Chorioamnionitis is 
an inflammatory response during pregnancy that is associated with preterm birth and long term 
complications for the fetus. Often the underlying cause of chorioamnionitis has been determined as a 
bacterium, through culture and/or 16S sequencing. However, there exist a large number of cases without 
etiological agent. Our results confirm the sterile conditions by a new method of diagnosis, namely microbial 
cfDNA sequencing that correspond with clinical determination of bacterial-negative chorioamnionitis. 
Furthermore, cfDNA sequencing with background correction is able to identify most cases of bacterial-
positive chorioamnionitis, and supports a broad range of work emphasizing a microbe-free amniotic fluid 
during healthy, full-term pregnancies.  
 
1.4.1 The low-biomass background correction pipeline 
We built a background correction pipeline, implemented as a package in R that identifies 
contaminant or falsely-assigned taxa for different information inputs (illustrated in Fig. 1.4.1.1a). In all 
cases detailed in this chapter, our input microbial abundance was determined from the relative genomic 
abundance (proportion of microbial genomes per human genome in sample) from cfDNA originating in 
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human biological fluid and prepared using our extraction and library preparation pipeline [4]. However, 
one could apply the pipeline to any type of microbial abundance measurements. We have employed this 
metric in various studies and found it accurately depicts cases of infection [5]. The measurement also 
normalizes microbiota both within and between samples to enable identification of enrichment. Relative 
abundance measurements are calculated by aligning nonhuman reads to a curated reference genome 
database via NCBI BLAST. The number of alignments is adjusted using GRAMMy, a maximum likelihood 
Figure 1.4.1.1 A pipeline for sparse metagenomic background correction with simulated cases of false 
identification. (a) Overview of pipeline. An initial file containing the abundance of microbes across 
samples is compared to external information (blue boxes) regarding alignment statistics, batch information, 
measured biomass, and taxa in negative control samples. (b-d) Simulated examples to identify contaminant 
through different means. (b) Sequencing coverage across three artificial microorganisms was simulated in 
the case of high and homogenous coverage (yellow), high and inhomogeneous coverage (blue), and low 
coverage (green). At right, the coefficient of variation (CV) was calculated for a uniformly sampled, 
uniformly sequenced at the same depth of sequencing for each organism and compared to the calculated 
CV was compared to the theoretical CV. Dotted line shows 1:1 correspondence. (c) Simulated cases for a 
microbe as a contaminant (orange) and true identification (blue) show the theoretical relationship between 
measured biomass and proportion of all sampled microbes. (d) Simulated cases of bacterial abundance for 
four microbes. Orange shows low variability within batches, so is likely a contaminant. {21} 
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estimator that adjusts reads based on sequence similarity [54]. Finally, the total number and length of 
assigned reads is compared to the genome length of the particular microbe, and a depth of sequencing for 
that microbe is determined. By dividing this value by the sequencing coverage of human chromosome 21 
(and adjusting for ploidy), we determine the relative genome abundance.  
While the collection of known microbiota is extremely diverse, there exists high amounts of genetic 
similarity between individual taxa. Even in cases of distinct genera, genomic similarity can exceed 80% 
[125]. Bacteria are able to transmit whole gene segments to genetically distinct organisms, to which 
metagenomic sequencing is sensitive [126]. For these reasons, it can be difficult to assign sequencing reads 
to the correct bacterial taxon through either k-mer or direct alignment strategies. Following alignment of 
nonhuman cfDNA reads to a microbial reference genome database, we observed that the distributions of 
reads across a microbial reference genome could be highly heterogeneous. While cfDNA sequencing is 
sensitive to protein-DNA interactions, the degree of coverage heterogeneity is not generally observed across 
the human genome, except in cases of low mappability. We reasoned that the pattern of genome coverage 
in these samples was due to either a region of low complexity or high similarity to that in the reference 
genome of another microbe present in the dataset.  
 To distinguish cases of false assignment in a generalizable manner we calculated the coefficient of 
variation (CV) for the number of reads originating from 1 kbp bins across the genome. We then simulated 
random sampling across a uniformly sequenced genome for the same number of reads as the direct 
calculation case. In general, we calculated the following from the sequencing coverage across individual 
species: 
𝐶𝑉 =  𝜎 µ⁄  , 
Δ𝐶𝑉 =  𝐶𝑉 −  𝐶𝑉uniform , 
where σ and μ are the standard deviation and mean in the sequencing depth within 1 kbp bins, respectively. 
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Utilizing these values discriminated cases of high homogenous genomic coverage, low 
homogenous genomic coverage, and heterogeneous coverage (Fig. 1.4.1.1b). Coefficient of variation was 
chosen over other distribution metrics, such as the Gini coefficient, due to its sensitivity to heavy tails and 
the scales invariance [127]. We simulated a case of three equivalent bacterial genomes with low (0.2x) or 
high (10x) genomic coverage and differing coverage heterogeneity (Fig. 1.4.1.1b, left). In the case of a high 
coverage genome that was sequenced homogeneously, CV and ΔCV were approximately zero. In the case 
of a low coverage genome that was sequenced homogeneously, ΔCV was approximately zero. This indicates 
that the genome was sequenced as randomly, even with a low depth of sequencing. However, the genome 
covered with high heterogeneity shows a large discrepancy between the CV and CVuniform, leading to a large 
ΔCV (Fig. 1.4.1.1b, right). ΔCV can be used therefore, to indicate and remove genomes with irregular 
coverage patterns. 
Following removal of microbes with inhomogeneous genome coverage, we aimed to address 
bacteria that we likely present in the dataset, but were derived from sources of contamination. The physical 
mass of DNA added in library preparation can be used to distinguish contaminating taxa [120]. Following 
taxon assignment, aggregated to the desired taxonomic level, the relative abundance of each taxa present in 
the sample can be assessed. For each taxa, the proportional abundance may be compared to the total input 
mass for library preparation. A reduced DNA input creates more opportunity to incidentally prepare and 
sequence contaminant genomic fragments. In the extreme case, a pure water sample prepared for 
sequencing would only contain environmental microbes. Conversely, beginning with a large input would 
“crowd out” contaminating genomic fragments.  
To utilize this method, we calculated the concentration of cfDNA following extraction from 
biological fluids, and marked the input volume of cfDNA into library preparation, allowing us to determine 
the total amount of cfDNA input. The relative proportion of each species was determined by dividing the 
relative genomic abundance of the given species by the aggregate relative genomic abundance of all species 
present in the sample. We determined if the correlation between the cfDNA input mass and the 
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proportionate abundance was negative and significant (p < 0.01). The theoretical relationship between 
biomass input and proportionate abundance for contaminants and true microbes present in samples is 
depicted in Figure 1.4.1.1c. Permitted significant negative correlation for the particular taxa, the 
proportionate abundance was transformed using a Box-Cox transform [128], and a z-score was determined. 
Samples with a z-score exceeding 1.65 (representing greater than 95% above mean) are considered to have 
a species rising above background, while those with z-score below 1.65 are filtered out.  
Simultaneously, we exploited the presence of batch effects to identify and remove bacteria with 
low variability within particular batches. Batch variation is a useful technique to remove species that could 
be introduced from reagents or broad cross contamination [129]. When calculating the variation of species 
within a particular batch, those with high variation can be interpreted as likely present within the sample, 
while those with low variation are likely an unintended contamination (simulated example in Fig. 1.4.1.1d). 
We annotated each sample with the batch number and calculated the within-batch variation of each taxon 
within the batch. Batches containing taxa below a variance threshold (𝜎2) were removed. 
Finally, the use of negative controls in metagenomic sequencing, as previously mentioned, can 
directly yield evidence of contamination [130]. An easily adapted method for the identification of 
contaminant sequences is the inclusion of a water control. To more accurately simulate the case of low-
biomass metagenomics we utilize a control which emulates the sample (e.g. in the length of molecules) but 
may be distinguished if there is cross contamination. We created a simple mixture of synthetic, short dsDNA 
oligos (25 bp, 40 bp, 55 bp, and 70 bp). Roughly 100 million oligos of this control were suspended in 1 mL 
of TE buffer and we processed the samples through cfDNA extraction and library preparation steps [5]. 
Each of these control libraries was sequenced at low depth (~1 million reads per sequencing run) and 
processed in the same bioinformatics pipeline as true cfDNA samples. The presence of microbiota assigned 
to these datasets should only be considered if they exceed a nominal abundance. Barcode-hopping, or 
misattributing indexing barcodes during Illumina sequencing, has been observed on multiple platforms 
[108]. Thus, microbial control samples, multiplexed with one or more samples containing an abundance of 
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infectious microbial cfDNA, could erroneously contain non-contaminants. To address this concern, we 
compared the relative number of BLAST hits in each sample and microbes were excluded if they exceeded 
an abundance threshold. We utilize this method as the last stage in the filtering pipeline. 
 
1.4.2 Training correction parameters using clinically informed interpretation 
In following the guidelines presented in Figure 1.4.1.1a, we have established the use of three critical 
thresholding parameters that affect the permissiveness of filtering, these are: (1) the maximum allowable 
coefficient of variation, CVmax, (2) the maximum allowable difference in CV from that of a uniformly 
sequenced sample at the same depth, ΔCVmax, (3) and the minimum allowable within-batch variation, 𝜎2min. 
We determined a scoring metric which would optimize the parameters on a well-described cfDNA 
sequencing dataset. We selected a subset of the urinary cfDNA samples from a kidney transplant cohort. In 
this cohort, we included 16 samples with known E. coli UTIs, 11 samples with known Enterococcus UTIs, 
and 17 samples with no current UTI and no UTI during the time the patients were monitored. 
We constructed a metric designed to evaluate the success of the filtering method. The score is 
calculated, as follows: 
BCscore = 𝑘𝑇𝑃(𝑇𝑃)  +  𝑘𝑇𝑁(𝑇𝑁) − 𝑘𝐹𝑃(𝐹𝑃)  − 𝑘𝐹𝑁(𝐹𝑁)  +  𝑘𝑈(𝑈), 
where {TP, TN, FP, FN} is the number of true positives, true negatives, false positives, and false negatives, 
respectively. We also include a term U to represent the total number of identified taxa for which a secondary 
methods of identification was not performed. The respective k coefficients for these values represent 
weights to optimize the filtering parameters based on assay interests. For example, if one wants to penalize 
the identification of untested bacteria, kU should be a negative value. To optimize the filtering we chose 
{kTP, kTN, kFP, kFN, kU} = {4, 2, -1, -2, -0.25}. Running a nonlinear minimization algorithm by gradient 




Applying these constraints on the kidney subset revealed true-positive rate (24/27) and true-
negative rate (57/61). These filtering parameters also led to few false-positives and false-negatives (4 and 
3, respectively). Moreover, there were relatively few bacteria identified outside of the Escherichia and 
Enterococcus genera that would be associated with contaminants or false-positives generated from 
sequence alignment (Fig. 1.4.2.1).  
We also observed that the filtering method did not remove the presence of known commensal 
bacteria in the genitourinary tract as shown the abundance of Gardnerella and Ureaplasma in female 
samples (and not in male samples), reflecting an effect we discussed in the original publication [5]. In one 
sample, we identified an abundance of bacteria associated with the human gut microbiome (Group 3 in Fig 
1.4.2.1). In many cases of UTI, particularly in transplant recipients, the causative uropathogen originated 
in the gut and traveled to genitourinary tract via external migration [121]. Metagenomic sequencing 
performed on the stool of this patient revealed that the E. coli strains between the stool and urine of this 
sample are more similar than comparative samples from other patients, and all genera present in urine were 
Figure 1.4.2.1 Low-biomass background correction (LBBC) on microbial abundance reveals pathogens, 
commensals, and sterile biomes. We applied LBBC to the microbial abundance arrays calculated in 44 
samples for Enterococcus UTI in females and males (Groups 1 and 2, n = 7 and 4, respectively), E. coli 
UTI in females and males (Groups 3 and 4, n = 12 and 4, respectively), and healthy females (Group 5, n = 
4) and males (Group 6, n = 13). The genera detected were then subset from the microbial abundance matrix 
without background correction (left of arrow). Relative genome abundance is indicated by color gradient, 
on left. Green borders indicate positive clinical identification by standard urine culture. {22} 
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similarly present in stool. It is therefore likely that the patients’ UTI was acquired from the patient's own 
gut microbiome (manuscript in review). 
 
1.4.3 Background corrected cfDNA sequencing confirms chorioamnionitis in sterile wombs  
Acute chorioamnionitis, a host response to a chemotactic gradient in the amniotic fluid [131], is 
related to half of all preterm births and occurs in up to 4% of pregnancies [131, 132]. The inflammation of 
the fetal and maternal tissue is often instigated as a response to bacterial infection. In many cases, however, 
no microbial pathogen is observable through clinical techniques, such as bacterial culture or 16S 
sequencing.  
Following the optimization of filtering parameters, we applied the low-biomass background 
correction pipeline to a novel dataset acquired from the amniotic fluid of a patient cohort with 
chorioamnionitis, as well as healthy controls. It has been shown in a multitude of cases that the amniotic 
fluid in healthy individuals is sterile, so it is important to reduce false positives in microbial identification 
[133]. We retrospectively selected 47 samples from patients with culture-positive and culture-negative 
chorioamnionitis. We extracted cfDNA from 175 μL of amniotic fluid using the 1 mL urine protocol in the 
QiaAMP circulating nucleic acid kit, which was then prepared using a ssDNA library preparation and 
sequenced to about 1x depth (human genome coverage). We observed high sequencing coverage and low 
duplication rates in 44 of the 47 samples, allowing for further analysis. We identified microbial cfDNA 
through alignment to a comprehensive database using our previously described microbial alignment 
pipeline [1, 5] and we applied the filtering pipeline with parameters described above. Clinical identification 
of chorioamnionitis was determined through presentation of symptoms, and the causative pathogen was 
identified through culture and subsequent 16S sequencing on the IBIS system. 
The results of the filtering pipeline, implemented with the optimized threshold parameters, are 
indicated in Figure 1.4.3.1. As expected, no bacteria were detected in the chorioamnionitis-negative group, 
reaffirming the utility of the filtering pipeline and supporting recent findings [134]. Furthermore, there was 
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only one species detected outside of those determined through 16S sequencing, Cutibacterium acnes, a 
known skin contaminant [89]. The cfDNA sequencing assay with background correction failed to detect 
several cases of bacterial infection. We asked if these false negatives were due to the application of the 
filtering scheme. A relaxation of the thresholding parameters revealed that three of the false-negative 
Ureaplasma parvum calls were removed by the batch variation filters. Ureaplasma and Mycoplasma often 
inhabit the female genitourinary tract [80], and, in the absence of background correction, show a presence 
in many samples. The presence of these commensals likely forces their removal by background correction 
algorithms, an effect that is undesirable, as Ureaplasma are often the main cause of chorioamnionitis [135]. 
We did observe two patients in culture-negative chorioamnionitis group with an abundance of 
Streptococcus agalactiae, in these cases, this bacteria may have caused inflammation. However, in 17 of 
Figure 1.4.3.1 cfDNA sequencing with background correction reveals causative chorioamnionitis 
pathogen. Species-level abundance is shown across 44 samples in cohort. Abundance value occupy a range 
from 10-2 RGE (blue) to 103 RGE (red). Samples are divided by clinical pathology and species are divided 
by superkingdom. Black crosshairs indicate clinical confirmation by culture and 16S sequencing. {23} 
69 
 
the 19 cases of culture-negative chorioamnionitis no bacterium (other than contaminant C. acnes) was 
identified.  
When cfDNA is present from two individuals in a biological fluid and the individuals are of 
opposite sex, the fractional abundance from each individual can be determined by the ratio in coverage of 
the Y chromosome to the autosomes. We applied this scheme to patients pregnant with a male fetus and 
determined that the fractional abundance of maternal cfDNA was strongly correlated with inflammatory 
markers such as IL6. During chorioamnionitis, leukocytes from the mother, fetus, or both individuals may 
enter the amniotic sac to fight infection; this is the likely source of maternal cfDNA [136, 137]. We 
identified two samples outside of the culture-positive chorioamnionitis group (and four within the group) 
with high amounts of maternal cfDNA. We hypothesized these samples may include the presence of 
pathogenic bacteria or viruses that were not clinically detected; however, none were observed. 
  The results of background-corrected microbial cfDNA sequencing support previous reports of a 
sterile amniotic sac in the absence of inflammation and the occurrence of chorioamnionitis in the absence 
of microbial invasion of the amniotic cavity [135]. In this scenario, microbial cfDNA sequencing with 
background correction should be employed with other methods, such as standard culture or 16s sequencing, 
due to its tendency to report false negatives. cfDNA sequencing was additionally sensitive to viral species 
present in amniotic fluid, for which clinically testing was not performed. Our results indicate high amounts 
of papillomavirus and bacteriophage in two separate samples. 
 
1.4.4 Detection of microbial cfDNA in peritoneal dialysis effluent 
 In a follow-up study to the isolation and sequencing urinary cfDNA in kidney transplant recipients, 
we performed the microbial cfDNA sequencing pipeline on peritoneal dialysis (PD) effluent samples for 
patients awaiting renal transplant. In PD, a solution is introduced in the peritoneal cavity and filters toxins 
from the blood following kidney failure [138–140]. PD presents a more comfortable and accessible method 
of dialysis, as compared to hemodialysis, which requires patients to regularly visit centers to perform fluid 
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exchange. Cases of peritonitis, infection of the peritoneum, reduce the efficacy of PD and make users more 
susceptible to infection in the future; for these reasons, clinicians often recommend patients change to 
hemodialysis after a case of PD [141]. 
 We examined the ability of cfDNA sequencing to detect and monitor cases of peritonitis by 
examining the microbiome in 1 mL PD effluent samples at or near cases of clinical peritonitis. We extracted 
cfDNA from PD effluent samples collected at New York Presbyterian Hospital where patients were 
monitored for peritonitis prior to kidney transplantation. If patients exhibited symptoms consistent with 
peritonitis, PD effluent was cultured for microorganisms. Our cohort (55 samples across 31 patients) 
consists of patients who had culture-positive and culture-negative peritonitis (n = 11 and 4, respectively) 
and patients without peritonitis (n = 16).  
Figure 1.4.4.1 Microbial cfDNA sequencing in PD effluent reveals pathogens and broad detection of skin 
flora. Relative genomic abundance is shown across samples (n = 55) for five genera tested using bacterial 
culture. Samples are grouped by clinical presentation of culture-positive peritonitis (Peritonitis/Positive), 
culture-negative peritonitis (Peritonitis/Negative), and no peritonitis. X = taxa identification removed by 




 We observed a variable sequencing depth across the human genome in the samples (1.08x ± 0.68x 
on chromosome 21) and a unique fragment length distribution (Fig. 1.2.6.1) of the human-aligned cfDNA. 
In particular, unlike plasma and urine cfDNA, the relative proportion of reads shorter than 100 bp was 
highly variable. When analyzing the microbial taxa across samples from peritonitis negative and positive 
patients, we observed a high amount of microbial promiscuity among reads. By subsampling the microbial 
genome abundance matrix to only those genera observed by PD effluent culture, we observe that there is a 
high amount of background. For example, while Pseudomonas bacteria was only isolated from one sample 
in culture, several samples without peritonitis and with culture-negative peritonitis exhibited high relative 
genomic abundance (RGE > 1, Fig. 1.4.4.1). To adjust for background, we applied the low-biomass 
background correction algorithm from Section 1.4.1, (though without the comparison to the microbial 
control). In applying the LBBC algorithm, we were able to reduce over 90% of assigned taxa, though this 
led to the inability to positively identify Streptococcus and Pseudomonas reads (Strep and Pseud, Fig. 
1.4.4.1). Other genera, including Escherichia, Klebsiella, and Staphylococcus, confirmed through bacterial 
culture were present in high abundance after background correction. 
 For several patients in the cohort who had culture-positive peritonitis, we acquired multiple samples 
at multiple time points following clinical confirmation of peritonitis. Clinicians treated these patients 
immediately once peritonitis is diagnosed and the causative pathogen is determined. To demonstrate the 
effect of treatment on the causative pathogen, we isolated the reads originating from the pathogen 
determined by culture and observed the change in relative genomic abundance over time (Fig. 1.4.4.2). 
Notably, the relative genomic abundance did not decrease for all samples after peritonitis onset (Fig. 1.4.4.2, 
inset). In most cases, we did observe a decrease in the relative genomic abundance of the causative pathogen 
by an order of magnitude within two days of peritonitis diagnosis. Microbial cfDNA sequencing was able 
to detect the causative pathogen up to five weeks after peritonitis diagnosis and down to a relative genomic 
abundance of ~ 0.01 RGE, or one bacterium for every one hundred human cells (Fig. 1.4.4.2). 
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 To our knowledge, our pilot study represents the first time that cfDNA sequencing was performed 
on the fluid from the peritoneum. For this reason we also explored the presence of potential pathogens 
outside of those detected using culture. When relaxing our filtering parameters we detected the presence of 
Enterococcus (0.38 RGE), of which only one other sample had presentation at low abundance (0.01 RGE). 
The sample was obtained four days prior to the onset of a gallbladder infection by Enterococcus. 
Additionally, we detected the presence of several clinically-relevant viruses present in the peritoneum of 
several patients including cytomegalovirus (CMV, 22.37 RGE), betapapillomavirus 1 (HPV, 4.76 RGE), 
and herpesvirus 6A (1.28 RGE).  
We hypothesize from the vignettes illustrated above (Enterococcus in gall bladder, CMV, and 
HPV), that cfDNA sequencing of PD effluent contains microbial cfDNA from both infections within the 
peritoneal cavity and infections in organs neighboring the peritoneum. In cases of neighboring infections, 
cfDNA from the microbial organisms could diffuse across barriers in the plasma or directly move the organ 
Figure 1.4.4.2 Microbial cfDNA sequencing in PD effluent is able to detect causative pathogens at low 
abundance and weeks after treatment. Relative genomic abundance of the clinically determined pathogen 
is shown for culture-positive peritonitis patients. Inset: Days 0 to 4 post-peritonitis are shown. Dotted line 
is the absolute limit of detection, 10-3 RGE. Red points are both detected and remain in abundance profiles 
after filtering. Blue points are detected but are filtered out through LBBC algorithm. Green points were not 
detected through microbial cfDNA sequencing. Lines connect samples from same patient. {25} 
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into the peritoneal cavity if there are lesions. Furthermore, cfDNA originating from enteric microbiota may 
have originated in the intestines, colon, or stomach, all of which border the peritoneal cavity. Due to the 
small scale nature of this study, we cannot confirm this hypothesis beyond these vignettes. Larger studies 
will need to be performed to establish the utility of PD effluent cfDNA sequencing to detect infections in a 
wide variety of organs. If this is proven to be true, monitoring the effluent of patients on PD via cfDNA 
sequencing could provide a comprehensive method to detect and treat infection.  
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Chapter 5: Applications of cfDNA sequencing for global health 
 
“Metagenomic sequencing has proven to be a powerful tool in clinical settings to identify oncogenesis, fetal 
aneuploidy, and graft failure and infection in transplant recipients. However, cfDNA sequencing has not 
yet been applied to diseases of particular interest to global health, including tuberculosis, malaria, and 
neglected tropical diseases. To describe the need and scope of cfDNA sequencing in issues related global 
health, we applied our analysis of genome replication dynamics and microbiome abundance measurements 
to patients in rural settings in South America. We performed whole genome sequencing of cultured 
Mycobacterium tuberculosis (MTB). We calculated the proportion of MTB under active replication using 
the sequencing coverage across the MTB genome and observed disruption of this signal when various 
antibiotics were introduced. By comparing genome replication dynamics to total DNA measurements, we 
propose a novel observation of high ploidy genomes in static MTB after introduction with ethambutol. We 
present the results of sequencing plasma cfDNA from TB individuals from a cohort in Ecuador. In a separate 
study, we sequenced plasma cfDNA from sixty pediatric patients in Peru with suspected environmental 
enteropathy. Analysis of the plasma microbiome following low-biomass background correction revealed 
the presence of enteric microbiota in the plasma in patients with high L:M sugar ratios, a measure of disease 
severity. We believe this supports a model of gut perfusion during EE, allowing the diffusion of enteric 
microbiota into the circulatory system, which can lead to systemic disease.” 
 
Experiments and sample collection in this chapter thanks to: Evgeniya Nazarova, David Russell, Margaret 
Kosek, Joan Sesing Lenz, Fanny, Chen, Jansy Sarathy, and Veronique Dartois.  
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1.5.0 cfDNA sequencing to study infectious disease in global health 
The patient groups mentioned up to this point, pregnant women and transplants recipients, are two 
groups for which the rapid and accurate diagnosis of infectious disease is paramount. The research on these 
groups, however, has taken place in the United States, where advanced resources are accessible in most 
healthcare settings. The overwhelming burden of infectious disease affects those from lower income nations 
[142]. For example, a 2017 survey by the WHO found 67% increase in the likelihood of dying from a lower 
respiratory tract infection as a citizen in sub-Saharan African nations compared with those in high income 
countries [142]. Furthermore, the incidence of outbreaks from emergent infectious diseases is increased in 
low-income nations and emerging economies [143]. With increased globalization, deforestation, and 
climate change, these countries have become the epicenter of recent pandemics including Ebola virus in 
West Africa (2014), Zika virus in Latin America (2016), and bubonic plague (caused by Yersinia pestis) in 
Madagascar (2017). It is therefore important for the development and implementation of broad diagnostic 
tests to track pathogens. 
Collaborating with research and global health companies through the Gates Foundation, we applied 
metagenomic sequencing with background correction to determine its sensitivity in detecting neglected 
tropical diseases. We explored the use of plasma cfDNA sequencing for the discrimination of latent and 
active Mycobacterium tuberculosis (MTB). Our experiments in culture and in an animal model revealed 
the ability to detect changes in the growth dynamics following treatment with a panel of antibiotics. As a 
follow-up we implemented microbial cfDNA sequencing in patients who were sputum-positive for 
tuberculosis, though our results indicate shortcomings of the technique. We also surveyed a pediatric cohort 
of several dozen patients with suspected environmental enteropathy, a syndrome caused by malnutrition 
which leads to a “leaky gut” or the migration of gut-specific microbiota into the circulatory system [144]. 
Our work in this area has shown both the limitations of implementing microbial cfDNA sequencing in these 




1.5.1 Analysis of MTB genome replication dynamics 
 Tuberculosis has been a prominent cause of death for centuries, and in the developing world is still 
responsible for over a million deaths a year worldwide [145]. Despite advances in antibiotics and 
vaccination, hundreds of millions of people around the world are seropositive for tuberculosis and harbor a 
latent for of the bacteria, which in 5% to 10% of individuals will reactivate into the deadly, infectious form 
[146]. The need to monitor these latently-infected individuals, and to distinguish them from those with 
actively-replicating MTB is great. We explored the use of cfDNA sequencing to indicate those infected by 
MTB and to distinguish latent and active MTB using genomic replication dynamics [87]. Before analyzing 
cfDNA samples, we performed sequencing directly on MTB cultures treated with a variety of 
pharmacological agents to see if MTB growth could be detected by sequencing coverage. 
A stock of cultured MTB was placed into one of five flasks and an initial aliquot of MTB was 
extracted from each of the stocks. We incubated stocks at 37 °C for 12 hours to allow for MTB replication, 
at which point another aliquot of suspended MTB was removed and replaced with growth medium. 
Immediately following isolation of the aliquot a clinically relevant dose of the following antibiotics was 
applied: ethambutol (ETH), rifampicin (RIF), moxifloxacin (MXF), and isoniazid (IZD). Following the 
introduction of the antibiotics, aliquots from each flask were removed at one, eight, sixteen and 24 hours, 
We removed an additional aliquot at 24 hours post antibiotic introduction from a control flask, which had 
no antibiotics introduced. The optical density of each sample was calculated to estimate the number of 
bacteria. Samples were pelleted and the medium supernatant was isolated for each sample. Pelleted MTB 
samples and media supernatant samples were digested and washed with ethanol to precipitate DNA. We 




We prepared sequencing libraries of genomic DNA for each MTB sample using the Illumina 
Nextera protocol. This library preparation technique uses tagmentation enzymes to simultaneously cut and 
adapt genomic DNA with sequencing primers. MTB libraries were multiplexed and sequenced to a depth 
of roughly 100-800x across the MTB genome. Following sequencing alignment, the MTB genome was 
binned to 10 kbp and the mean coverage within each bin was determined. We observed the enrichment in 
coverage between the replication origin and terminus via the same method as our earlier urinary cfDNA 
work (Section 1.3.5) and described in other publications [5, 87, 88]. At each time point of sample collection 
Figure 1.5.1.1 Whole genome sequencing of MTB reveals effects of antibiotics. (a) MTB cultures were 
treated with one of several drugs (Untreated, ethambutol (ETH), moxifloxacin (MXF), rifampicin (RIF), 
isoniazid (IZD)). The percentage of replicating bacteria was determined using the replication score, and the 
concentration of genomic DNA (gDNA, normalized for volume and optical density) and supernatant DNA 
(superDNA) were calculated for time 12 hours before and up to 24 hours after dosing. Dotted line indicates 
time of drug inoculation. (b) The sequencing coverage (normalized to mean coverage) across the MTB 
genome (binned to 10 kbp) is shown for untreated and ETH-treated MTB prior to dosing and 24 hours after 
dosing. Solid and dashed vertical lines represent positions of replication origin and terminus, respectively. 
(c) A model of ETH effects on MTB in culture is shown. When ETH is inoculated into culture, MTB cell 
walls do not grow. Concurrently, genomes duplicate until there are two copies. (d) Confocal fluorescent 
imaging of a MTB after 24 hours of dosing. Bacteria were stained with DAPI. {26} 
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we determined: (1) the fraction of replication MTB bacteria, (2) the concentration of genomic DNA 
(normalized by optical density), and (3) the concentration of DNA in the media supernatant (Fig. 1.5.1.1a).  
We compared these three measurements over time and between drug treatment conditions to 
observe how differences in how the drugs affected bacterial growth (Fig. 1.5.1.1a). Bacteriolytic 
antibacterial drugs, MXF and RIF, did not reduce the fraction of replicating MTB bacteria but did cause a 
reduction in genomic DNA over time. These results are consistent with bacteria lysis, as incomplete 
genomes would not finish replication before lysis. In comparison, bacteriostatic drugs affecting cell wall 
synthesis, ETH and IZD, showed a drastic reduction in the replicating fraction 24 hours after treatment.  
Interestingly, ethambutol-treated MTB also exhibited an increase in genomic DNA that doubled in 
an asymptotic manner after 24 hours (Fig. 1.5.1.1a). To assure the effect of replication was not a sequencing 
artifact at the terminus of replication, we directly analyzed the coverage pattern and compared to untreated 
samples (Fig. 1.5.1.1b); no artifact was observed. Since ethambutol inhibits arabinogalactan synthesis 
[147], we proposed a model for ethambutol action on MTB summarized in Figure 1.5.1.1c. In our model, 
ethambutol immediately acts on MTB bacteria, inhibiting new cell wall synthesis and preventing the 
formation of daughter cells. However, this effect does not restrict genome replication. Rather, all bacteria 
with a single or both a single and partial genome are permitted to continue genome replication until an 
entire copied genome is present within the cell (leaving two copies total). Because the cell cannot divide, 
the ethambutol treatment effectively creates a population of diploid MTB bacteria that are no longer 
replication active. We confirmed the excess of genomic DNA within single cells using fluorescent imaging 
of DAPI staining 24 hours after treatment with ETH, RIF, and MXF (Fig. 1.5.1.1d). While RIF- and MXF-
treated showed similar amounts of fluorescence compared to an untreated control, we observed ETH-treated 
bacteria had higher DNA concentrations within single cells (Fig 1.5.1.1d). 
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We applied the genome replication dynamics analysis to an in vivo MTB infection model. A rabbit 
was infected with Mycobacterium tuberculosis HN878 using a nose-only aerosol exposure system. The 
caseum in the rabbit cavity was sampled over a three week period (days 0, 5, 7, 14, 21). DNA was extracted 
from the caseum samples and sequenced on the Illumina MiSeq platform (2x75 bp) after Illumina Nextera 
library preparation. Sequencing reads were aligned to both the rabbit and MTB reference genomes, 
iteratively. We detected an MTB relative abundance of 1.7 RGE, corresponding to 0.17% of all assigned 
reads. The data presented an increase in bacterial abundance after three weeks but did not detect active 
replication at any time point (Fig. 1.5.1.2). These results were consistent with matching CFU/CEQ 
measurements [148] of the caseum samples in the same rabbit.. 
We extended our analysis to the analysis of cfDNA fragments in the sputum and blood plasma of 
patients in limited resource areas. In the case of sputum, six samples were collected from patients from a 
clinic in Malawi and cfDNA was extracted in a BSL3 facility using ethanol precipitation. For plasma cell-
free DNA samples, plasma was extracted from samples collected from patients visiting clinics in Peru who 
were determined positive or negative for MTB by sputum testing. cfDNA was extracted from plasma in a 
Figure 1.5.1.2 WGS of rabbit caseum shows presence of MTB, but lack of active replication. Samples 
collected from days 0, 5, 7, 14, and 21 post-inoculation are shown. Relative genomic abundance was 
calculated by dividing MTB genome coverage by the sequencing coverage of rabbit genome. Mean 
coverage shown for 10 kbp genome bins. Solid and dashed vertical lines represent positions of replication 
origin and terminus, respectively. {27} 
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BSL2 facility. We performed single-stranded library preparation on cfDNA from sputum and plasma 
(Illumina NextSeq, 2x75 bp) and analyzed data using the pipelines described above. 
 Few M. tuberculosis cfDNA molecules in either sample source were detected in the sputum or 
plasma. Furthermore, when comparing MTB cfDNA loads in plasma from patients with positive and 
negative sputum, no distinction could be made (Fig. 1.5.1.3). Past work has shown the presence of MTB 
DNA in human bodily fluids of those who were clinically diagnosed; though qPCR was used for diagnosis 
[149]. We believe that several factors could explain the dearth of MTB cfDNA fragments. In addition to 
host factors, the doubling time of MTB is very slow compared to other pathogenic bacteria (14-24 hours 
compared to roughly 20 minutes for E. coli) [150]. Furthermore, MTB has a high seroprevalence throughout 
the world; likely most individuals have been infected with MTB or are latently infected [146]. Low levels 
of MTB bacteria, and thus MTB cfDNA may persist as a result of these past or latent infections [148], 
making it difficult to discern positive and negative MTB cases, particularly when using background removal 
techniques. Finally, within the granulomas, a large amount of necrosis among WBCs takes place. 
Figure 1.5.1.3 Comparison of Mycobacterium (genus) and MTB cfDNA in plasma samples from patients 
with sputum diagnosis reveals no difference in relative genomic abundance. For 61 patients, relative 
genomic abundance for Mycobacterium genus and Mycobacterium tuberculosis species was calculated 
and compared by clinical diagnosis. Samples registering 10-5 RGE showed no cfDNA. {28} 
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Myeloblast-derived cells in healthy individuals have a relatively high turnover rate (1-5 days for neutrophils 
to completely renew) [151]. The necrosis of these cells by MTB would add to this already high cellular 
turnover and, in turn, create a large amount of host cfDNA, which would obscure the MTB cfDNA signal. 
The challenges presented in our pilot study in cfDNA sequencing of MTB present issues that need 
to be addressed in future studies and for those considering unsupervised use of microbial cfDNA 
sequencing. 
 
1.5.2 Enteric bacterial cfDNA detected in plasma during environmental enteropathy 
 Environmental enteropathy (EE) is a debilitating disorder that still lacks full explanation. A 
consequence of malnutrition, villi in the gut become blunted, creating chronic challenges for nutrient 
absorption, as well as the migration of gut bacteria into the circulatory system [144]. This migration can 
result in systemic inflammation from the presence of pathogen-associated molecular patterns [152]. There 
are very few diagnostic methods available to access environmental enteropathy, in part due to ignorance 
that still exists surrounding the disease, but also due to expense. While endoscopies are considered the gold 
standard in accessing villus blunting, the test is not appropriate for testing in the rural settings where EE is 
likely to occur [152]. One rudimentary method to access malabsorption is the dual sugar absorption test 
[153]. In this test, patients are given a mixture of mannitol (a monosaccharide) and lactulose (a 
disaccharide), at a known ratio. The ratio of these sugars is monitored in the voided urine up to 24 hours 
after intake [153]. High lactulose-to-mannitol ratios can reflect leakiness of the intestinal tract. However, 
the interpretation of this test is subjective to the time of sampling and fluctuations in the measurements can 
describe result from different pathologies [153]. 
Unlike our previous studies to evaluate the utility of cfDNA sequencing for infectious disease, in 
environmental enteropathy, there is not one particular pathogen responsible for disease. Rather, the 
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identification of taxa related to the gut microbiome are of interest. We received sixty plasma samples from 
pediatric patients (two years of age) in resource-limited settings in Peru. We processed samples through 
cfDNA extraction and single-stranded library preparation and sequencing in the manner discussed above in 
Section 1.2 [4]. We aligned sequencing data and compared the samples to the sugar ratio, which was 
collected within one day of plasma extraction. Unlike our previous observations of cfDNA concentrations 
in plasma for patients suffering infection, cfDNA concentration plasma in the EE cohort were near baseline 
Figure 1.5.2.1 cfDNA sequencing of plasma microbiome in pediatric patients with EE reveals presence 
of gut flora. Genus-level identifications are presented for the bacteria identified across all samples in the 
EE cohort after spare metagenomic background correction. Size of each point is relative to log10 
measurement of relative genomic abundance. Samples organized by sugar ratio measurement (top). {29} 
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(median concentration 30.4 ng/mL plasma). We applied the LBBC algorithm (Section 1.4) to the microbial 
abundance estimations of the cohort and identified the presence of enteric bacteria (Eubacterium, 
Bacteroides, and Ruminococcus) as well as a high presence of skin contaminants (Fig. 1.5.2.1). We did not 
observe the aforementioned bacteria in patients with sugar ratio less than 0.2.  
In our analysis, an abundance of viruses were present across nearly all samples in the cohort. We 
investigated the abundance of bacteriophages as an indicator of enteric dysfunction. We aggregated viral 
reads according to family, and compared the viral family abundance between samples and to the sugar 
ratios. The two most prominent viral families across our cohort were Siphoviridae (n = 55), a bacteriophage, 
and Anelloviridae (n = 59), a family of small human viruses shown to increase in abundance when patients 
are under immunosuppressants [1]. We also observed the presence of parvoviruses (n = 18), herpesviruses 
(n = 6), and polyomaviruses (n = 18). There was no significant correlation between a specific viral family 
and the sugar ratio. In comparing viral family abundance between samples, we were able to cluster data 
based on the plasma virome. We did, however, observe a strong effect of clustering according to viral 
Figure 1.5.2.2 Plasma virome in patient-samples with EE indicate diversity and breadth of viral infections. 
(a) UMAP clustering was performed on the family-level relative genomic abundance of viruses identified 
across samples in EE cohort. Ellipse indicates cluster with a high amount of human-tropic viruses. (b) 
Relative genomic abundance of viruses aggregated by host tropism (Bacteria, top; Eukaryote bottom). Color 
gradient (grey to red) corresponds to sugar ratio (low to high). {30} 
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tropism when using UMAP dimension reduction algorithm [154]. Additionally, while samples originating 
from patients with high sugar ratios were not exclusive to one cluster, samples with the four highest sugar 
ratio values clustered together in a group marked by low overall viral load (Fig. 1.5.2.2). We aggregated 
viral family abundance according to host tropism (Eukaryote or Bacteria) for each sample, and compared 
these aggregate measurements on a sample-by-sample basis with the sugar ratio. Again, we did not observe 
any significant correlation or anti-correlation between the clinical measurement and cfDNA sequencing 
(Fig. 1.5.2.2). 
Further analysis needs to be performed to elucidate the relationship between the various viruses 
and bacteria present in this sampling cohort in order to identify relationships with disease. It has been 
suggested that benchmarking cfDNA sequencing against the sugar ratio is not proper for the proof-of-
principle pilot study. Secondary clinical measurements, including qPCR panels of known enteric microbiota 






Chapter 6: Perspective in cell-free DNA diagnostics 
 
cfDNA sequencing, combined with bioinformatics approaches to remove background 
contamination, detects a wide array of microbial life in a variety of biological fluids. Since 2015, we have 
created over five hundred cfDNA sequencing datasets from ssDNA library preparation to comprehensively 
study infectious disease (Table 1.6.0.1). Our work has shown that our novel library preparation technique 
(Section 1.2) is capable of creating cfDNA sequencing libraries from low sample volumes (< 250 μL) and 
low sample biomasses (< 5 ng cfDNA), while accessing previously uncaptured sizes of cfDNA. The 
robustness of the technique has allowed us to uncover microbial cfDNA related to bacterial and viral 
infections for immunocompromised patients in the United States and children suffering from malnutrition 
in Peru. As we have shown, though, the presence of microbial cfDNA in a milliliter of biological fluid can 
span orders of magnitude and is highly dependent on the lifecycle and physiology of the microbe as well 
as the proximity of the infected tissue to the fluid collected for testing. 
More studies need to be performed in order to determine the efficacy of cfDNA sequencing to 
monitor other types of infectious disease, including tuberculosis (Section 1.5.1) and parasitic infections, 
such as those from soil transmitted helminths. The case of cfDNA to monitor eukaryotic pathogens is of 
particular interest and not well characterized. In our work in the De Vlaminck lab, we have prepared 
sequencing libraries from the plasma and urine of pigs inoculated with a roundworm, Ascaris suum, in both 
the larval and adult stages (Table 1.6.0.1). Our cfDNA sequencing pipeline did not uncover any reads 
aligning to this organism. We have also had difficulty in identifying clinical cases of funguria, the presence 
of fungus in urine. These cases of type II error could be explained by a high host cfDNA background 
coupled with low amounts of pathogen cfDNA in the biofluid. The lack of well-annotated and assembled 
reference genomes for complex eukaryotic pathogens may also drive the challenge in identifying eukaryotic 
parasites via cfDNA sequencing [155].  
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 Without curated reference genomes for these organisms, metagenomic sequencing alignment 
algorithms are unable to properly assign reads; our efforts to normalize reads to sequencing depth across 
the respective genome is also difficult. Some approaches to solve this problem include the assembly of 
large contigs by comparing cfDNA fragments for overlap patterns, and then comparing these large synthetic 
structures to known gene sequences unique to the pathogen[157]. Application of contig assembly to cfDNA 
sequencing datasets has recently revealed the presence of large amounts of microbial “dark matter” and 
dozens of novel anelloviruses in blood [158]. These methods, along with the exponentially increasing 
number of eukaryotic reference genomes in publically available databases, will likely remedy these 




















Lung Tx Human Plasma USA Bacterial / 
Viral 
Yes 40 
Peritonitis Kidney Tx Human PD 
effluent 
USA Bacterial Yes 56 
Chorio-
amnionitis 
Pregnancy Human Amniotic 
fluid 
USA Bacterial Yes 44 
Tuberculosis Global 
health 
Human Plasma Ecuador Bacterial No 100 
EE Global 
health 
Human Plasma Peru Bacterial Yes 60 
EE Global 
health 





Human Plasma Switz. Viral Yes 15 
Febrile illness Global 
health 










Pig Urine Belgium Eukaryotic No 6 
Table 1.6.0.1 Summary of datasets acquired using cfDNA sequencing with ssDNA library 
preparation. cfDNA sequencing datasets acquired in the De Vlaminck lab, according to: disease, 
interest, host organism, fluid from which biological fluid was extracted, country of sample origin, 
infectious organism superkingdom, whether cfDNA from the organism was general detectable, and the 
number of samples processed. Tx = Transplantation. Every sample listed in the last column was 
prepared and sequenced, but not all samples were used in publications or analysis. 
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A second consideration regarding cfDNA sequencing to monitor infectious disease involves the 
cost of testing and the time to diagnosis. New work in the private sector is showing the range and sensitivity 
of the technique to determine the presence of pathogen cfDNA, with the ability to issue a diagnosis in 40% 
of cases within 53 hours of sample collection [6]. By comparison, less than 10% of cases are diagnosed by 
clinical microbiology techniques in the same amount of time [6]. As I will discuss in the Conclusions 
section, the cost of sequencing for such tests will also likely decrease significantly in the coming years with 
the advent of new sequencing technologies. 
 Another consideration when designing studies using cfDNA sequencing should be the information 
required to make a positive diagnose or to intervene with therapy. Many clinicians rightfully argue that 
there is a difference between infection and infectious disease [156]. These arguments support the use of 
measurements to detect host tissue damage, as we have presented using donor-fraction and tissue-of-origin 
measurements (Section 1.3), and microbial cfDNA. These techniques often require deeper sequencing (> 
2x coverage of human genome for methylation markers and > 8x coverage for nucleosome depletion) than 
what is required to accurately determine pathogenic species alone (< 0.5x). New techniques are being 
developed, both in the De Vlaminck lab and in the general community, that make use of high-depth 
measurements at a limited number of predetermined sites to determine a tissue-of-origin profile for cfDNA. 
These techniques significantly reduce the cost and time to detect tissue damage, and make use of non-
sequencing based techniques including dPCR and Crispr-Cas-based identification methods [157]. Using 
tissue-of-origin measurements in clinical practice could be done in tandem with low-depth microbial 
cfDNA sequencing to determine the pathogen and site of infection without incurring heavy costs.  
 We have shown in this dissertation that cfDNA sequencing can also be used as a tool for molecular 
epidemiology. Our analysis of renal transplant recipients suffering BK polyomavirus nephropathy 
highlights the ability to determine phylogenetic information from viral cfDNA. Since microbial cfDNA 
sequencing is capable of single nucleotide resolution, consensus sequences for viruses within patient 
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samples can be determined. The sequences can then be compared to one another to determine genetic 
relatedness and to understand the adaptation of the pathogen within its host.  
Microbial cfDNA sequencing can go further than describing genetic properties, by providing 
protein binding information, similar to CHIP-seq. Ultrashort cfDNA molecules were previously determined 
to reflect sites of eukaryotic transcription factor binding [23]. It is likely that microbial cfDNA also 
represents molecules stabilized by proteins bound to the genomic DNA at time of cellular lysis. We have 
observed these protein binding signals in BK polyomavirus cfDNA, where fragment length distributions 
support previous observations that polyomavirus DNA is bound to nucleosomes in minichromosome 
complexes (Fig. 1.3.1.1). Such a signal suggests that, like eukaryotes, microbial cfDNA is not the product 
of random fragmentation. Because there is no sequence bias (based on degradation) in ssDNA library 
preparation, cfDNA sequencing could be used to validate protein binding sites on bacterial and viral DNA 
and associate patterns of microbial genome coverage to disease phenotype. More directly, the coverage 
patterns will be helpful to determine the optimum sequences for hybridization assays and PCR, as fragments 
associated with these coverage maxima would be most prevalent in the biological fluid under observation. 
In summary, our work indicates that performing next generation sequencing on cfDNA isolated 
from biological fluids can be used to identify viral and bacterial infections with high sensitivity. 
Furthermore, as the cost of sequencing decreases, cfDNA sequencing will prove to be a valuable diagnostic 
analyte in rural and resource-limited settings, particularly to monitor the spread of infections in 
communities and reconstruct novel genomes.  
89 
 
PART II: Single-cell sequencing in infected cell populations – understanding the innate and adaptive 
immune response 
 
“... Except in the case of viruses. They can turn off and go dead. Then, if they come in contact with a 
living system, they switch on and multiply.”  




Chapter 1: Introduction to virus-inclusive single-cell RNA sequencing 
 
Paintings among Parisian artists in the latter half of the 19th century emphasized a focus on ordinary 
subjects and, while masterful, were painted in the method common of the previous centuries - the 
application of oil-based paint blended across their subjects. Works at the end of the century, however, did 
not copy this style. A new group of young artists realized that the beauty within each scene was often 
masked by the application of colors in splotches and the habit of painting with dark colors. Rather, these 
artists understood the importance of emphasizing the distinction of each brushstroke, making them 
individually noticeable, yet also part of the ensemble. When one views a work from the Impressionist artists, 
it is immediately clear that each moment the artist applied paint is distinguishable from the last and that 
appreciation of heterogeneity reflects an illuminated scene. Since the beginning of the 21st century, genome 
scientists have been part of a movement that is similar to what was achieved by artists during the 
Impressionist period. Scientists have started to appreciate the importance of understanding an organism’s 
larger life processes by focusing on changes occurring at the single-cell level [158]. 
The single cell is the basic unit of biology. Yet, until recently, sequencing studies have focused on 
sequencing the genomes or transcriptomes of thousands of cells in a single assay. This technology, bulk 
RNA and DNA sequencing, has successfully identified the heterogeneity between individuals from 
different ethnic groups and the changes in transcriptomes for people with various genetic diseases [159]. 
However, bulk sequencing often neglects the biological contribution of rare cell types, since bulk 
sequencing effectively averages sequencing information from a group of cells.  
The field of single-cell studies has grown at a remarkable pace since the first individual single-cell 
transcriptome was isolated, amplified, and sequenced in 2009 [160]. Studies immediately following the 
pivotal work in single-cell RNA-seq (scRNA-seq) by Tang et al. [160] used microfluidics or fluorescence 
activated cell sorting (FACS) to isolate tens to hundreds of cells [161]. Often researchers interested in 
performing scRNA-seq on tissues or organisms are interested in observing the subpopulations of cells 
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making up the tissue; this requires many more cells in order to observe members present at low abundance 
in populations. The cellular throughput needed to be increased in order to make single-cell sequencing an 
established tool for groups studying cellular heterogeneity. 
In 2015, the development of droplet microfluidic platforms supporting scRNA-seq allowed 
researchers to prepare tens of thousands of single cells for sequencing in the matter of hours [7]. In this 
method, Drop-seq, the authors created functionalized beads to capture polyadenylated messenger RNAs 
(mRNAs) once cells were lysed within droplets. The oligos on the bead surfaces included a bead-specific 
cell barcode (12 bp) and an oligo specific unique molecular identifier (UMI, 8 bp), which allowed for the 
deconvolution of sequencing reads following analysis. A digital expression matrix can then be generated 
for the entire sample from the demultiplexed reads, according to the cell barcode, which depicts the number 
of host transcripts across all genes and all cells. 
Drop-seq, and other techniques, allowed for deep sequencing across the transcriptomes of cells at 
a low cost (< $0.10 per cell) [7, 162]. The access to this level of resolution across tissues has permitted the 
discovery of novel cell types, such as cells within mammalian lungs that are related to those in the 
respiratory system of fish [163]. These cells exist at low abundance, and would not have been detected by 
bulk sequencing assays or low throughput single-cell sequencing techniques. Moreover, new bioinformatics 
approaches have been developed to describe the unique properties of individual cells and their relationship 
to others in the sample. For example, recent works have detailed lineage tracing, understanding the 
developmental process that cells undergo, and prediction of future cell states in single-cell transcriptomic 
datasets [164, 165]. Since 2015, optimization of droplet microfluidics and the establishment of new 
technologies has allowed for a continuing trend of higher throughput in single-cell studies, now reaching 
into millions of cells [162, 166].  
These assays, while fast and cost-effective, have targeted eukaryotic mRNAs, and have largely 
ignored the abundance of other classes of RNA molecules. Eukaryotic mRNAs are polyadenylated, so that 
the 3’-end of the molecule is occupied with tens of adenines [167]. The polyadenylation is directly targeted 
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for hybridization with poly(dT) capture probes, making transcript capture efficient for these molecules, but 
restricting the capture of molecules that do not have a similar 3’-end. Eukaryotic noncoding RNAs and 
transfer RNAs, for example, do not have this feature and are not captured. Additionally, many prokaryotes 
and viruses do not have polyadenylated tails on their messenger RNA [168, 169], making generalizable 
scRNA-seq approaches to study host-pathogen interactions difficult.  
The study of viruses using scRNA-seq has so far been limited, in part because Drop-seq, 10x 
Genomics, and other library preparation platforms are unable to generally capture and sequence viral 
mRNAs. In this part of the dissertation, I will describe a modification that can be made to existing scRNA-
seq technologies allowing for simultaneous capture of polyadenylated and targeted, non-polyadenylated 
mRNAs, particularly as it relates to virology. We identified four aims of virus-inclusive scRNA-seq:  
1. Determine host cell transcriptional profiles and identify of subpopulations through data structure. 
2. Identify which cells are infected with viral particles. 
3. Understand how viral gene expression is correlated to subsets of host gene expression. 
Figure 2.1.0.1 Clustering of infected cells reflects dynamics of cell populations during EHV1. (a) t-SNE 
representation of 13,156 PBMCs from mock (blue) and EHV1-infected (yellow) horses. Cell subtypes, 
listed beside clusters, were determined by marker genes after k-nearest neighbor clustering. Black 
diamonds represent cells with detectable amounts of EHV1 transcripts; size of diamond corresponds to 
relative viral transcript abundance. (b) Percentage of cells from mock (blue) and EHV1-infected (yellow) 
horses making up each cluster (numbers corresponding to groups in (a)). {31} 
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4. Analyze viral intracellular heterogeneity and determine how it relates to host gene expression. 
Differential gene expression is used broadly to understand complex cell populations, as is described in 
Aim 1, and does not require innovation beyond current technologies. To properly address the other three 
goals, though, researchers needed to focus on viruses with polyadenylated mRNAs. A typical result of an 
analysis of a complex collection of cells infected with a virus transcribing polyadenylated mRNA is shown 
in Figure 2.1.0.1a. In this pilot study, we isolated peripheral blood mononuclear cells (PBMCs) from three 
horses infected with Equid herpesvirus 1 (EHV1) and three control horses. We then processed isolated cells 
from the six samples using the Drop-seq [7]. The expression of E. caballus and EHV1 genes was quantified 
and cells of low quality (mitochondrial gene expression over 5%, number of genes detected under 200) 
were removed. Through dimensional reduction and k-nearest neighbor clustering (Seurat pipeline [170]), 
we identified several distinct clusters across 13,156 cells from the six samples. We then related these 
clusters to cell type in the blood through known marker genes (e.g. MS4A1 upregulation in B cell 
lymphocytes). Additionally, we observed that nearly twice as many cells in EHV1-infected samples were 
classified as NK cells as compared to mock samples (17.6% versus 9.9%, Fig 2.1.0.1b). NK cells are known 
to increase in abundance during viral infection and have an antagonistic effect on herpesvirus infected cells 
[171, 172]. 
As expected, we did not capture transcripts from EHV1 in the three uninfected samples. However, 
very few cells in infected horses had detectable viral transcripts (0.6% to 7.6% of cells in samples), and of 
these infected cells, only a small proportion of the transcripts originated from EHV1 (0.02% to 0.04% of 
transcripts). Across all filtered cells in all samples, seven of the sixty-eight EHV1 transcripts made up more 
than half of all captured viral transcripts. The lack of EHV1 gene coverage indicates the shortcomings of 
using standard scRNA-seq of the viral life cycle within infected cells.  
It cannot be assumed, due to the low viral transcript abundance, that cells without detected viral 
transcripts are not infected; however, we assume that cells expressing viral transcripts are infected with 
EHV1. These infected cells were not restricted to one PBMC subtype. EHV1-infected cells were observed 
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in all clusters with the exception of a small group of dendritic cells. The most highly expressed viral gene 
across the six samples, EHV1 ORF34, was only expressed in cells within the monocyte and T cell cluster. 
These clusters also showed the highest fraction of viral transcripts with infected cells (represented by size 
of black diamonds in Fig. 2.1.0.1a). As EHV1 ORF34 is associated with viral egress [172], monocytes and 
T cells may be the most fruitful environments for EHV1 replication. 
This brief study illustrates both the promise and challenges of scRNA-seq. Our pilot dataset 
identifies changing cell populations in response to infection. Furthermore, we resolved viral transcripts at 
single-cell resolution and associated partial gene expression in distinct clusters. Of the four aims listed 
above, however, only the first can be achieved using the Drop-seq platform [7]. Though in this case, EHV1 
mRNA is polyadenylated, we have shown that it is sparse within these cells. Thus, sampling of the 
transcriptome does not produce adequate read coverage at single-cell resolution to assess the number of 
cells in each subtype that are infected or the viral intracellular heterogeneity [173].  
cDNA amplification of viral sequences can also be used to enrich the libraries, and has been shown 
in recent studies for viruses lacking polyadenylated mRNAs [174, 175]. However, this method still relies 
on initial capture by the poly(dT) probe. Furthermore, in complex tissues and communities, viral tropism 
for cells making up only a small portion of the sample may lead to relatively few viral reads in sequencing 
datasets, regardless of capture efficiently. To adjust for this scenario, some groups have used fluorescence 
activated cell sorting (FACS) so that low abundance cell types are sequenced at similar depth to high 
abundance subpopulations [175]. Such a system requires the user to know cell surface markers a priori, but 
has been shown to work well for peripheral blood mononuclear cells (PBMCs) infected with dengue virus 
[175]. 
Beyond accessing non-polyadenylated transcripts, we envisioned that a targeting approach could 
enrich for low abundance reads, as in the case of the EHV1 infected PBMCs or viral models exploring 
questions of persistence or latency (both states of relative little viral replication). To meet our goals, we 
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developed an adaptable ligation chemistry that could be applied to existing high throughput scRNA-seq 
technologies. We chose to optimize our method on segmented RNA viruses. 
Segmented viruses, those with genomes partitioned into multiple, separable molecules, are of 
interest in viral evolution, particularly on short time scales. In addition to highly mutable genomes, 
segmented viruses may evolve through genetic reassortment. In these cases, two or more separate virions 
infect the same cell, and progeny virions may assemble a heterogeneous mixture of genomic segments 
corresponding to the original infecting virions [176] (Fig. 2.1.0.2). Reassortment can therefore allow viruses 
to gain new phenotypic traits over one infection cycle and permit the escape from the adaptive immune 
system [177]. Seasonal, potentially epidemic viruses such as influenza A virus benefit from this type of 
evolution [178]. 
Due to the potential consequences of evolution by reassortment, it is important to understand how 
cells react to progeny virions. Single-cell sequencing provides a tool to observe the cellular response to 
observe these viral properties within individual cells. While some species of segmented viruses produce 
messenger RNAs with polyadenylated tails (such as influenza), others do not, including reovirus and 
rotavirus. Reovirus and rotavirus, both members of the Reoviridae family, in addition to being segmented, 
have double-stranded RNA (dsRNA) genomes [179]. Upon infecting the cells, proteases partially uncoat 
the viral capsid and move the core particles into the cytoplasm. The genome segments are denatured to 
allow transcription of the positive-sense mRNA. Virions in the Reoviridae family have an innate RNA-
Figure 2.1.0.2 Representation of viral genetic reassortment occurring when two genetically distinct viruses 
infect and replicate within a cell. Progeny viruses have a likelihood of encapsidating gene segments from 
both parent viruses, allowing for the formation of novel viral genotypes. {32} 
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dependent RNA polymerases that are used to transcribe their mRNA. The viruses create negative-sense 
RNA from positive-sense mRNA to allow for the creation of dsRNA genomes for progeny viruses. Host-
derived protein complexes are used to translate mRNA into viral proteins [179].  
We performed a series of experiments to characterize a novel technology capable of simultaneously 
sequencing polyadenylated mRNA and targeted amplicons in a high-throughput, single-cell manner. We 
termed the technology DART-seq, droplet-assisted RNA targeting by single-cell sequencing. DART-seq 
uses a ligation chemistry to append targeted oligonucleotide probes onto existing poly(dT) capture 
technologies, such as Drop-seq beads. We applied DART-seq to enrich both non-polyadenylated transcripts 
in the case of reovirus-infected cells and polyadenylated transcripts in B cell lymphocytes.  
In applying DART-seq to murine fibroblasts infected with T3D orthoreovirus, we showed that 
DART-seq was able to capture non-polyadenylated viral transcripts with high targeting precision. Using 
this technique we measured the abundance of infected fibroblasts and compare the relative abundance of 
viral transcripts with respect to cell state. Using a second capture array, we showed that an entire viral 
transcript sequence can be assembled using DART-seq. We utilized these sequencing features to determine 
the mutational profile of viral mRNAs after infection. In a separate study, we applied DART-seq and non-
targeted scRNA-seq to characterize the host-pathogen interactions in rotavirus-infected primate fibroblasts. 
From these experiments, we were able to recapitulate rotavirus infection biology. We are actively 
developing infection models using Reoviridae in organoid systems to understand the innate immune system 
at higher complexity. 
We also used DART-seq to enable the capture of heavy chain and light chain isotype transcripts in 
populations of B cell lymphocytes, proving that DART-seq can improve the capture of polyadenylated 
mRNAs present at low abundance within single cells. Our results indicated that even at a modest depth-of-
sequencing, DART-seq greatly enriches the abundance of heavy and light chains in B cells. We used the 
transcript enrichment to validate known phenomenon in these isotypes, and show the ability to pair heavy 
and light chain variable regions to characterize the immune repertoire in a population of PBMCs. 
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Taken together, our exploration of DART-seq applied to infected cell populations and PBMCs 
indicate targeted scRNA-seq is a potent tool understand the innate and adaptive immune system.   
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Chapter 2: Simultaneous multiplexed amplicon sequencing and transcriptome profiling in single cells 
 
“We describe droplet-assisted RNA targeting by single-cell sequencing (DART-seq), a versatile 
technology that enables multiplexed amplicon sequencing and transcriptome profiling in single cells. 
We applied DART-seq to simultaneously characterize the non-A-tailed transcripts of a segmented 
dsRNA virus and the transcriptome of the infected cell. In addition, we used DART-seq to 
simultaneously determine the natively paired, variable region heavy and light chain amplicons and the 
transcriptome of B lymphocytes.” 
 
Chapter adapted from [8]: 
Saikia M*, Burnham P*, Keshavjee SH, Wang MFZ, Heyang M, Moral-Lopez P, Hinchman MM, 
Danko CG, Parker JSL, De Vlaminck I. Simultaneous multiplexed amplicon sequencing and 




2.2.0 Targeted amplicon sequencing in single cells to fully describe cell heterogeneity 
High-throughput single-cell RNA-seq (scRNA-seq) is being widely adopted for phenotyping of 
cells in heterogeneous populations[7, 162, 180, 181]. The most common implementations of this technology 
utilize droplet microfluidics to co-encapsulate single cells with beads that are modified with barcoded oligos 
to enable capturing the ends of RNA transcripts[7, 162, 181]. Although these approaches provide a means 
to perform inexpensive single-cell gene expression measurements at scale, they are limited to assaying the 
ends of mRNA transcripts. Therefore, they are ill-suited for the characterization of non-A-tailed RNA, 
including the transcripts of many viruses, viral RNA genomes, and non-coding RNAs. They are also 
uninformative of RNA segments that are located at a distance greater than a few hundred bases from 
transcript ends that often comprise essential functional information, for example the complementarity 
determining regions (CDRs) of immunoglobulins (B cell antibody) [182]. Additionally, these techniques 
are often unable to provide information on low copy number transcripts and splice variants [173].  
Here we report DART-seq, a method that combines enriched measurement of targeted RNA 
sequences with unbiased profiling of the poly(A)-tailed transcriptome across thousands of single cells in 
the same biological sample. DART-seq achieves this by implementing a simple and inexpensive alteration 
of the Drop-seq strategy [7]. Barcoded primer beads that capture the poly(A)-tailed mRNA molecules in 
Drop-seq are enzymatically modified using a tunable ligation chemistry [31]. The resulting DART-seq 
primer beads are capable of priming reverse transcription of poly(A)-tailed transcripts as well as other RNA 
species of interest.  
DART-seq is easy to implement and enables a range of new biological measurements. Here, we 
explored two applications. We first applied DART-seq to profile viral-host interactions and viral genome 
dynamics in single cells. We implemented two distinct DART-seq designs to investigate murine L929 cells 
(L cells) infected by the reovirus strain Type 3 Dearing (T3D). We demonstrate the ability of DART-seq to 
profile all 10 non-A-tailed viral gene transcripts of T3D reovirus individually, as well as to recover a 
complete genome segment, while simultaneously providing access to the transcriptome of the infected L 
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cells. In the second application, we applied DART-seq to determine natively paired antibody sequences of 
human B cells. DART-seq was able to determine B cell clonotypes, as well as variable heavy and light 
(VH:VL) pairings, even in mixed human peripheral blood mononuclear cells (PBMCs), highlighting the 
versatility of the approach. 
 
2.2.1 DART-seq primer bead synthesis 
  Droplet microfluidics based scRNA-seq approaches rely on co-encapsulation of single cells with 
barcoded primer beads that capture and prime reverse transcription of mRNA molecules expressed by the 
cell [7, 162, 181]. In Drop-seq, the primers on all beads comprise a common sequence used for PCR 
amplification, a bead-specific cell barcode, a unique molecular identifier (UMI), and a poly-dT sequence 
for capturing polyadenylated mRNAs and priming reverse transcription. To enable simultaneous 
measurement of the transcriptome and multiplexed RNA amplicons in DART-seq, we devised a scheme to 
enzymatically attach custom primers to a subset of poly-dTs on the Drop-seq bead (Fig. 2.2.1.1). 
Conversion is achieved by annealing a double-stranded toehold probe with a 3’ ssDNA overhang that is 
complementary to the poly-dT sequence of the Drop-seq primers. The toehold is then ligated to the bead 
Figure 2.2.1.1 DART-seq is an easily implemented and multiplex technology for single cell studies. Drop-
seq beads (with oligos containing a poly(dT) tail) are combined with a diverse mixture of toehold molecules 
including the targeting primer and a splint oligo with a polyA overhang. A DNA ligase is added to the 
suspension, which binds the toehold oligos to the Drop-seq beads. A light heat treatment (65 °C) is used to 
denature splint oligos which are subsequently washed away. The procedure retains all oligo information 
present on the original bead. {33} 
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using T4 DNA ligase. Toeholds with a variety of different sequences can be attached to the same primer 
beads in a single reaction in this manner. The complementary toehold strand is removed after ligation.  
After synthesis of DART-seq primer beads, DART-seq follows the Drop-seq workflow without 
modification (see Section 2.2.4). Briefly, cells and barcoded primer beads are co-encapsulated in droplets 
using a microfluidic device. Cellular RNA is captured by the primer beads, and is reverse transcribed after 
breaking the droplets. The DART-seq beads prime reverse transcription of both A-tailed mRNA transcripts 
and RNA segments complementary to the custom primers ligated to the beads. The resulting 
complementary DNA (cDNA) is PCR-amplified, randomly fragmented via tagmentation, and again PCR 
amplified to create libraries for sequencing. Sequences of mRNAs and RNA amplicons derived from the 
same cells are identified by decoding cell-specific barcodes, allowing for gene expression and amplicon 
measurements across individual cells.  
We characterized the efficiency, tunability and variability of the ligation reaction using 
fluorescence hybridization assays based on emission intensity measured in a Qubit fluorometer (Fig. 
2.2.1.2a). We found the fluorescence measurements were capable of measuring the number of oligos 
Figure 2.2.1.2 Qubit fluorometer measurements can resolve the number of fluorescent oligos bound to 
DART-seq beads. (a) To evaluate DART-seq ligation efficiency we designed an assay able to indirectly 
measure probe binding. (1) Toehold molecules are added to Drop-seq beads via the DART-seq conversion 
protocol. (2) Fluorescent oligos with sequence complementary to DART-seq probes are added to DART-
seq beads. (3) The fluorescence of suspensions of 2000 beads are measured via Qubit 3.0 fluorometer in 
the 647 nm channel. (b) For four different toehold probes we compared the fluorescence (in A.U., arbitrary 
units) as a response to the number of fluorescent probes added to the Qubit measurement. {34} 
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over many orders of magnitude (Fig. 2.2.1.2b). By comparing the number of input fluorescent oligos 
with those determined via fluorescent measurements, we found that the primer ligation reaction is highly 
efficient (25–40%), and the number of custom primers ligated to the beads is directly proportional to 
the number of primers included in the ligation reaction (Fig. 2.2.1.3a). This was true for four primer 
sequences tested over a wide range of primer concentrations and in mixed proportions. The efficiency 
of probe ligation decreased for ligation reactions with more than 1010 molecules per bead, indicating 
saturation of available oligonucleotide(dT)s. We compared the fluorescence hybridization signal across 
individual beads under a fluorescent microscope and found that the bead-to-bead variability in 
Figure 2.2.1.3 Conversion od Drop-seq beads to DART-seq beads is efficient and uniform, and DART-
seq beads enrich targeted RNAs. (a) DART-seq beads were created from a mixture of four probes and 
complementary fluorescent oligos were bound to beads and measured by Qubit fluorometer. Dotted line 
represents 100% conversion efficiency. Inset: diagram of fluorescent oligos bound to beads. (b) DART-
seq beads with bound fluorescent oligos were imaged using a fluorescence microscope and the average 
pixel intensity across 741 beads was determined. (c) Enrichment of targeted RNAs with respect to Gapdh, 
as measured by qPCR on cDNA from bulk RNA samples, is shown for various concentrations of probes 
added (106 to 1012 probes per bead). (d) DART-seq was used to capture two viral mRNAs at seven loci and 
qPCR was performed at positions above the plot and compared to Gapdh. {35} 
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fluorescence signal was small (s.d. 3.0%; Figure 2.2.1.3b). The homogeneity of coverage was replicated 
for various input concentrations of toehold probes. We observed that failures to keep beads well mixed 
during the ligation step revealed differential toehold coverage both between beads and across the surface 
of individual beads.  
We assessed reverse transcription priming efficiency as a function of the number of custom primers 
ligated to DART-seq beads. We used quantitative PCR (qPCR) to measure the yield of cDNA copies of a 
non-polyadenylated viral mRNA in reovirus-infected murine fibroblasts (L cells, Fig. 2.2.1.3c). Two 
distinct primers were ligated, targeting the same viral genome segment (S2). The yield of cDNA copies of 
viral mRNA, relative to cDNA copies of a host transcript (Gapdh), increased with the number of primers 
included in the ligation reaction, and saturated for reactions with over 109 primers per bead (Fig. 2.2.1.3c). 
Reverse transcription of Gapdh was not affected for DART-seq beads prepared with up to 1010 primers per 
bead. These measurements allowed us to determine the optimal range of custom primers to impart onto 
beads for scRNA-seq experiments. Between 109 and 1010 custom primers per bead, we observe no change 
in the relative amount of capture of viral transcripts to Gapdh, implying that we are not affecting host 
capture and have likely captured all targeted viral transcripts. 
Next, we evaluated the abundance of amplicons in sequencing libraries of reovirus-infected cells 
generated by Drop-seq and a DART-seq assay targeting all ten viral genome segments. We designed seven 
qPCR assays with amplicons distributed across two viral genome segments (S3 and L3). To account for 
assay-to-assay and sample-to-sample variability, we normalized the number of molecules detected in 
DART-seq and Drop-seq libraries to the number of Gapdh transcripts. We observed substantial enrichment 
upstream (5′-end), but not downstream (3′-end), of the custom primer sites (Fig. 2.2.1.3d). Consistent with 
sequencing library preparation via tagmentation, we found that the degree of enrichment decreased with 
distance from the primer site. 
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Utilizing these proof-of-principle experiments allowed us to understand the limits and performance 
of the DART-seq assay. In general, the use of DART-seq should include the addition of between one and 
ten billion custom primer toeholds per bead. Toehold beads should be designed for genetically unique 
targeting regions, include few thymine and adenine repeats, and target at least 250 nt upstream of the 5’-
end of the RNA molecules of interest. Last, during DART-seq bead synthesis, beads should remain well 
mixed during enzymatic reactions. With these considerations, we performed DART-seq on two unique 
systems related to innate and adaptive immunity. 
 
2.2.2 DART-seq reveals heterogeneity of cellular phenotypes and viral genotypes 
There is a great need for novel single-cell genomics tools that can dissect the heterogeneity in viral 
genotypes and cellular phenotypes during viral infection [183]. We used DART-seq to examine infection 
of murine L cells with T3D reovirus. The reovirus polymerase transcribes non-polyadenylated mRNAs 
from each of its ten dsRNA genome segments [184, 185]. We infected L cells at a multiplicity of infection 
of 10 (MOI 10), and allowed the virus to replicate for 15 hours after inoculation, creating a condition for 
which nearly all cells are infected (Fig. 2.2.2.1a). We performed Drop-seq and DART-seq experiments on 
infected L cells and non-infected L cells as control. We implemented two distinct DART-seq designs. The 
first DART-seq design targeted each viral genome segment with a single amplicon. The second DART-seq 
design was comprised of seven amplicons targeting loci distributed relatively evenly across the S2 genome 
segment (Fig. 2.2.2.1b).  
To determine the efficiency by which DART-seq retrieves viral transcripts near the target sequence, 
we analyzed the per-base coverage of positions upstream of the DART-seq target sites. For DART-seq 
design-1, we observed a mean enrichment of 34.7x in the gene regions 200 nt upstream of the ten toeholds. 
In both DART-seq design-1 and 2, all targeted sites were enriched compared to standard Drop-seq beads 
(Fig. 2.2.2.1c,d). Viral transcripts were detected in Drop-seq libraries upstream of A-rich sequences in the 
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viral genome, consistent with spurious priming of reverse transcription by poly-dT sequences on the oligo, 
as expected for Drop-seq. For example, a 200 nt gene segment upstream of an A5 sequence on segment M3 
(position 1952) was significantly enriched in the Drop-seq dataset (Fig. 2.2.2.1c; marked by arrow).  
Figure 2.2.2.1 DART-seq reveals heterogeneity in viral genotypes and host response to infection. (a) 
Experimental design. MOI, multiplicity of infection. b, Schematic of DART-seq designs (design-1, red 
bars; design-2, blue bars). c, Comparison of sequence coverage (normalized to host UMI detected × 106) 
of the ten reovirus gene segments (columns) for three library preparations (rows). An A5 pentanucleotide 
sequence part of segment M3 is shown (arrow). Dotted lines, DART-seq target positions. d, Per-base 
coverage upstream (5′ end) of ten custom primers of DART-seq design-1 (light red; average shown in dark 
red), and mean coverage achieved with Drop-seq (yellow). e, Per-base coverage of S2 gene segment 
achieved with DART-seq design-2 (bottom; dashed lines indicate custom primer positions) and Drop-seq 
(top). f, Frequency and pattern of base mutations (top); histogram of nucleotide ratios for positions with 
reference nucleotide G detected in single cells (bottom). g, Clustering analysis for variable gene expression 
of reovirus-infected L cells (DART-seq design-1; yellow/purple indicates higher/lower expression). Similar 
clustering was observed in all three experiments with infected cells. h, Relative abundance of viral 
transcripts in L cell clusters (P values determined by two-tailed Wilcox rank-sum test). Lower and upper 
hinges correspond to 25th and 75th percentiles, respectively. Lower/upper whisker corresponds to 
smallest/largest value within 150% of the interquartile range from the nearest hinge (cluster 1, n = 411; 
cluster 2, n = 397; cluster 3, n = 50; cluster 4, n = 69). i, Fraction of cells in metaclusters for four experiments 
depicted in panel a with assay type and infection status (+ or −) indicated. {36} 
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To test the utility of DART-seq to measure the heterogeneity of viral genotypes in single infected 
cells, we used DART-seq design-2 (Fig. 2.2.2.1b), which was tailored to retrieve the complete S2 viral gene 
segment. The S2 segment encodes inner capsid protein σ2. Across cells with at least 1500 UMIs, DART-
seq design-2 increased the mean coverage across the S2 segment 430-fold compared to Drop-seq, thereby 
enabling the investigation of the rate and pattern of mutations (Fig. 2.2.2.1e). 176 single-nucleotide variants 
(SNVs) were identified across the S2 segment (minor allele frequency greater than 10%, and per-base-
coverage greater than 50x). Mutations from guanine-to-adenine (G-to-A) were most common (58%; Figure 
2.2.2.1f, top). We did not observe such a mutation pattern in a highly-expressed host transcript (Actb). We 
examined the mutation load of viral transcripts at the single-cell level, and observed a wide distribution in 
mutation load, with a mean G-to-A conversion rate of 13%, and up to 41% (Fig. 2.2.2.1f, bottom).  
The reason for such a high rate of mutation is unclear. G-to-A transamidation is an uncommon 
post-transcriptional modification that is not been previously seen as a host response to reovirus infection 
[186, 187]. The high rate of G-to-A transition in the viral transcript could also be secondary to a defect in 
the fidelity of viral transcription. The T3D orthoreovirus strain used in this study has strain-specific allelic 
variation in the viral polymerase co-factor, µ2, that has been shown to affect the capacity of µ2 to associate 
with microtubules and the encapsidation of viral mRNAs within capsids [188, 189]. Following the 
publication of DART-seq, experiments to determine the origin the G-to-A hypermutation were performed1. 
Negative-stranded genomic RNA and viral mRNA were isolated individually from the S2 and S4 segments 
for T3D and T1L reovirus infected murine fibroblasts under the same conditions as described above. These 
eight unique RNA libraries were reverse-transcribed and sequenced to a depth of over 5000x across 95% 
of the segment (Illumina Miseq 2x75bp). We found strong concordance between the targeted sequence and 
the most abundant segment determined through sequence alignment (> 95% of reads align to targeted 
segment). In one of the eight libraries, representing genomic RNA from the S2 segment of T3D reovirus, 
                                                          
1 Experiments performed by Mercedes Lewandrowski of John Parker’s laboratory. 
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we observed an increased mutation burden from guanine to adenine of 2% (across 73 sites). No other 
libraries yielded significant mutational burden deviant from the reference sequences. Additional 
experiments are currently being performed to confirm our observations in scRNA-seq data. 
To identify distinct host cell populations based on patterns of gene expression, we performed 
dimensional reduction and unsupervised clustering using approaches implemented in Seurat [170, 190]. We 
identified four distinct cell clusters for the monoculture infection model (DART-seq design-1, Figure 
2.2.2.1g). Two major clusters comprised of cells with elevated expression of genes related to viral RNA 
transcription and replication (Rpl36a, cluster 1) and metabolic pathways (Ugdh, cluster 2). Two additional 
clusters were defined by the upregulation of genes related to mitotic function (Cdc20, Cenpa; cluster 3) and 
innate immunity (Ifit1, Rsad2; cluster 4), respectively (Fig. 2.2.2.1g). The abundance of viral gene 
transcripts relative to host transcripts was significantly elevated for cells in cluster 3 (n = 69 of 927 total 
cells) compared to cells in all other clusters (Fig. 2.2.2.1h; two-tailed Mann Whitney U test, p = 1.0 x 10-
4). We merged all datasets for the Drop-seq and three DART-seq assays and quantified the cell type 
composition for each experiment. We did not observe cells related to cluster 4 (immune response), for the 
non-infected control, as expected (Fig. 2.2.2.1i). These results support the utility of DART-seq to study 
single-cell heterogeneity in viral genotypes and cellular phenotypes during viral infection. 
 
2.2.3 DART-seq allows high-throughput paired repertoire sequencing of B lymphocytes 
As a second application of DART-seq, we explored the biological corollary of viral infection, the 
cellular immune response. The adaptive immune response is reliant upon the generation of a highly diverse 
repertoire of B lymphocyte antigen receptors, the membrane-bound form of antibodies expressed on the 
surface of B cells, as well as antibodies secreted by plasmablasts [191, 192]. We applied DART-seq to 
investigate the B cell antibody repertoire in human PBMCs. We compared the performance of DART-seq 
and Drop-seq to describe the antibody repertoire (Fig. 2.2.3.1a). Antibodies are comprised of heavy (μ, α, 
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γ, δ, ε) and light chains (κ, λ), linked by disulfide bonds (Fig. 2.2.3.11). Each chain contains variable and 
constant domains. The variable region of the heavy chain is comprised of variable (V), diversity (D) and 
joining (J) segments, whereas the variable region of the light chain consists of a V and J segment (Fig. 
2.2.3.1a). We designed DART-seq to target the site where the constant domain is joined to the VDJ gene 
segment in both heavy and light chain loci [193] (Fig. 2.2.3.1a). This design allows us to investigate the 
complementarity-determining region 3 (CDR3), which plays a key role in antigen binding. This region 
often goes undetected in regular scRNA-seq methods due to its distance from the 3’-end of the transcript. 
Figure 2.2.3.1 DART-seq measures paired heavy and light chain B cell transcripts at single-cell 
resolution. (a) DART-seq custom primer design targeting the constant region of human heavy and light 
isotypes. (b) cDNA copies of immunoglobulin (Ig) transcripts relative to GAPDH as a function of the 
number of custom primers included in the ligation reaction (left panel, LC-λ + V primers; right panel, 
IgG + V primers; 62,500 cells, 12,000 beads, bulk assay). Points are mean of two replicate measurements; 
bars indicate minimum and maximum. (c) Percentage of B cells for which heavy and/or light chain 
transcripts were detected as a function of the UMI count per cell. Cells were binned by the number of UMI 
detected (bin width 200 UMI, 0–2,400 UMI per cell, bins with fewer than 20 cells omitted, 26–2,396 cells 
per bin). Distributions were fit with a sigmoid curve (Methods). (d) Drop-seq and DART-seq assays of 
human PBMCs. Experiments were performed on two distinct PBMC samples (n = 2). Representative t-SNE 
for one DART-seq assay shown here (4,997 single cells). Cells are colored on the basis of heavy and/or 
light chain transcript detection. € Bar graph of isotype distribution for CD27+ B cells and B cells for which 
CD27 was not detected. (f) CDR3L and CDR3H length distribution. n = 818 B cells. (g) Paired heavy 




We examined the efficiency of heavy and light chain reverse transcription by qPCR (CD19+ B 
cells) and observed an enrichment of transcripts for all isotypes tested, as the number of custom primers on 
DART-seq beads was increased (Fig. 2.2.3.1b). The response in enrichment to the addition of custom 
primers reflected the same pattern seen for targeted viral mRNAs in reovirus-infected cells (Fig. 2.2.1.3b). 
Next, we compared the performance of DART-seq and Drop-seq to describe antibody repertoires (Fig. 
2.2.3.1c). Approximately 120,000 B cells were loaded in each reaction, yielding 4,909 and 4,965 
transcriptomes for DART-seq and Drop-seq, respectively. The number of UMIs and genes detected per cell 
was similar for DART-seq and Drop-seq. We mapped transcript sequences to an immunoglobulin sequence 
database (see Section 2.2.4). For both DART-seq and Drop-seq, the percentage of cells for which 
immunoglobulin transcripts were detected scaled with the number of UMIs detected in the cells (Fig. (Fig. 
2.2.3.1c). The immunoglobulin transcript recovery rate was substantially greater for DART-seq. For cells 
with 1,000–1,200 UMIs, we identified both heavy and light chain transcripts in 29% of cells using DART-
seq, but in only 3% of cells using Drop-seq. 
Next we applied DART-seq to determine the B cell antibody repertoire within human peripheral 
blood mononuclear cells (PBMCs) (120,000 PBMCs, 4,997 single-cell transcriptomes). [170] (Fig. 
2.2.3.1d, top). We identified B cells based on expression of the B cell specific marker MS4A1 [194]. We 
mapped transcript sequences obtained from B cells to the immunoglobulin (IG) sequence database, to find 
matches for the heavy and light chain transcripts in these cells, using MiXCR 2.1.5 [195]. We visualized B 
cells for which heavy and/or light chain transcripts were detected using t-SNE [190] (Fig. 2.2.3.1d, bottom). 
We detected immunoglobulin transcripts in 564 of the 818 cells in the B cell cluster, and immunoglobulin 
expression mapped accurately onto the B cell population. 
We performed isotype distribution analysis on CD27+ B cells (Fig. 2.2.3.1e). As expected, CD27+ 
B cells were a mixed population of heavy chain isotypes, with IgM most frequently observed, followed by 
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IgD and IgA [196] (Fig. 2.2.3.1e). Kappa and lambda light chain isotypes were equally represented, as 
expected [197–199] (Fig. 2.2.3.1e). B cells for which we did not detect CD27 were predominantly of the 
IgM isotype [200] (Fig. 2.2.3.1e).  
B cells derive their repertoire diversity from the variable regions of their heavy (IGHV) and light 
chains [201] (IGKV, IGLV). DART-seq captured a more diverse population of variable isoforms than 
Drop-seq. DART-seq can pair variable heavy and light chain transcripts in single cells. Out of 564 
immunoglobulin-transcript-positive cells, we mapped the complete CDR3L in 339 cells and the complete 
CDR3H in 236 cells. The complete CDR3L+ CDR3H region was detected in 120 B cells. The number of 
variable heavy chain (VH) and variable light chain (VL) transcripts in single cells was correlated, as expected 
(corr. = 0.683, Pearson, p << 10-10, n = 120). The CDR3L and CDR3H length distributions had maxima 
around 30 and 50 nucleotides, respectively, as described previously [193, 202] (Fig. 2.2.3.1f). In line with 
previous reports, promiscuous light chain pairing was observed in 73.5% of the repertoires in CD27− B 
cells [202]. Finally, we measured clone-specific pairing for the heavy (IGHV) and light chain variable 
regions (IGKV, IGLV) in 164 single B cells (Fig. 2.2.3.1g). The highest pairing frequency was observed 
between the most highly expressed heavy and light chain transcripts, in agreement with previous reports 
[192, 203]. The observed trend for preferred pairings in single cells was similar to published data [203].  
 
2.2.4 Detailed methods of DART-seq assay 
Primer bead synthesis. Single-stranded DNA (ssDNA) probe sequences were designed to complement 
regions of interest. The probes were annealed to the complementary splint sequences that also carry a 10-
12 bp overhang of A-repeats. All oligos were resuspended in Tris-EDTA (TE) buffer at a concentration of 
500 μM. Double-stranded toehold adapters were created by heating equal volumes (20 μL) of the probe and 
splint oligos in the presence of 50 mM NaCl. The reaction mixture was heated to 95 °C and cooled to 14 
°C at a slow rate (-0.1 °C/s). The annealed mixture of toehold probes was diluted with TE buffer to obtain 
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a final concentration of 100 μM. Equal amounts of toehold probes were mixed and the final mixture diluted 
to obtain the desired probe concentration (2 pmoles for reovirus DART-seq design-1 and B-cell DART-
seq, and 10 pmoles for reovirus DART-seq design-2). 16 μL of this pooled probe mixture was combined 
with 40 μL of PEG-4000 (50% w/v), 40 μL of T4 DNA ligase buffer, 72 μL of water, and 2 μL of T4 DNA 
Ligase (30 U/μL, Thermo Fisher). Roughly 12,000 beads were combined with the above ligation mix and 
incubated for 1 hr at 37 °C (15 second alternative mixing at 1800 rpm). After ligation, enzyme activity was 
inhibited (65 °C for 3 minutes) and beads were quenched in ice water. To obtain the desired quantity of 
DART-seq primer beads, 6-10 bead ligation reactions were performed in parallel. All reactions were pooled, 
and beads were washed once with 250 μL Tris-EDTA Sodium dodecyl sulfate (TE-SDS) buffer, and twice 
with Tris-EDTA-Tween 20 (TE-TW) buffer. DART-seq primer beads were stored in TE-TW at 4 °C. 
Cell preparation. Murine L929 cells (L cells) in suspension culture were infected with recombinant Type 
3 Dearing reovirus at MOI 10. After 15 hours of infection, the cells were centrifuged at 2300 rpm for 10 
minutes and resuspended in PBS containing 0.01% BSA. Two additional washes were followed by 
centrifugation at 1200 rpm for 8 min, and then resuspended in the same buffer to a final concentration of 
300,000 cells/mL. Human PBMCs were obtained from Zen-Bio. Cells were washed three times with PBS 
containing 0.01% BSA, each wash followed by centrifugation at 1500 rpm for 5 min, and then resuspended 
in the same buffer. The cell suspension was filtered through a 40 micron filter and resuspended to a final 
concentration of 120,000 cells/mL.  
Single cell library preparation. Single cell library preparation was carried out as described previously2. 
Briefly, single cells were encapsulated with beads in a droplet using a microfluidics device (FlowJEM, 
Toronto, Ontario). After cell lysis, cDNA synthesis was carried out (Maxima Reverse Transcriptase, 
Thermo Fisher), followed by PCR (2X Kapa Hotstart Ready mix, VWR, 15 cycles). cDNA libraries were 
tagmented and PCR amplified (Nextera tagmentation kit, Illumina). Finally, libraries were pooled and 
sequenced (Illumina Nextseq 500, 20x130 bp). 
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qPCR measurement of viral gene segments. 0.1 ng DNA from sequencing libraries was used per qPCR 
reaction. Each reaction was comprised of 1 μL cDNA (0.1 ng/μL), 10 μL of iTaq™ Universal SYBR® 
Green Supermix (Bio-Rad), 0.5 μL of forward primer (10 μM), 0.5 μL of reverse primer (10 μM) and 13 
μL of DNAse, RNAse free water. Reactions were performed in a sealed 96-well plate using the following 
program in the Bio-Rad C1000 Touch Thermal Cycler: (1) 95 °C for 10 minutes, (2) 95 °C for 30 seconds, 
(3) 65 °C for 1 minute, (4) plate read in SYBR channel, (5) repeat steps (2)-(4) 49 times, (6) 12 °C infinite 
hold. The resulting data file was viewed using Bio-Rad CFX manager and the Cq values were exported for 
further analysis. Each reaction was performed with two technical replicates. 
Toehold ligation measurement via fluorescent hybridization. Roughly 6000 DART-seq beads were added 
to a mixture containing 18 μL of 5M NaCl, 2 μL of 1M Tris HCl pH 8.0, 1 μL of SDS, 78 μl of water, and 
1 μL of 100 μM Cy5 fluorescently labeled oligo. The beads were incubated for 45 minutes at 46 ˚C in an 
Eppendorf ThermoMixer C (15”, at 1800 RPM). Following incubation, the beads were pooled and washed 
with 250 μL TE-SDS, followed by 250 μL TE-TW. The beads were suspended in water and imaged in the 
Zeiss Axio Observer Z1 in the Cy5 channel and bright field. A custom Python script was used to determine 
the fluorescence intensity of each bead.  
Single cell host transcriptome profiling in viral infected cells. We used previously described bioinformatics 
tools to process raw sequencing reads [7], and the Seurat package for downstream analysis [170]. Cells 
with low overall expression or a high proportion of mitochondrial transcripts were removed. For clustering, 
we used principal component analysis (PCA), followed by k-means clustering to identify distinct cell states. 
For meta-clustering, host expression matrices from all four experiments were merged using Seurat [170]. 
Cells with fewer than 2000 host transcripts were excluded. k-means clustering on principal components 
was used to identify cell clusters.  
Viral genotype analysis. Sequencing reads that did not align to the host genome were collected and aligned 
to the T3D reovirus genome [204] (GenBank Accession EF494435-EF494445). Aligned reads were tagged 
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with their cell barcode and sorted. The per-base coverage across viral gene segments was computed 
(Samtools [50] depth). Positions where the per-base coverage exceeded 50, and where a minor allele with 
frequency greater than 10% was observed, were labeled as SNV positions. The frequency of SNVs was 
calculated across all cells. For the combined host virus analysis, the host expression matrix and virus 
alignment information were merged. The per-base coverage of the viral genome was normalized by the 
number of host transcripts. Cells with fewer than 1500 host transcripts were excluded from the analysis.  
IG heavy and light chain identification. Sequences derived from B cells (cells that are part of the cluster of 
B cells identified in Seurat, and that have nonzero expression of the MS4A1 marker gene) were collected 
and aligned to a catalog of human germline V, D, J and C gene sequences using MiXCR version 2.1.5 
[195]. For each cell, the top scoring heavy and light chain variable regions were selected for subtyping and 
pairing analyses (Fig. 2.2.3.1g). 
Sigmoidal fitting heavy/light chain capture. The mapping for the fractions of B cells containing heavy 
chains or light chains was fit with the following sigmoidal function: 
𝑦 =
1
1 + 𝑒−𝑏 (𝑥−𝑐)⁄
, 
where the parameter b was a free parameter for the fit of the light chain or heavy chain data, and then fixed 
for the light chain only, heavy chain only, and combined light chain and heavy chain data. 
Statistical analysis. Statistical tests were performed in R version 3.3.2. Groups were compared using the 
nonparametric Mann-Whitney U test. 
Supplementary materials available at https://www.nature.com/articles/s41592-018-0259-9#Sec20. Code 




2.2.5 Conclusions from DART-seq proof-of-principle experiments  
We have presented an easy-to-implement, high-throughput scRNA-seq technology that overcomes 
the limitation of 3’-end focused transcriptome measurements. DART-seq allows sequencing of all RNA 
types and all regions of the polyadenylated transcriptome in a single cell while maintaining the ability to 
perform single-cell transcriptome profiling. A straightforward and inexpensive ligation assay is used to 
synthesize DART-seq primer beads (Fig. 2.2.1.1). The additional experiment time required for DART-seq 
compared to Drop-seq is minimal (2 hours) as is the cost per experimental design (~ $100 per experiment). 
DART-seq is compatible with simultaneous querying of many amplicons. Here, we present example 
designs with 7-10 amplicons. The design and ratio of probes can be tailored to individual applications 
allowing researchers the flexibility to use their existing scRNA-seq set-up for a wide variety of biological 
measurements.  
We have highlighted two potential applications of DART-seq technology. First, we demonstrated 
that DART-seq provides a means to study the heterogeneity in viral genotypes and cellular phenotypes 
during viral infection. We were able to recapitulate a full segment of a dsRNA viral genome, while 
simultaneously profiling the transcriptome of the infected host cells (Fig. 2.2.2.1). DART-seq opens new 
avenues for studies of host-virus interactions. We further applied DART-seq to measure endogenously 
paired, heavy and light chain amplicons within the transcriptome of human B lymphocyte cells in a mixed 
human PBMC population, while having access to full transcriptome data of all other cell types (Fig. 
2.2.3.1). Determination of the paired antibody repertoire at depth can provide insights into several medically 




Chapter 3: Virus-inclusive scRNA-seq to understand enteric viral infections 
 
“Enteric viruses cause broad morbidity and mortality across the world and particularly in resource-limited 
countries without access to adequate treatment. As vaccines for many of these viruses become more 
available, questions about their biology, particularly as it pertains to evolution, infectivity, and proliferation 
remain unanswered. Here we apply scRNA-seq technologies to describe host-virus interactions for the 
Reoviridae family viruses in two different infection models. We infected a monoculture of green monkey 
kidney fibroblasts with rotavirus and used DART-seq to profile single cells during the infection lifecycle. 
By using the relative viral transcript abundance as a pseudo-time measurement, we were able to construct 
a timeline for the transcription of various rotavirus genes. In a second experiment, we performed scRNA-
seq on murine intestinal organoids infected with T1L orthoreovirus. We describe an initial dataset 
originating from this system and technical challenges that need to be addressed in performing scRNA-seq 
on organoids. We propose that marrying these two studies, performing scRNA-seq on a rotavirus infection 
in an intestinal organoid system, will yield novel insights into the host-pathogen biology.” 
 
Experiments and sample collection in this chapter thanks to: Meleana Hinchmann, John S. L. Parker, 




2.3.0 Motivations to expand studies to greater pathogenicity and complexity 
 Diarrheal diseases, many of which are caused by enteric viruses, are among the highest causes of 
death worldwide and particularly burdensome for young children [205]. Here, we described the enteric 
pathogen, rotavirus, in order to understand one of the drivers of enteric disease and due to its similarity to 
reovirus. Similar to orthoreovirus, rotavirus virions contain a double-stranded RNA genome made up of 
many segments (eleven segments in rotavirus compared to ten segments in the reovirus) and does not 
modify mRNA with polyadenylated tails [179]. Because the genome is segmented, it is possible for progeny 
virions to contain a mixture of genomes from parent viruses that co-infected the same cell (Fig. 2.1.0.2). 
While the genetics of rotavirus and reovirus are similar, rotavirus is more virulent. Rotavirus infects 
hundreds of thousands of children a year and is capable of causing severe gastrointestinal distress [206]. 
From the discovery of the virus in 1973 up to the development of a vaccine in the late 2000s, rotavirus was 
the primary cause for childhood death in sub-Saharan Africa, and persists as a burden on within 
communities lacking strong medical infrastructure [206].  
Significant questions surrounding rotavirus biology and evolution remain. For example, though 
rotavirus is associated with gastrointestinal distress following infection of enterocytes, there are examples 
of systemic rotavirus infections with viral particles found in multiple organs [206]. This behavior suggests 
a form of cooperation among various viral subtypes, as has previously been noted in other enteric viruses 
[207]. We applied viral DART-seq to a monoculture of cells exposed to simian rotavirus (SA11).  
We sought questions related to viral response within a community of diverse cells. As shown in the 
case of the EHV1-infected cells (Section 2.1), viral infection in an organism affects multiple cell types even 
if they are not directly infected. Furthermore, recent studies exploring cellular heterogeneity during viral 
infection in PBMCs and lung tissue have uncovered the actions of bystander cells due to infections [175, 
208]. These cells, while not infected, are affected by the infection of neighboring cells, and likely play a 
role in the immune response [209]. Infections in monoculture are important to characterize viruses and for 
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technical development. However, it is only by understanding systems closer to natural infection that we can 
uncover the true behavior of cells, tissues, and the entire organism during infection.  
Intestinal organoids (enteroids) represent a tractable system to study gastrointestinal diseases and 
are typically made up of several cell types [210]. The enteroids have a unique morphology bearing structural 
similarity to crypt-villi structure in vivo [210]. We developed a viral infection system using T1L 
orthoreovirus at a high MOI to infect murine enteroids. We will present the challenges with single-cell 
sequencing in organoid systems and describe the results of our preliminary experiments. We conclude this 
section by describing future directions in this field of research. 
 
2.3.1 Rotavirus infections in monkey fibroblasts 
Reovirus and rotavirus are part of the Reoviridae family of viruses and have similar genomic 
architecture and transcriptional mechanisms. However, the GC content of rotavirus is much lower than that 
of T3D reovirus across all segments (mean GC: rotavirus = 34.7% ± 3.4%, T3D reovirus = 47.3% ± 1.4%). 
As a result, rotavirus mRNAs have accumulated multiple regions with adenine repeats. We previously 
identified a correspondence between A(5) repeats in reovirus positive-strand RNA (mRNA) molecules and 
Figure 2.3.1.1 Targeted sequencing is not necessary for all viral transcripts. (a) The number of A(5) 
repeats per kilonucleotide (knt) is shown for three dsRNA, segmented viruses. (b) Mean normalized 
sequencing coverage across eleven rotavirus segments was calculated based on experimental results. {38} 
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upstream sequencing coverage, due to the spurious binding of these regions to the poly(dT) regions of 
standard Drop-seq beads. The distribution of A(5) repeats per kilobase across the segments of T3D reovirus, 
T1L reovirus, and rotavirus is depicted in Figure 2.3.1.1a. We believe that due to the high density of A(5) 
repeats, targeted and untargeted scRNA-seq methods would both effectively capture rotavirus mRNAs. To 
test the efficiency of viral capture across various systems we prepared DART-seq (targeting each 
transcript’s 3’ region) for infected and control samples.  
 Green monkey kidney fibroblast (MA104) cells were suspended in a deep well plate and 
incubated with rotavirus A for one hour. Unlike reovirus, rotavirus was highly cytopathic in the MA104 
cells at similar times and multiplicity. To avoid cytopathic effects in the fibroblasts, we used low 
multiplicity of infection and shorter incubation times. We trypsinized the cells prior to washing with PBS 
+ 0.01% BSA; infecting at lower MOI (0.1, 1.0, 5.0); and incubating infected cells shorter time (3 to 5 
hours). Cells were incubated at 37 °C for five hours. Following incubation, cells were trypsinized from the 
plate (TrypLE) and washed three times with PBS + 0.01% BSA to prepare for scRNA-seq library prep.  
Following alignment of single-cell sequencing data to a hybrid reference transcriptome (Green 
Vervet Monkey [211]and Rotavirus A), we determined sequencing quality based on various single-cell 
metrics (Fig. 2.3.1.2a-d). We collected few cells in the Mock and High MOI samples (Fig. 2.3.1.2). 
However, the metrics reveal single-cell sequencing of the rotavirus-infected cells yielded a high amount of 
viral transcripts (Fig. 2.3.1.2d), which likely caused a reduction in the number of total genes and 
mitochondrial transcripts detected in cells, since the average number of UMIs per cell did not change 
between infection conditions. Following filtering we examine the read coverage across the viral genome 
segments in the cells with high viral fitness in the Low MOI sample. We examined the viral genome 
coverage across twenty-five high quality cells with a large amount of virus present in the cell (> 10% of 
transcripts originating from the virus). The sequencing coverage of the viral genome was significantly 
enriched upstream of A(5) repeats, while enrichment at the 3’-end of the DART-seq probe had varying 




Figure 2.3.1.2 Rotavirus infected fibroblast quality analysis in single cells sequencing. (a-d) For Mock, 
Low MOI (MOI 0.1), and High MOI (MOI 5.0) single-cell sequencing analysis revealed the number of (a) 
UMI per cell, (b) genes per cell, (c) percentage of transcripts from the mitochondria, and (d) the percentage 
of transcripts from rotavirus. (e) Sequencing coverage across the rotavirus genome segments (ordered 
largest to smallest) 25 cells with the highest percentage of viral reads. Traces of each cell are in grey and 
mean of the traces is shown in black. Scale is square-root transformed. {39} 
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 To our knowledge, the distribution of rotavirus gene transcripts during the virus lifecycle has not 
been reported. The rate of transcription by the viral RNA-dependent RNA polymerase (RdRp) is constant 
across segments for Reoviridae [179]. However, confounding factors such as mRNA protection via RNA-
binding proteins and mRNA decay make it difficult to assess the veracity of the mean relative abundance 
for the eleven viral gene segments. We observed a pronounced variability in the expression of viral genes 
in the Low MOI samples. Most notably, as the relative proportion of viral to host transcripts decreased, an 
increasing proportion of rotavirus NSP3 gene expression was observed.  
During the rotavirus infection lifecycle, NSP3 proteins recognize and bind to the 3’-end viral 
mRNA motif (UGACC), synonymous to the binding of polyA binding protein (PABP) to eukaryotic 
polyadenylated mRNAs [212]. NSP3 has a higher affinity for eIF4G than PABP, another protein in the host 
translational machinery, allowing viral mRNAs to be preferentially translated over host mRNAs [212, 213]. 
This process coincides with a forced relocalization of PABP into the nucleus, and occurs with fairly few 
NSP3 proteins, not long after the initial infection (within three hours) [214]. We demarcated cells that likely 
had no viral infection by comparing to the fraction of viral transcripts in the Mock dataset. Viral mRNAs 
detected in this dataset are likely from barcode hopping (cut-off of 1.00%) [108]. Thirty-seven genes were 
determined to be significantly correlated (Spearman, p < 10-10) with the relative abundance of viral 
transcripts. Most of these genes corresponded to binding and structural activity. To find transcripts 
significantly affected between the low and high viral abundance groups, we compared cells for which fewer 
than 5% of mRNAs originated from rotavirus to those with higher than 5% of mRNAs from rotavirus. A 
single gene, PABPC1, was significantly altered, having a 2-fold decrease in the high versus the low group; 
PABPC1 encodes a protein that is part of the PABP complex. 
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In addition to the higher relative abundance of NSP3 with increased viral abundance (29.1% of 
viral mRNAs to 48.8% of viral mRNAs), we also observed a corresponding decrease in the abundance of 
VP1 (5.2% to 1.6% of viral reads) and NSP4 (24.1% to 11.5% of viral reads). The relative abundance of 
other viral genes was not significantly altered. VP1 and NSP4 genes encode the viral RdRp and a 
nonstructural enterotoxin, respectively [215]. We hypothesize that the decrease in mRNAs corresponding 
to the RdRp could be an effect of the viral lifecycle. As the cell is preparing to reduce progeny virions, there 
is no longer a need for active transcription, leading to a decrease in VP1 protein. Similarly, infections at 
this stage of the viral lifecycle could be downregulating enterotoxin production, leading to a decrease in the 
relative abundance of NSP4. Indeed, NSP4 has been shown to be a transcription regulator [216]. 
This pilot study revealed a heterogeneity in infection likely caused by the time of infection. In our 
experiments, the only condition altered was the multiplicity of infection. However, it is likely that there is 
some heterogeneity in specific time of infection and number of virions infecting individual cells. At an MOI 
of 0.1, for instance, it is likely that 1 in 200 cells is infected by multiple virions. Because we use a stock of 
pure viruses on a monoculture, the transcriptome of cells likely represents a look into cellular progression 
Figure 2.3.1.3 Viral gene transcription is altered through infection progression. Viral mRNAs are 
averaged in groups of thirty cells after ordering by the percent of transcripts of viral origin in each cell. The 
fractional abundance of each transcript in the cell bin (30 cells) is shown as a stacked barplot. Line indicates 
the fraction of reads originating from the virus in each cell bin. Dotted line represents the cutoff of 
uninfected cells. Bar color represents viral gene segment (annotated on right). {40} 
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through infection. Further experiments need to be conducted to confirm these observations and access 
deeper information about rotavirus infection. Due to the high A(5) repeat density across the rotavirus 
segments, non-targeted sequencing strategies such as 10x genomics sequencing can be used. This will 
greatly improve the depth of sequencing per cell. These experiments are currently underway. 
 
2.3.2 Single-cell sequencing of complex cellular communities 
 It is appreciated that virus-inclusive scRNA-seq can reveal the extent of heterogeneity in infected 
cells and their associated viruses [174, 217]. Uninfected cells within infected hosts and those neighboring 
infected cells can may also exhibit extreme heterogeneity driven by paracrine signaling and other 
intercellular communication [208]. Having shown the ability to perform Drop-seq and DART-seq in single 
cells to describe the changes induced by viral infections, we sought to expand our host system to one with 
greater cellular heterogeneity. The formation of intestinal organoids from Lgr5+ stem cells has become an 
accessible system to study gastrointestinal disorders outside of live animal models [210, 218]. Enteroids 
contain several cell types including enterocytes, goblet cells, enteroendocrine cells, stem cells, and Paneth 
cells [219]. Viruses in the Reoviridae family have been shown to infect the enterocyte and enteroendocrine 













 We explored the use of enteroids to describe infection with T1L reovirus. Enteroids were created 
by isolating the intestinal crypts from mice and allowed to develop in a nutrient-rich Matrigel for three 
weeks. We infected murine enteroids with reovirus (MOI 50), allowing binding to occur for one hour and 
followed by incubation for 24 hours. Following incubation, we dissociated enteroids by adding TrypLE 
enzyme pipetting vigorously. Following dissociation, the cell suspension was washed with PBS + 0.01% 
BSA and centrifuged at 200xg for five minutes between wash steps. After the final wash, cells were passed 
through a 100 micron filter to remove cell clusters (Fig. 2.3.2.1a-c). We processed filtered cells using 
droplet microfluidics for scRNA-seq as described previously [7, 8]. 
 We performed Drop-seq as a proof-of-principle sequencing assay, with the intent to perform 
DART-seq. Drop-seq sequencing data from infected and mock organoids revealed a failure to capture viral 
transcripts (no T1L reovirus detected in both cases). The T1L reovirus genome has several A(5) repeat 
regions across the genome, so it is likely if the virus was replicating in the cells we would detect viral 
transcripts. We believe the lack of reads from viral mRNAs could be a result of a failed infection of the 
Figure 2.3.2.1 Dissociation of organoids leaves cellular aggregates but represents all cell types. (a) 10x 
phase contrast image of dissociated enteroid on Fuchs-Rosenthal hemocytometer. (b-c) The diversity of 
cell types is observed by morphological features, as shown at 40x by the presence of (b) goblet cells and 
(c) remnants of crypts. Images taken on Zeiss Axio Observer Z1 under phase contrast. {41} 
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enteroids or a high amount of host transcripts leading to under-sampling of the viral mRNAs. However, we 
were able to perform single-cell sequencing analysis based on differential gene expression on the data 
aggregated from the two experiments [170]. 
 Our results indicated that the scRNA-seq pipeline worked efficiently, though the enteroid system 
was likely under stress at the time of sample processing. It is possible that there was a high amount of cell 
lysate present in the cell suspension due to the dissociation technique. We observed a high relative 
abundance of mitochondrial transcripts compared to other single-cell sequencing datasets; the 
mitochondrial gene expression was bimodal distributed (Fig. 2.3.2.2a). Cells with high mitochondrial 
transcription had a corresponding low number of expressed genes (Fig. 2.3.2.2a) and were removed from 
the dataset. Following this quality control measure (reducing total number of cells to 2,696), we regressed 
the effect of 97 genes related to the murine cell cycle from our data and clustered based on the principal 
components [220]. Cells clustered on the cell cycle regressed gene expression did not segregate by 
experiment (Fig. 2.3.2.2b). However, we did observe small clusters of cells corresponding to the four major 
cell types based on enrichment of known gene markers (enterocytes, Sis; enteroendocrine cells, Chga; 
Figure 2.3.2.2 Differential gene expression and clustering analysis of low quality cells from enteroids. (a) 
The percentage of transcripts originating from the mitochondria is compared to the total number of genes 
expressed. Dotted lines represent cutoffs for filtering. Density plot overlaid on cells (colored by 
experiment). (b,c) t-SNE dimensional reduction of cell-cycle regressed gene expression. (b) Colors indicate 
Mock and Infected datasets. (c) Colors indicate increased expression of Sis, Lyz1, Chga, and Tff3. Intensity 
of color corresponds to intensity of gene expression. (1) Enterocyte cluster. (2) enteroendocrine + goblet 
cell cluster. (3) Paneth cell + goblet cell cluster. {42} 
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goblet cells, Tff3; and Paneth cells, Lyz1) (Fig. 2.3.2.2c) [219, 221]. We defined enrichment as any gene 
expression value greater than one after scaling the UMI counts. Enterocytes made up the plurality of cell 
types (20.8%), followed by goblet cells (13.3%), Paneth cells (5.0 %), and enteroendocrine cells (1.7%). 
We found no gene enrichment of the four marker genes in 64.7% of cells. 
 There are several factors that could account for the unassigned majority of cells. High expression 
of mitochondrial, ribosomal, and cell cycle mRNA contributed to the majority of reads in all cell clusters. 
Lower abundance reads that likely carried cell markers were under-sampled and did not appear in datasets. 
The unassigned cells could also be an effect of proliferation and stem-ness among the cell population. We 
detected nonzero expression of Lgr5, the gene involved in stem-ness in the organoid system, and Mki67, a 
cell marker of proliferation, in many cells that were not assigned to the four cell types mentioned above 
[210, 222]. Unassigned cells could also be an effect of cell clusters trapped inside single droplets within the 
microfluidic device. As shown in Figure 2.3.2.1, we have observed cell aggregates resemble the crypts and 
villi, likely leading to larger numbers of cell doublets (triplets, quadruplets, etc...) in the datasets. Finally, 
the low number of enteroendocrine cells, coupled with the high amount of mitochondrial gene expression 
might explain the low abundance of viral reads in our dataset. 
 In summary, while our results do indicate the ability to sequence murine intestinal organoids at 
single-cell resolution, technical hurdles must be overcome to develop an accurate understanding of organoid 
systems during infection. In particular, the aspects that need to be understood and addressed concern: (1) 
the high number of mitochondrial gene transcripts, (2) the lack of transcripts originating from the reovirus, 
(3) the high number of nondescript cells (provided they are not accounted for after reduction of 




2.3.3 Future experiments: rotavirus infections in organoid systems  
 In this section we have described virus-inclusive scRNA-seq from the highly pathogenic rotavirus 
and for reovirus in a complex organoid system. We have shown that rotavirus infections are well 
characterized in a DART-seq experiment, but, importantly have found that standard scRNA-seq methods 
will likely capture the heterogeneity of infection due to A(5) repeats in the rotavirus messenger RNA. In 
contrast, our results in the organoid system and in previous experiments indicate the need for targeted 
amplicon sequencing to recover reovirus transcripts. These observations indicate that a more sophisticated 
probe design algorithm can be used to create future DART-seq libraries. For example, non-polyadenylated 
mRNA with A(5) repeats near the 3’-end of the molecule do not need to be probed. The reduction in the 
probe pool complexity would, in turn, increase capture of other targets as well. 
 Intestinal organoids have been shown to be a powerful tool in which rotavirus infection can be 
studied [219]. Human rotavirus infection of intestinal organoids revealed tropism for multiple cell types, 
including enterocytes and enteroendocrine cells, and showed structural changes in the organoids after 
infection, such as luminal swelling [219]. Infections in the organoid system, compared to monoculture, also 
revealed an increase in the viral titer [219]. Given the ability to robustly capture rotavirus using any scRNA-
seq technology, merging the studies discussed in this section would yield a robust system to study 
Reoviridae in a complex community. Though previous studies characterized gross changes to the intestinal 
organoids during human rotavirus infection, analysis at the single-cell level has not been documented. 
Analyses on viral mRNAs at single-cell resolution could therefore identify novel host defense mechanisms 
depending on cell type. 
 Infecting intestinal organoids with rotavirus could also reveal a new perspective on how bystander 
cells react during infection. In their analysis of bystander cells in influenza infections, Steuerman et al. 
observed that the bystander cells produce a strong interferon response [208]. Such an effect may be 
observed in Paneth and goblet cells in the organoid. Lastly, the addition of non-enteroid cell types into the 
Matrigel during development, the collective group called assembloids, have yielded systems that more 
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strongly resemble organs in vivo [223]. Adapting this method to include, for example, white blood cells 
into the enteroids might yield insights into viral adaptation that can describe the mechanism that leads to 
viremia and extraintestinal infections during some cases of infection, which is not well understood [224, 
225].  
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Chapter 4: Afterwards on virus-inclusive single-cell sequencing 
 
Virus-inclusive scRNA-seq, while nascent, has provided a unique perspective to understanding the 
host-pathogen biology. However, there are still many aspects of virology which have not yet been described 
at single-cell resolution, including viral evolution. In this part we have described the implementation of a 
novel and facile scRNA-seq modification to interrogate viral infections in any system. We have applied the 
technique, DART-seq, to describe intercellular heterogeneity in both host and viral mRNA during infection 
with mammalian orthoreovirus and rotavirus. There are many questions that can be interrogated in these 
systems, but which will likely require technical developments. In particular, we believe that targeted 
scRNA-seq could be used to describe: (1) differences in genomic and messenger RNA in viruses, (2) 
polymicrobial infections, and (3) full viral transcripts, using long-read sequencing technologies. 
Many viruses, including influenza, utilize a negative-stranded RNA to synthesize positive-stranded 
messenger RNAs. By capturing and analyzing SNPs between the genomic and messenger RNA for single 
virions, one could determine host defense mechanisms employed to, for instance, hypermutate viral mRNA 
[226]. We have previously attempted to use DART-seq to describe differences in the gRNA and mRNA for 
reovirus. Like influenza, dsRNA viruses use the negatives-strand as a template to create positive-stranded 
mRNAs. We targeted one locus on the positive-stranded RNA and one locus on the negative-stranded 
gRNA for three segments in T3D orthoreovirus following murine fibroblast infection. We performed the 
DART-seq pipeline on these samples as described in Section 2.2.4. Our results indicated capture of positive-
stranded mRNA at all three targeted loci, similar to what was depicted in Figure 2.2.3.1. We did not observe 
capture and enrichment at the three loci targeted on the negative-stranded gRNA. Moreover, the capture 
rate of sequencing reads aligning to the negative strand across all ten segments was similar to other 
experiments where the negative strand was not targeted. 
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The inability to reliably capture negative-stranded RNA is likely caused by the relative abundance 
of negative-stranded RNA to positive-stranded RNA. Since there is an abundance of positive-stranded 
mRNA relative to gRNA, negative-stranded RNA is almost always hybridized to the complementary 
positive-strand. dsRNA genomes are difficult to denature, and often require high temperatures and some 
form of chemical treatment [227, 228]. Therefore, it is unlikely that the DART-seq probe is able to displace 
the positive-stranded RNA to capture the negative-stranded RNA. Adaptations to scRNA-seq protocols are 
likely necessary to perform simultaneous strand capture. We are currently working to evaluate gRNA 
capture in single-stranded RNA viruses. 
 Another area of interest, as mentioned in the introduction of this part, involves the sequencing of 
single cells following infection by multiple virions. For example, Russell et al. previously performed 
synonymous coinfections with influenza in cell culture [217]. Furthermore, a recent discovery that enteric 
viruses, including rotavirus and norovirus, can achieve high titers through assembly within vesicles 
provides further impetus to study coinfections at single-cell resolution [229]. DART-seq can be used to 
target transcripts from various viral genotypes and explore the effect of multiple virions within single cells. 
 A third direction for future viral scRNA-seq studies involves the sequencing of full length cDNA 
to identify genetic variants on a cell-by-bell basis. DART-seq allows users to sequence transcripts at 
specific positions, and is not relegated to the 3’-end of the molecule like Drop-seq and 10x genomics based 
library preparation. However the sequence coverage is limited to the chosen read length on Illumina 
sequencing platforms, with a maximum length of roughly 300 bp. In contrast, long-read sequencing 
technologies have recently gained popularity and broad user accessibility, with no theoretical limit on the 
length of the fragment to be sequenced. Long-read scRNA-seq has recently been achieved using nanopore 
sequencing [230] and was applied to study viral genomic diversity in influenza virus [231]. Long read 
sequencing revealed that the host response in infected cells showed a varied expression based on SNPs and 
structural variants during infection [231]. These insights could not be easily resolved with standard scRNA-
seq pipelines. It is likely that combining short-read scRNA-seq technologies, to broadly determine 
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differential gene expression in the host, with long-read scRNA-seq technologies on viral reads will further 
describe viral infections in the future. 
 Finally, we believe that as the field of scRNA-seq moves towards an understanding of spatial 
heterogeneity of gene expression in tissues, so too will research in viral scRNA-seq. It is well understood 
that a viral infection can begin with countably few virions [232] and that can trigger a wide-ranging immune 
response through paracrine signaling [209, 233]. Application of fluorescence in situ hybridization to 
localize transcripts of interest has become a reliable tool to measure single-cell heterogeneity and spatial 
distribution of transcripts [173, 234]. We envision that the next stage of understanding intracellular 
infections will employ these techniques to understand viral dissemination and intercellular signaling effects 




In this dissertation, I have described a new series of biomolecular and bioinformatics techniques 
that can be used to better surveil and understand infectious disease. 
 We have shown the ability of cfDNA sequencing to accurately detect and describe viral and 
bacterial pathogens over time and space. In Section 1.2, I described how the implementation of a novel 
single-stranded library preparation strategy increased the abundance of ultrashort cfDNA molecules (< 100 
bp in length). These molecules represent highly degraded forms of cell-free DNA in biological fluids, but 
have been neglected in past sequencing assays. We compared matched plasma cfDNA samples prepared 
using both single-stranded and double-stranded library preparation approaches. Our results indicated a 
higher relative abundance of microbial cfDNA in these samples, leading us to hypothesize that cfDNA 
sequencing could be employed to monitor infections. 
We applied our single-stranded library preparation to cell-free DNA extracted from the urine 
supernatant of 141 samples from renal allograft recipients (Section 1.3). These patients are particularly 
prone to both bacterial and viral urinary tract infections. We compared the microbial abundance detected 
in cell-free DNA with clinical diagnoses determined through quantitative PCR and urine culture; we found 
high concordance between cfDNA sequencing and these gold standard techniques. Moreover, urinary 
cfDNA sequencing was sensitive to an array of viral and bacterial pathogens that were not detected in 
standard screens, including herpesvirus and Haemophilus influenzae. cfDNA sequencing also provided 
functional information regarding infections, including growth kinetics and antibiotic resistance of bacteria, 
as well as a measure of the extent of host damage. 
As we observed in our analysis of urinary cfDNA from renal allograft recipients, cfDNA 
sequencing was sensitive to the matched, clinically diagnosed uropathogen in nearly every case. However, 
our analysis showed an abundance of nonpathogenic bacteria, including commensals and contaminants. To 
address the issue of contamination, we developed a pipeline to determine falsely-assigned microbial 
sequencing reads in datasets from samples with low microbial biomass (Section 1.4). We optimized our 
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background correction algorithm on a refined dataset from patients with monomicrobial UTIs; this allowed 
us to apply cfDNA sequencing with background correction to several novel datasets, including cfDNA 
extracted from amniotic fluid and peritoneal dialysis effluent. 
The development of our cfDNA sequencing assay allowed us to pursue analyte validation in 
neglected tropical diseases for which current diagnostics may be insufficient (Section 1.5). We implemented 
cfDNA sequencing with background correction to analyze the presence of enteric microbiota in the plasma 
of pediatric patients in rural settings. Comparison to the standard dual-sugar assay revealed a group of 
bacteria associated with gut flora that was abundant in more severe cases of environmental enteropathy. In 
a separate study, we hypothesized that genome replication dynamics, ascertained by sequencing coverage 
across the Mycobacterium tuberculosis genome, could discrepant cases of latent and active MTB 
replication. This hypothesis was validated using whole genome sequencing of antibiotic-treated MTB in 
culture and MTB from the caseum in a rabbit model. We sequenced plasma cfDNA from adult patients 
with active MTB, but detected very few MTB molecules. 
While cell-free DNA sequencing is able to capture the causative agent of infection in many cases 
of disease, several shortcomings in the processing of samples need to be resolved before it becomes a broad 
tool for clinical labs. In our own experiences, the ability to detect microbial cfDNA changes dramatically 
between biological fluids. Blood plasma, while having the ability to provide infection information from any 
vascularized tissue, often has low levels of microbial cfDNA, even in cases of infection. This effect is likely 
due to the presence of immune cells and nucleases clearing out cfDNA molecules. In contrast, urine and 
peritoneal effluent, have proven to be excellent reservoirs of microbial cfDNA during UTI and peritonitis, 
respectively. Other fluids, such as cerebrospinal and synovial fluid, have proven to be of interest to analyze 
host cell-free DNA, but have not been thoroughly analyzed for the presence of healthy and infected 
individuals [15, 235, 236]. 
There exist time and cost barriers for using cell-free DNA sequencing to monitor and diagnose 
infections. At the time of writing this dissertation, cfDNA sequencing can cost hundreds to thousands of 
133 
 
dollars to properly implement and requires an investment of large amount of capital in next generation 
sequencing platforms. Improvements are being made in the turn-around time to produce a diagnosis. A 
recent report illustrated that patients submitting plasma samples for cfDNA sequencing would have 
diagnostic reports in 24-36 hours [6]. While the costs of next generation sequencing are not prohibitive in 
many Western countries, the ability to implement the technique in rural areas and emerging economies, 
which are those most affected by infectious disease, is currently out of reach.  
However, the decreasing cost of genome sequencing and the emergence of new sequencing 
technologies are moving cfDNA measurements to the realm of effective, field-deployable diagnostics. For 
example, in the last five years, the use of nanopore sequencing has been employed to rapidly sequence the 
genomes of hundreds of organisms in real-time. Nanopore sequencing works by detecting changes in 
electrical impedance as DNA and RNA molecules are pulled through enzymatic pores in a membrane [237]. 
The technique does not require prior sample amplification, is not restricted to a maximum molecule size, 
and can produce results in real time [238]. Microbiologists have recently used nanopore sequencing to 
detect the presence of bacteria in a variety of surveillance setting, including foodborne illnesses [239] and 
pandemic virus outbreaks [240]. Furthermore, the size and cost of the nanopore sequencers allow for easy 
transport to resource-limited settings including the International Space Station [241]. While nanopore 
sequencing of cell-free DNA has not yet been realized, short DNA sequencing via the ON Minion system 
has recently been demonstrated [242]. 
As described in Section 1.3.8, our work has shown that non-standard methods of cell-free DNA 
sequencing can be used to more deeply understand the origin of cfDNA molecules. Treating single-stranded 
cfDNA molecules with bisulfite can be used to identify the tissue-of-origin of molecules via their patterns 
of CpG methylation. Work in our lab has shown that non-human cfDNA can still be accurately mapped to 
microbes after bisulfite treatment, allowing for the simultaneous measure of host tissue and microbial 
cfDNA in biological fluids. While the ability to, for example, observe SNP changes in the microbial 
genomes is obscured by the bisulfite treatment, this technique gives unprecedented molecular detail about 
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the host-pathogen dynamics from cfDNA. We have used this technique to indicate kidney damage and 
white blood cell recruitment in viral and bacterial UTIs, respectively, which has expanded on standard 
metagenomic sequencing. 
Cell-free RNA (cfRNA) sequencing provides another exciting potential biomarker to diagnose and 
monitor infectious disease. Somewhat analogous to bisulfite-treated cfDNA sequencing, cfRNA 
sequencing allows for the identification of tissue-level and cell-level histories of cfRNA molecules, which 
can be used to describe cellular migration, damage, and signaling [243, 244]. cfRNA is, theoretically, more 
comprehensive than cfDNA in identifying causative pathogens during infection (e.g. RNA viruses). In cases 
of bacterial infection, cfRNA could be used to identify active transcription of bacteria at the time of their 
lysis, which could determine if the bacteria are expressing genes related to growth, virulence, or antibiotic 
resistance. To date, few studies evaluating the clinical efficacy of cfRNA sequencing have been published, 
likely due to the technical challenges in isolating cfRNA and preventing sample degradation. 
In the second part of the dissertation, I outlined the state of virus-inclusive scRNA-seq and 
described our efforts to further scRNA-seq  technology in the context of infectious disease. High throughput 
scRNA-seq has produced novel insights into development, immunology, and neuroscience. However, many 
popular approaches to scRNA-seq use poly(dT) probes to capture polyadenylated RNA molecules. 
Polyadenylation, however, is not present on many noncoding RNAs or the messenger RNAs of many 
prokaryotes or viruses. To address this issue, we developed a straightforward modification protocol that 
allows for simultaneous capture of the polyadenylated transcriptome and specific RNA molecules using a 
multiplexible, custom probe array (Section 2.2). We validated our new technology, DART-seq, on cells 
infected with mammalian orthoreovirus, a segmented virus that does not modify its mRNA with 
polyadenylated tails. Our results indicated that DART-seq can more fully describe host-pathogen 
interactions, allowing for the depth of sequencing to categorize viral mutations and determine host 
transcriptomic programming that alters viral fitness. 
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We also illustrated that DART-seq may be employed to enrich the abundance of low abundance 
polyadenylated mRNAs in sequencing datasets. We targeted the constant regions of mRNAs corresponding 
to the heavy and light chain in antibodies in commercially available B-cells and a population of PBMCs. 
The capture of heavy and light chain targets was validated, and we showed that these molecules reciprocate 
known features of the immune repertoire, such as CDR3 length and relative abundance of various variable 
regions. The enrichment in heavy and light chain variable regions allowed us to produce a paired immune 
repertoire consistent with previous reports.  
We extended our research into host-virus interactions at single-cell resolution using other models 
of infection by viruses in the Reoviridae family (Section 2.3). Rotavirus provides a more clinically relevant 
infectious organism compared to reovirus, as it is responsible for tens of thousands of deaths worldwide, 
annually. We performed rotavirus infection in cell culture at various multiplicities of infection to observe 
response in the host cell population. Differential expression among viral and host genes revealed the 
progressive life cycle of the virus through infection. To increase cellular complexity and analyze the 
infection response among bystander cells, we performed infection of murine enteroids (composed of four 
cell types), with T1L orthoreovirus. In our first experiment we were unable to detect viral transcripts; 
however, this pilot study has allowed us to establish guidelines for proper experimentation and analysis. 
We envision the expansion of virus-inclusive scRNA-seq studies using rotavirus will yield novel insights 
into viral cooperation and the innate immune response. Taken together, our experiments reveal the utility 
of the DART-seq platform to more completely describe the innate and adaptive immune system during 
infection. 
Though preliminary, several studies have described the application of single-cell sequencing as a 
platform for novel, high-resolution biomarker discovery. Virus-inclusive scRNA-seq has recently been 
implemented to discern RNA analytes of severe dengue fever, a disease which can have as high as 20% 
mortality rate if untreated [175]. PBMCs were isolated by fluorescence-activated cell sorting into a 384-
well plate and sequencing libraries were prepared. By sorting patient PBMC cells prior to scRNA-seq 
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library preparation, the authors enriched underrepresented populations of cells. scRNA-seq analysis 
determined several viable markers to predict severe dengue analysis including MX2 in naive B cells and 
CD163 in CD14+ CD16+ monocytes. In a separate study, scRNA-seq was applied to patient-derived 
placental tissue to explore biomarkers for preeclampsia [245]. Differential expression among single cells 
allowed the researchers determine cell population trajectories around the time of preeclampsia onset. 
cfRNA datasets reanalyzed by the group indicated a previously unseen enrichment in transcripts related to 
extravillous trophoblasts [245]. While both the works described above are preliminary, the studies illustrate 
potential for single-cell sequencing to become a platform for analyte discovery.  
Future work in the De Vlaminck lab will expand the community’s knowledge of infectious disease 
using single cells and circulating nucleic acids, and it is likely these two perspectives will overlap. In 
summary, I hope that my efforts in this field has contributed novel tools and approaches to understanding 
host-microbe interactions. Microbes are the most highly represented organisms on Earth [246]. This 
dissertation has focused mainly on their role in disease and disruption; however, our story and wellbeing is 
intricately woven into theirs. It will be exciting to see how our understanding of microbiology and 
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